[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_d1f20098-9bd1-40b5-8169-2ad0db923504":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:d1f20098-9bd1-40b5-8169-2ad0db923504,\"}":174},{"code":4,"data":5,"meta":22},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":24,"manageAffiliations":37,"indexDatabases":52,"url":22,"thumbnailPath":22,"statistic":89,"gsStatistic":22,"type":173,"analyzePriority":22},"d1f20098-9bd1-40b5-8169-2ad0db923504","2024-04-06T04:32:10.392+00:00","2025-11-21T10:00:37.583+00:00",[],"Current-Neurology-and-Neuroscience-Reports",{"eissn":12,"issn":14,"title":16,"url":18},{"VOID":13},"15284042",{"VOID":15},"15346293",{"EN":17},"Current Neurology and Neuroscience Reports",{"VOID":19},"https:\u002F\u002Flink.springer.com\u002Fjournal\u002F11910","PUBLISHER","PENDING",null,0,[25,31],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":27,"label":28,"description":30,"parentId":22,"standard":22,"scholarHubFieldId":22},"228d6ea6-4b2a-4153-bf22-36784b0cd31c",[],{"EN":29},"Neurology (clinical)",{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":33,"label":34,"description":36,"parentId":22,"standard":22,"scholarHubFieldId":22},"ad2df4fc-f3aa-41d5-b713-331b2df73f42",[],{"EN":35},"Neuroscience (miscellaneous)",{},[38,45],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":40,"slug":22,"properties":41,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":44,"statistic":22},"26a19206-5cad-4456-bb2f-49abd254fbc6",[],{"title":42},{"EN":43},"SPRINGER",[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":47,"slug":22,"properties":48,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":51,"statistic":22},"aeebfe70-bb47-4404-91bd-6d44079a5c1d",[],{"title":49},{"EN":50},"Current Medicine Group",[],[53,71],{"id":54,"indexDatabase":55,"url":67,"indexYears":22,"academicFieldIds":68,"indexDatabaseRanking":22},"7adfe9f6-54e8-4dcf-a94a-de2fa1b3b543",{"id":56,"createTime":22,"updateTime":22,"relativeEntities":57,"label":58,"description":60,"key":63,"publicationTags":64,"standard":22},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":59,"VI":59},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":61,"VI":62},"SCIE database","Cơ sở dữ liệu SCIE","scie",[65,66],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1528-4042",[69,70],"8d10567b-4ae4-42f8-b554-ff4a4364e08f","cfec6a06-0ac1-4490-82a0-b35d384ee92c",{"id":72,"indexDatabase":73,"url":83,"indexYears":84,"academicFieldIds":85,"indexDatabaseRanking":88},"ff8579e8-c6bd-4b03-8b42-e16ced8d72dc",{"id":74,"createTime":22,"updateTime":22,"relativeEntities":75,"label":76,"description":78,"key":80,"publicationTags":81,"standard":22},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":77,"VI":77},"Scopus - Elsevier",{"EN":77,"VI":79},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[82],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F14989","2001-2025",[86,87],"fcfab063-8c6c-4582-8a75-e1ae02713ec5","c75f06a2-b70a-4b9b-8c02-99f3ab012851","SCOPUS__Q2",{"impactFactor":23,"impactFactorByYear":90,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":106,"totalCitation":123,"totalCitationByYear":124,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":148,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},1.53,1.41,0.9,1.26,1.06,1.18,1.23,1.31,1.11,1.09,1.67,1.37,187,24,1328,{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},63,52,60,65,50,53,43,68,37,59,67,74,75,48,49,4,9131,{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},299,230,414,180,370,161,296,153,413,1243,424,969,643,344,584,840,476,328,235,217,16,1,6.88,{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},4.75,4.42,3.83,6.37,3.6,6.98,3.74,4.35,4.14,7.79,23.9,7.19,14.46,9.46,7.89,12.35,6.35,4.43,5.47,4.52,1.33,0.3,0.25,55,"JOURNAL",{"meta":175,"data":177},{"total":176},"1329",[178,563,670,786,1432,1616,1732,1878,2362,2929],{"id":179,"createTime":180,"updateTime":181,"relativeEntities":182,"slug":183,"properties":184,"entityType":195,"verifyStatus":196,"verifyTime":197,"verifyNote":198,"languages":199,"translateLanguages":22,"viewCount":23,"primaryUrl":201,"fullTextUrl":22,"authors":202,"publicationType":243,"publisherRelationship":244,"citationCount":298,"citationInfo":299,"publishDate":305,"publishYear":300,"citationAnalyzeStatus":306,"lastCitationAnalyze":307,"indexDatabases":308,"openAccess":22,"references":309,"isForceReanalyzing":562},"7c7f3d9b-ff9b-44dd-80bf-9d058dacea28","2024-04-16T21:52:50.149+00:00","2026-07-23T19:49:57.309+00:00",[],"Updated-Response-Assessment-in-Neuro-Oncology-RANO-for-Gliomas",{"openalex":185,"title":187,"gsPaper":189,"pm":191,"doi":193},{"VOID":186},"W4390571345",{"EN":188},"Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas",{"VOID":190},"[\"6070115610593384484\"]",{"VOID":192},"38170429",{"VOID":194},"10.1007\u002Fs11910-023-01329-4","PUBLICATION","VERIFIED","2024-05-12T23:30:08.373+00:00","Auto Verify",[200],"EN","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11910-023-01329-4",[203,224],{"id":204,"sortIndex":23,"researcher":22,"roles":205,"affiliations":206,"properties":215,"displayName":219,"givenName":22,"familyName":22},"f4c204d5-c011-4f82-95d6-1c00274da3a3",[],[207],{"id":208,"sortIndex":23,"affiliation":209,"properties":22},"dc4d31eb-875b-40e9-8cf2-72a0cec6cee9",{"id":208,"createTime":22,"updateTime":22,"relativeEntities":210,"slug":22,"properties":211,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":214,"statistic":22},[],{"title":212},{"EN":213},"Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA",[],{"orcid":216,"title":218,"gsAuthor":220,"openalex":222},{"VOID":217},"https:\u002F\u002Forcid.org\u002F0000-0001-6109-7692",{"EN":219},"Gilbert Youssef",{"VOID":221},"[\"OZxEOXIAAAAJ\"]",{"VOID":223},"A5025462204",{"id":225,"sortIndex":146,"researcher":22,"roles":226,"affiliations":227,"properties":234,"displayName":238,"givenName":22,"familyName":22},"57f98e80-e3a8-4023-bef2-8abfaf01077c",[],[228],{"id":208,"sortIndex":23,"affiliation":229,"properties":22},{"id":208,"createTime":22,"updateTime":22,"relativeEntities":230,"slug":22,"properties":231,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":233,"statistic":22},[],{"title":232},{"EN":213},[],{"orcid":235,"title":237,"gsAuthor":239,"openalex":241},{"VOID":236},"https:\u002F\u002Forcid.org\u002F0000-0002-0774-7700",{"EN":238},"Patrick Y. Wen",{"VOID":240},"[\"ihvj-aIAAAAJ\"]",{"VOID":242},"A5021656597","ARTICLE",{"url":22,"publisher":245,"properties":291},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":246,"slug":10,"properties":247,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":251,"manageAffiliations":260,"indexDatabases":271,"url":22,"thumbnailPath":22,"statistic":286,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":248,"title":249,"eissn":250},{"VOID":15},{"EN":17},{"VOID":13},[252,256],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":253,"label":254,"description":255,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":257,"label":258,"description":259,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[261,266],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":262,"slug":22,"properties":263,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":265,"statistic":22},[],{"title":264},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":267,"slug":22,"properties":268,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":270,"statistic":22},[],{"title":269},{"EN":50},[],[272,279],{"id":54,"indexDatabase":273,"url":67,"indexYears":22,"academicFieldIds":278,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":274,"label":275,"description":276,"key":63,"publicationTags":277,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":280,"url":83,"indexYears":84,"academicFieldIds":285,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":281,"label":282,"description":283,"key":80,"publicationTags":284,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":287,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":288,"totalCitation":123,"totalCitationByYear":289,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":290,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"issue":292,"pages":294,"volume":296},{"VOID":293},"2",{"VOID":295},"17-25",{"VOID":297},"24",19,{"total":298,"publishYear":300,"statisticByYear":301},2024,{"2024":302,"2025":303,"2026":304},7,10,2,"2024-02-01","DONE_ANALYZE_CITATION","2026-07-23T19:49:57.308+00:00",[88,65],[310,314,318,322,326,330,334,338,342,346,350,354,358,362,366,370,374,378,382,386,390,394,398,402,406,410,414,418,422,426,430,434,438,442,446,450,454,458,462,466,470,474,478,482,486,490,494,498,502,506,510,514,518,522,526,530,534,538,542,546,550,554,558],{"id":22,"text":311,"url":22,"identifiers":312},"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro-Oncol. 2023;25(Supplement_4):iv1-99.",{"doi":313},"10.1093\u002Fneuonc\u002Fnoad149",{"id":22,"text":315,"url":22,"identifiers":316},"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.",{"doi":317},"10.1056\u002FNEJMoa043330",{"id":22,"text":319,"url":22,"identifiers":320},"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol. 2020;22(8):1073–113.",{"doi":321},"10.1093\u002Fneuonc\u002Fnoaa106",{"id":22,"text":323,"url":22,"identifiers":324},"Lamborn KR, Yung WKA, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol. 2008;10(2):162–70.",{"doi":325},"10.1215\u002F15228517-2007-062",{"id":22,"text":327,"url":22,"identifiers":328},"Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572–2572.",{"doi":329},"10.1200\u002FJCO.1999.17.8.2572",{"id":22,"text":331,"url":22,"identifiers":332},"Han K, Ren M, Wick W, Abrey L, Das A, Jin J, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-Oncol. 2014;16(5):696–706.",{"doi":333},"10.1093\u002Fneuonc\u002Fnot236",{"id":22,"text":335,"url":22,"identifiers":336},"Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, et al. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncol. 2023;25(6):1017–28.",{"doi":337},"10.1093\u002Fneuonc\u002Fnoad002",{"id":22,"text":339,"url":22,"identifiers":340},"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4733–40.",{"doi":341},"10.1200\u002FJCO.2008.19.8721",{"id":22,"text":343,"url":22,"identifiers":344},"Thiesse P, Ollivier L, Di Stefano-Louineau D, Négrier S, Savary J, Pignard K, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d’Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(12):3507–14.",{"doi":345},"10.1200\u002FJCO.1997.15.12.3507",{"id":22,"text":347,"url":22,"identifiers":348},"Provenzale JM, Ison C, Delong D. Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol. 2009;193(6):W515–522.",{"doi":349},"10.2214\u002FAJR.09.2615",{"id":22,"text":351,"url":22,"identifiers":352},"Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978–85.",{"doi":353},"10.3174\u002Fajnr.A2397",{"id":22,"text":355,"url":22,"identifiers":356},"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270–8.",{"doi":357},"10.1016\u002FS1470-2045(15)70057-4",{"id":22,"text":359,"url":22,"identifiers":360},"Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, et al. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018;19(1):e33-42.",{"doi":361},"10.1016\u002FS1470-2045(17)30692-7",{"id":22,"text":363,"url":22,"identifiers":364},"Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018;19(1):e20-32.",{"doi":365},"10.1016\u002FS1470-2045(17)30693-9",{"id":22,"text":367,"url":22,"identifiers":368},"Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017;19(4):484–92.",{"doi":369},"10.1093\u002Fneuonc\u002Fnow183",{"id":22,"text":371,"url":22,"identifiers":372},"Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, et al. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncol. 2018;20(1):13–23.",{"doi":373},"10.1093\u002Fneuonc\u002Fnox087",{"id":22,"text":375,"url":22,"identifiers":376},"Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47(3):329–35.",{"doi":377},"10.3171\u002Fjns.1977.47.3.0329",{"id":22,"text":379,"url":22,"identifiers":380},"Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology. 1988;38(5):724–6.",{"doi":381},"10.1212\u002FWNL.38.5.724",{"id":22,"text":383,"url":22,"identifiers":384},"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.",{"doi":385},"10.1002\u002F1097-0142(19810101)47:1\u003C207::AID-CNCR2820470134>3.0.CO;2-6",{"id":22,"text":387,"url":22,"identifiers":388},"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New Guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.",{"doi":389},"10.1093\u002Fjnci\u002F92.3.205",{"id":22,"text":391,"url":22,"identifiers":392},"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.",{"doi":393},"10.1016\u002Fj.ejca.2008.10.026",{"id":22,"text":395,"url":22,"identifiers":396},"Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.",{"doi":397},"10.1200\u002FJCO.1990.8.7.1277",{"id":22,"text":399,"url":22,"identifiers":400},"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72. This paper reports RANO-HGG, the most widely used response assessment criteria in high-grade gliomas.",{"doi":401},"10.1200\u002FJCO.2009.26.3541",{"id":22,"text":403,"url":22,"identifiers":404},"Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–87.",{"doi":405},"10.1212\u002F01.wnl.0000304121.57857.38",{"id":22,"text":407,"url":22,"identifiers":408},"Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152–60.",{"doi":409},"10.1016\u002FS1474-4422(08)70260-6",{"id":22,"text":411,"url":22,"identifiers":412},"Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684–92.",{"doi":413},"10.1212\u002FWNL.0000000000000402",{"id":22,"text":415,"url":22,"identifiers":416},"Hagiwara A, Schlossman J, Shabani S, Raymond C, Tatekawa H, Abrey LE, et al. Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation. J Neurooncol. 2022;159(3):509–18.",{"doi":417},"10.1007\u002Fs11060-022-04088-3",{"id":22,"text":419,"url":22,"identifiers":420},"Youssef G, Rahman R, Bay C, Wang W, Lim-Fat MJ, Arnaout O, et al. Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma. J Clin Oncol. 2023;41(17):3160–71. Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma.",{"doi":421},"10.1200\u002FJCO.22.01579",{"id":22,"text":423,"url":22,"identifiers":424},"Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35(21):2439–49.",{"doi":425},"10.1200\u002FJCO.2017.72.7511",{"id":22,"text":427,"url":22,"identifiers":428},"van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJB, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93.",{"doi":429},"10.1016\u002FS1470-2045(11)70057-2",{"id":22,"text":431,"url":22,"identifiers":432},"Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, et al. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncol. 2017;19(1):12–21.",{"doi":433},"10.1093\u002Fneuonc\u002Fnow190",{"id":22,"text":435,"url":22,"identifiers":436},"Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.",{"doi":437},"10.1056\u002FNEJMoa1003466",{"id":22,"text":439,"url":22,"identifiers":440},"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.",{"doi":441},"10.1056\u002FNEJMoa1305133",{"id":22,"text":443,"url":22,"identifiers":444},"Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.",{"doi":445},"10.1158\u002F1078-0432.CCR-09-1624",{"id":22,"text":447,"url":22,"identifiers":448},"Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(3):330–6.",{"doi":449},"10.1200\u002FJCO.2010.30.7744",{"id":22,"text":451,"url":22,"identifiers":452},"Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(19):2050–8.",{"doi":453},"10.1200\u002FJCO.2013.54.0526",{"id":22,"text":455,"url":22,"identifiers":456},"Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4722–9.",{"doi":457},"10.1200\u002FJCO.2010.28.6963",{"id":22,"text":459,"url":22,"identifiers":460},"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86.",{"doi":461},"10.1038\u002Fs41591-018-0337-7",{"id":22,"text":463,"url":22,"identifiers":464},"Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.",{"doi":465},"10.1016\u002FS1470-2045(15)00088-1",{"id":22,"text":467,"url":22,"identifiers":468},"Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14(2):307–20.",{"doi":469},"10.1007\u002Fs13311-016-0507-6",{"id":22,"text":471,"url":22,"identifiers":472},"Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, et al. Modified RANO, immunotherapy RANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma. Clin Cancer Res. 2021;27(14):3916–25.",{"doi":473},"10.1158\u002F1078-0432.CCR-21-0446",{"id":22,"text":475,"url":22,"identifiers":476},"Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, et al. The impact of T2\u002FFLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res. 2016;22(3):575–81.",{"doi":477},"10.1158\u002F1078-0432.CCR-14-3040",{"id":22,"text":479,"url":22,"identifiers":480},"Perez-Larraya JG, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, Houillier C, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro-Oncol. 2012;14(5):667–73.",{"doi":481},"10.1093\u002Fneuonc\u002Fnos070",{"id":22,"text":483,"url":22,"identifiers":484},"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23(8):1231–51. This paper reports on the most recent WHO classification of CNS tumors.",{"doi":485},"10.1093\u002Fneuonc\u002Fnoab106",{"id":22,"text":487,"url":22,"identifiers":488},"Arrillaga-Romany I, Kurz S, Tarapore R, Lu G, Sumrall A, Butowski N, et al. LTBK-05. clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients. Neuro-Oncol. 2021;23(Supplement_6):230.",{"doi":489},"10.1093\u002Fneuonc\u002Fnoab196.230",{"id":22,"text":491,"url":22,"identifiers":492},"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(33):5187–99. This paper presents the updated response assessment criteria that should be used in future clinical trials for gliomas.",{"doi":493},"10.1200\u002FJCO.23.01059",{"id":22,"text":495,"url":22,"identifiers":496},"Wen PY, van den Bent M, Vogelbaum MA, Chang SM. RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future. Neuro-Oncol. 2023;noad189. Online ahead of print.",{"doi":497},"10.1093\u002Fneuonc\u002Fnoad189",{"id":22,"text":499,"url":22,"identifiers":500},"Ellingson BM, Kim GHJ, Brown M, Lee J, Salamon N, Steelman L, et al. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: evidence from a phase I trial of ivosidenib. Neuro-Oncol. 2022;24(5):770–8. This paper highlights the importance of volumetric assessment in IDH-mutant nonenhancing gliomas.",{"doi":501},"10.1093\u002Fneuonc\u002Fnoab256",{"id":22,"text":503,"url":22,"identifiers":504},"Shah GD, Kesari S, Xu R, Batchelor TT, O’Neill AM, Hochberg FH, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas1. Neuro-Oncol. 2006;8(1):38–46.",{"doi":505},"10.1215\u002FS1522851705000529",{"id":22,"text":507,"url":22,"identifiers":508},"Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, et al. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. Neuro-Oncol. 2017;19(6):853–61.",{"doi":509},"10.1093\u002Fneuonc\u002Fnow311",{"id":22,"text":511,"url":22,"identifiers":512},"Wen P, Mellinghoff I, van den Bent M, Blumenthal D, Touat M, Peters K, et al. LTBK-06. impact of vorasidenib treatment on mutant IDH1 or IDH2 diffuse glioma tumor growth rate: results from the randomized, double-blind, phase 3 indigo study. Neuro-Oncol. 2023;25(Supplement_5):v310-1.",{"doi":513},"10.1093\u002Fneuonc\u002Fnoad179.1202",{"id":22,"text":515,"url":22,"identifiers":516},"Peng J, Kim DD, Patel JB, Zeng X, Huang J, Chang K, et al. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro-Oncol. 2022;24(2):289–99.",{"doi":517},"10.1093\u002Fneuonc\u002Fnoab151",{"id":22,"text":519,"url":22,"identifiers":520},"Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, et al. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro-Oncol. 2019;21(11):1412–22.",{"doi":521},"10.1093\u002Fneuonc\u002Fnoz106",{"id":22,"text":523,"url":22,"identifiers":524},"JayachandranPreetha C, Meredig H, Brugnara G, Mahmutoglu MA, Foltyn M, Isensee F, et al. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. Lancet Digit Health. 2021;3(12):e784–94.",{"doi":525},"10.1016\u002FS2589-7500(21)00205-3",{"id":22,"text":527,"url":22,"identifiers":528},"Kickingereder P, Isensee F, Tursunova I, Petersen J, Neuberger U, Bonekamp D, et al. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncol. 2019;20(5):728–40.",{"doi":529},"10.1016\u002FS1470-2045(19)30098-1",{"id":22,"text":531,"url":22,"identifiers":532},"Fu R, Szidonya L, Barajas RF, Ambady P, Varallyay C, Neuwelt EA. Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis. Neuro-Oncol Adv. 2022;4(1):vdac027.",{"doi":533},"10.1093\u002Fnoajnl\u002Fvdac027",{"id":22,"text":535,"url":22,"identifiers":536},"Galldiks N, Langen KJ. Amino acid PET in neuro-oncology: applications in the clinic. Expert Rev Anticancer Ther. 2017;17(5):395–7.",{"doi":537},"10.1080\u002F14737140.2017.1302799",{"id":22,"text":539,"url":22,"identifiers":540},"Soni N, Ora M, Mohindra N, Menda Y, Bathla G. Diagnostic performance of PET and perfusion-weighted Imaging in differentiating tumor recurrence or progression from radiation necrosis in posttreatment gliomas: a review of literature. AJNR Am J Neuroradiol. 2020;41(9):1550–57.",{"doi":541},"10.3174\u002Fajnr.A6685",{"id":22,"text":543,"url":22,"identifiers":544},"Strauss SB, Meng A, Ebani EJ, Chiang GC. Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis. Neuroimaging Clin N Am. 2021;31(1):103–20.",{"doi":545},"10.1016\u002Fj.nic.2020.09.010",{"id":22,"text":547,"url":22,"identifiers":548},"Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncol. 2017;19(5):625–35.",{"doi":549},"10.1093\u002Fneuonc\u002Fnox029",{"id":22,"text":551,"url":22,"identifiers":552},"Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncol. 2018;20(7):897–906.",{"doi":553},"10.1093\u002Fneuonc\u002Fnoy056",{"id":22,"text":555,"url":22,"identifiers":556},"Dirven L, Armstrong TS, Taphoorn MJB. Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. Neuro-Oncol Pract. 2015;2(1):2–5.",{"doi":557},"10.1093\u002Fnop\u002Fnpv002",{"id":22,"text":559,"url":22,"identifiers":560},"Vera E, Christ A, Grajkowska E, Briceno N, Choi A, Crandon SK, et al. Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: a retrospective cohort study. EClinicalMedicine. 2023;55: 101718.",{"doi":561},"10.1016\u002Fj.eclinm.2022.101718",false,{"id":564,"createTime":565,"updateTime":566,"relativeEntities":567,"slug":568,"properties":569,"entityType":195,"verifyStatus":196,"verifyTime":580,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":581,"fullTextUrl":22,"authors":582,"publicationType":243,"publisherRelationship":609,"citationCount":661,"citationInfo":662,"publishDate":668,"publishYear":663,"citationAnalyzeStatus":21,"lastCitationAnalyze":566,"indexDatabases":669,"openAccess":22,"references":22,"isForceReanalyzing":562},"3c131f72-534f-46f4-813d-0625c20fe408","2024-02-08T03:20:01.698+00:00","2026-07-23T16:43:32.778+00:00",[],"Dysautonomia-Hypermobility-Spectrum-Disorders-and-Mast-Cell-Activation-Syndrome-as-Migraine-Comorbidities",{"abstract":570,"title":572,"gsPaper":574,"references":576,"doi":578},{"EN":571},"Dysautonomia refers to the dysfunction of the autonomic nervous system and encompasses a wide variety of autonomic symptoms and disorders. The most common autonomic disorders are postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS), and orthostatic hypotension (OH), which may be encountered in clinical practice as part of a triad of dysautonomia, hypermobility spectrum disorders (HSD), and mast cell activation syndrome (MCAS). Migraine is one of the most common comorbidities of POTS, HSD, and MCAS; conversely, these conditions are also prevalent in patients with migraine, especially in those with multiple systemic symptoms, such as chronic dizziness, lightheadedness, orthostatic intolerance, joint pain, and allergic symptoms. Diagnostic criteria, pathophysiologic mechanisms, and therapeutic considerations in patients with migraine and comorbid dysautonomia, HSD, and MCAS are reviewed. Numerous studies indicate a significant overlap and shared pathophysiology in migraine, dysautonomia, HSD, and MCAS. In clinical setting, dysautonomia, HSD, and MCAS may present a diagnostic and therapeutic challenge in patients with migraine and require a high index of suspicion on the part of the neurologist. Diagnosis and treatment of these complex disorders in patients with migraine is essential to comprehensive patient-centric care, reduced symptom burden, and improved functional impairment secondary to both migraine and comorbidities.",{"EN":573},"Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities",{"VOID":575},"[\"3271138089852565026\"]",{"VOID":577},"Sheldon RS, Grubb BP II, Olshansky B, et al. Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;2015(12):e41-63.\nFreeman R, Weiling W, Axelrod F, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72.\nRobertson D. The Epidemic of Orthostatic Tachycardia and Orthostatic Intolerance. Am J Med Sci. 1999;317:75–7.\nKizilbash SJ, Ahrens SP, Bruce BK, et al. Adolescent fatigue, POTS, and recovery: a guide for clinicians. Curr Probl Pediatr Adolesc Health Care. 2014;44:108–33.\nLow PA, Sandroni P, Joyner M, et al. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20:352–8.\nBlitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Lupus. 2015;24:1364–9.\nKharraziha I, Axelsson J, Ricci F, et al. Serum activity against g protein-coupled receptors and severity of orthostatic symptoms in postural orthostatic tachycardia syndrome. J Am Heart Assoc. 2020;9:e015989.\nGunning WT 3rd, Kvale H, Kramer PM, et al. Postural orthostatic tachycardia syndrome is associated with elevated g-protein coupled receptor autoantibodies. J Am Heart Assoc. 2019;8:e013602.\nWatari M, Nakane S, Mukaino A, et al. Autoimmune postural orthostatic tachycardia syndrome. Ann Clin Transl Neurol. 2018;5:486–92.\nYu X, Li H, Murphy TA, Nuss Z, et al. Angiotensin II type 1 receptor autoantibodies in postural tachycardia syndrome. J Am Heart Assoc. 2018;7:e008351.\nThieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:308–13.\nLi H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc. 2014;3:e000755.\nPeroutka SJ. Migraine: a chronic sympathetic nervous system disorder. Headache. 2004;44:53–64.\nShechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology. 2002;58:422–7.\nGass JJ, Glaros AG. Autonomic dysregulation in headache patients. Appl Psychophysiol Biofeedback. 2013;38:257–63.\nVuković V, Plavec D, Galinović I, et al. Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine. Headache. 2007;47:1427–35.\nThijs RD, Kruit MC, van Buchem MA, et al. Syncope in migraine: the population-based CAMERA study. Neurology. 2006;66:1034–7.\nBlitshteyn S, Cheshire WP Jr. Syncope in migraine: the population-based CAMERA study. Neurology. 2007;68:878.\nThieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clinic Proc. 2007;82:308–13.\nUlas UH, Chelimsky TC, Chelimsky G, et al. Comorbid health conditions in women with syncope. Clin Auton Res. 2010;20:223–7.\nKhurana RK, Eisenberg L. Orthostatic and non-orthostatic headache in postural tachycardia syndrome. Cephalalgia. 2011;31:409–15.\nShaw BH, Stiles LE, Bourne K et al. The face of postural tachycardia syndrome – insights from a large cross-sectional online community-based survey. JIM. 2019;286:438–448. This study describes the most common comorbidities in a large cohort of patients with POTS.\nBlitshteyn S. Is postural orthostatic tachycardia syndrome (POTS) a central nervous system disorder? J Neurol. 2021;7:1–8. This review discusses the shared pathophysiology of POTS and migraine and outlines supporting evidence of both conditions being central nervous system disorders.\nGoadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97:553–622.\nAkerman S, Holland P, Goadsby P. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12:570–84.\nKruit MC, Thijs RD, Ferrari MD, et al. Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology. 2013;80:1958–65.\nRaj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127:2336–42.\nBlitshteyn S. Dietary sodium intake and migraine: is salt the answer? Headache. 2016;56:1210–1.\nPogoda JM, Gross NB, Arakaki X, et al. Severe headache or migraine history is inversely correlated with dietary sodium intake: NHANES 1999–2004. Headache. 2016;56:688–98.\nThijs RD, Brignole M, Falup-Pecurariu C, et al. Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. Clin Auton Res. 2021;31:369–84.\nGoodman BP. Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci. 2018;215:12–9.\nBlitshteyn S, Whiteson JH, Abramoff B, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022;14(10):1270–91.\nSchofield JR, Hassell KL. What you need to know about migraine in Hughes syndrome patients. Lupus. 2023;32:319–24.\nDel Pozzi AT, Enechukwu M, Blitshteyn S. Postural orthostatic tachycardia syndrome in primary care: diagnosis, treatment and a case of African-American man presenting with POTS. BMJ Case Rep. 2019;12:e229824.\nBourne KM, Sheldon RS, Hall J, et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77:285–96.\nRuzieh M, Baugh A, Dasa O, et al. Effects of intermittent intravenous saline infusions in patients with medication-refractory postural tachycardia syndrome. J Interv Card Electrophysiol. 2017;48:255–60.\nSilberstein SD, Yuan H, Najib U, et al. Non-invasive vagus nerve stimulation for primary headache: a clinical update. Cephalalgia. 2020;40:1370–84.\nDeng J, Li H, Guo Y, et al. Transcutaneous vagus nerve stimulation attenuates autoantibody-mediated cardiovagal dysfunction and inflammation in a rabbit model of postural tachycardia syndrome. J Interv Card Electrophysiol. 2022. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10840-022-01144-w\nMalfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8–26.\nBoris JR, Bernadzikowski T. Prevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndrome. Auton Neurosci. 2021;231:102770.\nPuledda F, Viganò A, Celletti C et al. A study of migraine characteristics in joint hypermobility syndrome a.k.a. Ehlers-Danlos syndrome, hypermobility type. Neurol Sci. 2015;36:1417–1424.\nZloof Y, Simchoni M, Derazne E et al. Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.Headache. 2023;63:934–941. This recent study found a significant association between HSD\u002FhEDS and active migraine in adolescents.\nMalhotra A, Pace A, Ruiz MT, et al. Headaches in hypermobility syndromes: A pain in the neck? Am J Med Genet A. 2020;182:2902–8.\nSahjwani D, Cameron M, Stelzik J. et al. Joint hypermobility and associated headache disability. CNS 2019, Abstract 101. CNS Annual Meeting, October 24–26, 2019, Charlotte, NC. 48th National Meeting of the Child Neurology Society 2019. Ann Neurol. 2019;86(Supplement 23):S1–S177. https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002F10.1002\u002Fana.25559.\nHenderson FC, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175C:195–211.\nIgharo D, Thiel JC, Rolke R, et al. Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndromes. Eur J Neurol. 2023;30:719–28.\nCazzato D, Castori M, Lombardi R, et al. Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes. Neurology. 2016;87:155–9.\nAfrin LB, Self S, Menk J, Lazarchick J. Characterization of Mast Cell Activation Syndrome. Am J Med Sci. 2017;353:207–15.\nAfrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global \"consensus-2\". Diagnosis (Berl) 2020;8:137–152. Diagnostic criteria for mast cell activation syndrome is discussed.\nZha K, Brook J, McLaughlin A, Blitshteyn S. Gluten-free diet in postural orthostatic tachycardia syndrome (POTS). Chronic Illn. 2023;19:409–17.\nBaun M, Pedersen MH, Olesen J, et al. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia. 2012;32:337–45.\nRamachandran R, Wang Z, Saavedra C, et al. Role of Toll-like receptor 4 signaling in mast cell-mediated migraine pain pathway. Mol Pain. 2019;15:1744806919867842.\nKilinc E, Torun IE, Baranoglu Kilinc Y. Meningeal mast cell-mediated mechanisms of cholinergic system modulation in neurogenic inflammation underlying the pathophysiology of migraine. Eur J Neurosci. 2022. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fejn.15888.\nWang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42:243–6.\nKohno R, Cannom DS, Olshansky B et al. Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association. J Am Heart Assoc. 2021;10:e021002. The authors found clinical and laboratory evidence of mast cell activation disorder in a majority of 69 patients with POTS who present with migraine, gastrointestinal, cutaneous, and allergic symptoms.\nNovak P, Giannetti MP, Weller E, et al. Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy. Ann Allergy Asthma Immunol. 2022;128:299–306.",{"VOID":579},"10.1007\u002Fs11910-023-01307-w","2024-08-30T12:55:59.228+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-023-01307-w",[583],{"id":584,"sortIndex":23,"researcher":22,"roles":585,"affiliations":587,"properties":604,"displayName":606,"givenName":22,"familyName":22},"e433b84d-531c-4325-b8e1-f65ce94cd7be",[586],"AUTHOR",[588,596],{"id":589,"sortIndex":23,"affiliation":590,"properties":22},"3c01d90a-7517-4a22-8ac5-31be25359945",{"id":589,"createTime":22,"updateTime":22,"relativeEntities":591,"slug":22,"properties":592,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":595,"statistic":22},[],{"title":593},{"VI":594},"Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, USA",[],{"id":597,"sortIndex":146,"affiliation":598,"properties":22},"4508e3ba-0d77-4bd4-bf4a-9a8481cdd3ca",{"id":597,"createTime":22,"updateTime":22,"relativeEntities":599,"slug":22,"properties":600,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":603,"statistic":22},[],{"title":601},{"VI":602},"Dysautonomia Clinic, Williamsville, USA",[],{"title":605,"gsAuthor":607},{"VI":606},"Svetlana Blitshteyn",{"VOID":608},"[\"l7aOFUAAAAAJ\"]",{"url":581,"publisher":610,"properties":656},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":611,"slug":10,"properties":612,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":616,"manageAffiliations":625,"indexDatabases":636,"url":22,"thumbnailPath":22,"statistic":651,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":613,"title":614,"eissn":615},{"VOID":15},{"EN":17},{"VOID":13},[617,621],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":618,"label":619,"description":620,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":622,"label":623,"description":624,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[626,631],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":627,"slug":22,"properties":628,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":630,"statistic":22},[],{"title":629},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":632,"slug":22,"properties":633,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":635,"statistic":22},[],{"title":634},{"EN":50},[],[637,644],{"id":54,"indexDatabase":638,"url":67,"indexYears":22,"academicFieldIds":643,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":639,"label":640,"description":641,"key":63,"publicationTags":642,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":645,"url":83,"indexYears":84,"academicFieldIds":650,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":646,"label":647,"description":648,"key":80,"publicationTags":649,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":652,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":653,"totalCitation":123,"totalCitationByYear":654,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":655,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":657,"volume":659},{"VOID":658},"769-776",{"VOID":660},"23",35,{"total":661,"publishYear":663,"statisticByYear":664},2023,{"2023":146,"2024":665,"2025":666,"2026":667},14,11,9,"2023-10-17",[88,65],{"id":671,"createTime":672,"updateTime":673,"relativeEntities":674,"slug":675,"properties":676,"entityType":195,"verifyStatus":196,"verifyTime":687,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":146,"primaryUrl":688,"fullTextUrl":22,"authors":689,"publicationType":243,"publisherRelationship":724,"citationCount":141,"citationInfo":776,"publishDate":784,"publishYear":777,"citationAnalyzeStatus":306,"lastCitationAnalyze":673,"indexDatabases":785,"openAccess":22,"references":22,"isForceReanalyzing":562},"583c2bba-ae81-4526-8123-2508b79a398d","2024-02-14T10:25:08.743+00:00","2026-07-17T15:58:43.467+00:00",[],"Modern-Medical-Management-of-Spinal-Cord-Injury",{"abstract":677,"title":679,"gsPaper":681,"references":683,"doi":685},{"EN":678},"Spinal cord injury (SCI) shows an incidence of 10.4–83 cases\u002Fmillion\u002Fyear globally and remains a significant source of morbidity and cost to society. Despite greater understanding of the pathophysiology of SCI, neuroprotective and regenerative approaches to treatment have had limited clinical utility to date. Here, we review the key components of supportive care that are thus the mainstay of therapy and that have improved outcomes for victims of acute SCI in recent decades. Current management strategies for acute SCI involve early surgical decompression and fixation, the use of vasopressor medications for mean arterial blood pressure (MAP) augmentation to improve spinal cord perfusion, and corticosteroids. We highlight recent literature supporting the role of norepinephrine in acute SCI management and also an emerging neurocritical care strategy that seeks to optimize spinal cord perfusion pressure with the assistance of invasive monitoring. This review will highlight key pathophysiologic principles and targets for current acute clinical treatments in SCI, which include early surgical decompression, MAP augmentation, and corticosteroids. We discuss anticipated future research in these areas and focus on potential risks inherent to these treatments.",{"EN":680},"Modern Medical Management of Spinal Cord Injury",{"VOID":682},"[\"14492439131818713813\"]",{"VOID":684},"Hawryluk GFM. Current status and future direction of management of spinal cord injury. In: Winn RH, editor. Youman's Neurological Surgery. 6th ed. Philadelphia: Elsevier; 2006. p. p. 2730–40.\nWyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord. 2006;44(9):523–9. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.sc.3101893.\nNational Spinal Cord Injury Statistical Center. National spinal cord injury statistical center. Birmingham, AL: Facts and Figures at a Glance. University of Alabama at Birmingham; 2016. https:\u002F\u002Fwww.nscisc.uab.edu\u002F. Accessed May 1, 2019\n• Fehlings MG, Tetreault LA, Wilson JR, Kwon BK, Burns AS, Martin AR, et al. A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope. Global Spine J. 2017;7(3 Suppl):84S–94S. https:\u002F\u002Fdoi.org\u002F10.1177\u002F2192568217703387 New guidelines from the AOSpine on the management of spinal cord injury.\nHadley MN, Walters BC. Introduction to the guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery. 2013;72(Suppl 2):5–16. https:\u002F\u002Fdoi.org\u002F10.1227\u002FNEU.0b013e3182773549.\n• Badhiwala JH, Ahuja CS, Fehlings MG. Time is spine: a review of translational advances in spinal cord injury. J Neurosurg Spine. 2018;30(1):1–18. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2018.9.SPINE18682 A comprehensive review of early surgical decompression and current clinical trials involving spinal cord injury.\nHadley MN, Walters BC, Grabb PA, Oyesiku NM, Przybylski GJ, Resnick DK, et al. Guidelines for the management of acute cervical spine and spinal cord injuries. Clin Neurosurg. 2002;49:407–98.\nHurlbert RJ, Hadley MN, Walters BC, Aarabi B, Dhall SS, Gelb DE, et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery. 2015;76(Suppl 1):S71–83. https:\u002F\u002Fdoi.org\u002F10.1227\u002F01.neu.0000462080.04196.f7.\nWalters BC, Hadley MN, Hurlbert RJ, Aarabi B, Dhall SS, Gelb DE, et al. Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery. 2013;60(CN_suppl_1):82–91. https:\u002F\u002Fdoi.org\u002F10.1227\u002F01.neu.0000430319.32247.7f.\nConsortium for Spinal Cord Medicine. Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med. 2008;31(4):403–79. https:\u002F\u002Fdoi.org\u002F10.1043\u002F1079-0268-31.4.408.\nFehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, et al. A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate. Global Spine J. 2017;7(3 Suppl):203S–11S. https:\u002F\u002Fdoi.org\u002F10.1177\u002F2192568217703085.\nO'Toole JE, Kaiser MG, Anderson PA, Arnold PM, Chi JH, Dailey AT, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the evaluation and treatment of patients with thoracolumbar spine trauma: executive summary. Neurosurgery. 2019;84(1):2–6. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fneuros\u002Fnyy394.\nAllen A. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column. JAMA. 1911;11(LVII):878–80.\nTator CH, Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg. 1997;86(3):483–92. https:\u002F\u002Fdoi.org\u002F10.3171\u002Fjns.1997.86.3.0483.\nPopovich PG. Immunological regulation of neuronal degeneration and regeneration in the injured spinal cord. Prog Brain Res. 2000;128:43–58. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS0079-6123(00)28006-0.\nJuurlink BH, Paterson PG. Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med. 1998;21(4):309–34.\nBeattie MS, Farooqui AA, Bresnahan JC. Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma. 2000;17(10):915–25. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2000.17.915.\nKarsy M, Hawryluk G. Pharmacologic management of acute spinal cord injury. Neurosurg Clin N Am. 2017;28(1):49–62. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.nec.2016.07.002.\nJug M, Kejzar N, Vesel M, Al Mawed S, Dobravec M, Herman S, et al. Neurological recovery after traumatic cervical spinal cord injury is superior if surgical decompression and instrumented fusion are performed within 8 hours versus 8 to 24 hours after injury: a single center experience. J Neurotrauma. 2015;32(18):1385–92. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2014.3767.\nWilson JR, Singh A, Craven C, Verrier MC, Drew B, Ahn H, et al. Early versus late surgery for traumatic spinal cord injury: the results of a prospective Canadian cohort study. Spinal Cord. 2012;50(11):840–3. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsc.2012.59.\nvan Middendorp JJ, Hosman AJ, Doi SA. The effects of the timing of spinal surgery after traumatic spinal cord injury: a systematic review and meta-analysis. J Neurotrauma. 2013;30(21):1781–94. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2013.2932.\nFehlings MG, Vaccaro A, Wilson JR, Singh A, D WC, Harrop JS, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS One. 2012;7(2):e32037. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0032037.\nGhajarzadeh M, Saberi H. Transportation mode and timing of spinal cord decompression and stabilization in patients with traumatic spinal cord injury in Iran. Spinal Cord. 2019;57(2):150–5. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41393-018-0189-5.\nWutte C, Klein B, Becker J, Mach O, Panzer S, Strowitzki M, et al. Earlier decompression (\u003C 8 hours) results in better neurological and functional outcome after traumatic thoracolumbar spinal cord injury. J Neurotrauma. 2019;36:2020–7. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2018.6146.\n• Holland CM, Mazur MD, Bisson EF, Schmidt MH, Dailey AT. Trends in patient care for traumatic spinal injuries in the United States: a national inpatient sample study of the correlations with patient outcomes from 2001 to 2012. Spine (Phila Pa 1976). 2017;42(24):1923–9. https:\u002F\u002Fdoi.org\u002F10.1097\u002FBRS.0000000000002246 Novel evaluation of assessing the impact of patient transfer after spinal cord injury or vertebral fracture on outcomes.\nThompson C, Feldman DE, Mac-Thiong JM. Surgical management of patients following traumatic spinal cord injury: identifying barriers to early surgery in a specialized spinal cord injury center. J Spinal Cord Med. 2018;41(2):142–8. https:\u002F\u002Fdoi.org\u002F10.1080\u002F10790268.2016.1165448.\nBurke JF, Yue JK, Ngwenya LB, Winkler EA, Talbott JF, Pan JZ, et al. Ultra-early (\u003C12 hours) surgery correlates with higher rate of American spinal injury association impairment scale conversion after cervical spinal cord injury. Neurosurgery. 2018. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fneuros\u002Fnyy537.\nTalbott JF, Huie JR, Ferguson AR, Bresnahan JC, Beattie MS, Dhall SS. MR imaging for assessing injury severity and prognosis in acute traumatic spinal cord injury. Radiol Clin N Am. 2019;57(2):319–39. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.rcl.2018.09.004.\nVale FL, Burns J, Jackson AB, Hadley MN. Combined medical and surgical treatment after acute spinal cord injury: results of a prospective pilot study to assess the merits of aggressive medical resuscitation and blood pressure management. J Neurosurg. 1997;87(2):239–46. https:\u002F\u002Fdoi.org\u002F10.3171\u002Fjns.1997.87.2.0239.\nLevi L, Wolf A, Belzberg H. Hemodynamic parameters in patients with acute cervical cord trauma: description, intervention, and prediction of outcome. Neurosurgery. 1993;33(6):1007–16 discussion 16-7.\nRyken TC, Hurlbert RJ, Hadley MN, Aarabi B, Dhall SS, Gelb DE, et al. The acute cardiopulmonary management of patients with cervical spinal cord injuries. Neurosurgery. 2013;72(Suppl 2):84–92. https:\u002F\u002Fdoi.org\u002F10.1227\u002FNEU.0b013e318276ee16.\nMartirosyan NL, Kalani MY, Bichard WD, Baaj AA, Gonzalez LF, Preul MC, et al. Cerebrospinal fluid drainage and induced hypertension improve spinal cord perfusion after acute spinal cord injury in pigs. Neurosurgery. 2015;76(4):461–8; discussion 8-9. https:\u002F\u002Fdoi.org\u002F10.1227\u002FNEU.0000000000000638.\nStreijger F, So K, Manouchehri N, Tigchelaar S, Lee JHT, Okon EB, et al. Changes in pressure, hemodynamics, and metabolism within the spinal cord during the first 7 days after injury using a porcine model. J Neurotrauma. 2017;34(24):3336–50. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2017.5034.\nStreijger F, So K, Manouchehri N, Gheorghe A, Okon EB, Chan RM, et al. A direct comparison between norepinephrine and phenylephrine for augmenting spinal cord perfusion in a porcine model of spinal cord injury. J Neurotrauma. 2018;35(12):1345–57. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2017.5285.\nHawryluk G, Whetstone W, Saigal R, Ferguson A, Talbott J, Bresnahan J, et al. Mean arterial blood pressure correlates with neurological recovery after human spinal cord injury: analysis of high frequency physiologic data. J Neurotrauma. 2015;32(24):1958–67. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2014.3778.\nCatapano JS, John Hawryluk GW, Whetstone W, Saigal R, Ferguson A, Talbott J, et al. Higher mean arterial pressure values correlate with neurologic improvement in patients with initially complete spinal cord injuries. World Neurosurg. 2016;96:72–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.wneu.2016.08.053.\nSaadeh YS, Smith BW, Joseph JR, Jaffer SY, Buckingham MJ, Oppenlander ME, et al. The impact of blood pressure management after spinal cord injury: a systematic review of the literature. Neurosurg Focus. 2017;43(5):E20. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2017.8.FOCUS17428.\nInoue T, Manley GT, Patel N, Whetstone WD. Medical and surgical management after spinal cord injury: vasopressor usage, early surgerys, and complications. J Neurotrauma. 2014;31(3):284–91. https:\u002F\u002Fdoi.org\u002F10.1089\u002Fneu.2013.3061.\nReaddy WJ, Whetstone WD, Ferguson AR, Talbott JF, Inoue T, Saigal R, et al. Complications and outcomes of vasopressor usage in acute traumatic central cord syndrome. J Neurosurg Spine. 2015;23(5):574–80. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2015.2.SPINE14746.\nAltaf F, Griesdale DE, Belanger L, Ritchie L, Markez J, Ailon T, et al. The differential effects of norepinephrine and dopamine on cerebrospinal fluid pressure and spinal cord perfusion pressure after acute human spinal cord injury. Spinal Cord. 2017;55(1):33–8. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsc.2016.79.\nYue JK, Tsolinas R, Burke JF, Deng H, Upadhyayula PS, Robinson CK, et al. Vasopressor support in managing acute spinal cord injury: a knowledge update. J Neurosurg Sci. 2017. https:\u002F\u002Fdoi.org\u002F10.23736\u002FS0390-5616.17.04003-6.\nBracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med. 1990;322(20):1405–11. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJM199005173222001.\nBracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg. 1985;63(5):704–13. https:\u002F\u002Fdoi.org\u002F10.3171\u002Fjns.1985.63.5.0704.\nBracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997;277(20):1597–604.\nJones CF, Newell RS, Lee JH, Cripton PA, Kwon BK. The pressure distribution of cerebrospinal fluid responds to residual compression and decompression in an animal model of acute spinal cord injury. Spine (Phila Pa 1976). 2012;37(23):E1422–31. https:\u002F\u002Fdoi.org\u002F10.1097\u002FBRS.0b013e31826ba7cd.\nSaadoun S, Bell BA, Verkman AS, Papadopoulos MC. Greatly improved neurological outcome after spinal cord compression injury in AQP4-deficient mice. Brain. 2008;131(Pt 4):1087–98. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawn014.\nOshio K, Binder DK, Yang B, Schecter S, Verkman AS, Manley GT. Expression of aquaporin water channels in mouse spinal cord. Neuroscience. 2004;127(3):685–93. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neuroscience.2004.03.016.\nSquair JW, Belanger LM, Tsang A, Ritchie L, Mac-Thiong JM, Parent S, et al. Spinal cord perfusion pressure predicts neurologic recovery in acute spinal cord injury. Neurology. 2017;89(16):1660–7. https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000004519.\nGrassner L, Winkler PA, Strowitzki M, Buhren V, Maier D, Bierschneider M. Increased intrathecal pressure after traumatic spinal cord injury: an illustrative case presentation and a review of the literature. Eur Spine J. 2017;26(1):20–5. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00586-016-4769-9.\nKwon BK, Curt A, Belanger LM, Bernardo A, Chan D, Markez JA, et al. Intrathecal pressure monitoring and cerebrospinal fluid drainage in acute spinal cord injury: a prospective randomized trial. J Neurosurg Spine. 2009;10(3):181–93. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2008.10.SPINE08217.",{"VOID":686},"10.1007\u002Fs11910-019-0984-1","2024-05-28T09:20:24.721+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-019-0984-1",[690,707],{"id":691,"sortIndex":23,"researcher":22,"roles":692,"affiliations":693,"properties":702,"displayName":704,"givenName":22,"familyName":22},"cc76891e-59f2-4d73-b6fa-69e21732a232",[586],[694],{"id":695,"sortIndex":23,"affiliation":696,"properties":22},"26eb138f-b2a2-4c73-b243-d32ae73ecdfb",{"id":695,"createTime":22,"updateTime":22,"relativeEntities":697,"slug":22,"properties":698,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":701,"statistic":22},[],{"title":699},{"VI":700},"Department of Neurosurgery, University of Utah, Salt Lake City, USA",[],{"title":703,"gsAuthor":705},{"VI":704},"Michael Karsy",{"VOID":706},"[\"Ym_oAUkAAAAJ\"]",{"id":708,"sortIndex":146,"researcher":22,"roles":709,"affiliations":710,"properties":719,"displayName":721,"givenName":22,"familyName":22},"d74a8f4b-64a7-42ba-b1dc-198f34251c94",[586],[711],{"id":712,"sortIndex":23,"affiliation":713,"properties":22},"7798c83d-5352-4b5e-9826-5816c94ef7e0",{"id":712,"createTime":22,"updateTime":22,"relativeEntities":714,"slug":22,"properties":715,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":718,"statistic":22},[],{"title":716},{"VI":717},"Section of Neurosurgery, GB1 - Health Sciences Centre, University of Manitoba, Winnipeg, Canada",[],{"title":720,"gsAuthor":722},{"VI":721},"Gregory Hawryluk",{"VOID":723},"[\"ZkqNbuUAAAAJ\"]",{"url":688,"publisher":725,"properties":771},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":726,"slug":10,"properties":727,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":731,"manageAffiliations":740,"indexDatabases":751,"url":22,"thumbnailPath":22,"statistic":766,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":728,"title":729,"eissn":730},{"VOID":15},{"EN":17},{"VOID":13},[732,736],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":733,"label":734,"description":735,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":737,"label":738,"description":739,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[741,746],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":742,"slug":22,"properties":743,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":745,"statistic":22},[],{"title":744},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":747,"slug":22,"properties":748,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":750,"statistic":22},[],{"title":749},{"EN":50},[],[752,759],{"id":54,"indexDatabase":753,"url":67,"indexYears":22,"academicFieldIds":758,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":754,"label":755,"description":756,"key":63,"publicationTags":757,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":760,"url":83,"indexYears":84,"academicFieldIds":765,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":761,"label":762,"description":763,"key":80,"publicationTags":764,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":767,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":768,"totalCitation":123,"totalCitationByYear":769,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":770,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":772,"volume":774},{"VOID":773},"1-7",{"VOID":775},"19",{"total":141,"publishYear":777,"statisticByYear":778},2019,{"2020":779,"2021":780,"2022":116,"2023":781,"2024":781,"2025":782,"2026":783},6,34,94,121,56,"2019-07-30",[88,65],{"id":787,"createTime":788,"updateTime":789,"relativeEntities":790,"slug":791,"properties":792,"entityType":195,"verifyStatus":196,"verifyTime":801,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":802,"fullTextUrl":22,"authors":803,"publicationType":243,"publisherRelationship":847,"citationCount":23,"citationInfo":899,"publishDate":902,"publishYear":900,"citationAnalyzeStatus":306,"lastCitationAnalyze":789,"indexDatabases":903,"openAccess":22,"references":904,"isForceReanalyzing":562},"bf97efa8-a98c-4507-8071-a6f50c69c7f7","2024-02-10T07:01:37.895+00:00","2026-07-15T11:02:50.061+00:00",[],"Cognitive-and-Neuropsychiatric-Impairment-in-Dystonia",{"abstract":793,"title":795,"gsPaper":797,"doi":799},{"EN":794},"To review recent literature evaluating psychiatric and cognitive symptoms in dystonia, the two non-motor symptom groups most frequently evaluated in dystonia research and recognised in clinical practice. Recent work has embedded clinical recognition of psychiatric symptoms in dystonia, with depressive and anxiety-related symptoms routinely observed to be the most common. Less explored symptoms, such as self-harm, suicidal ideation, and substance abuse, represent newer areas of investigation, with initial work suggesting higher rates than the background population. Investigation of cognitive function has provided less consistent results, both within individual dystonia subtypes and across the spectrum of dystonias, partly reflecting the heterogeneity in approaches to assessment. However, recent work indicates impairments of higher cognitive function, e.g. social cognition, and disrupted visual and auditory sensory processing. Dystonia demonstrates psychiatric and cognitive symptom heterogeneity, with further work needed to recognise endophenotypes and improve diagnostic accuracy, symptom recognition, and management.",{"EN":796},"Cognitive and Neuropsychiatric Impairment in Dystonia",{"VOID":798},"[\"3698610436599365014\"]",{"VOID":800},"10.1007\u002Fs11910-022-01233-3","2024-05-03T21:46:47.438+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-022-01233-3",[804,819,834],{"id":805,"sortIndex":23,"researcher":22,"roles":806,"affiliations":807,"properties":816,"displayName":818,"givenName":22,"familyName":22},"2ddfe45e-32d7-4edb-85f5-09885bbe669a",[586],[808],{"id":809,"sortIndex":23,"affiliation":810,"properties":22},"c3cf9189-8cf7-468f-8d5d-98ec0ec66a80",{"id":809,"createTime":22,"updateTime":22,"relativeEntities":811,"slug":22,"properties":812,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":815,"statistic":22},[],{"title":813},{"VI":814},"Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK",[],{"title":817},{"VI":818},"Grace A. Bailey",{"id":820,"sortIndex":146,"researcher":22,"roles":821,"affiliations":822,"properties":831,"displayName":833,"givenName":22,"familyName":22},"748bb44c-00d5-472e-9df7-27eebac2dd8e",[586],[823],{"id":824,"sortIndex":23,"affiliation":825,"properties":22},"3959b088-7184-4d5b-b247-987c1503c58b",{"id":824,"createTime":22,"updateTime":22,"relativeEntities":826,"slug":22,"properties":827,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":830,"statistic":22},[],{"title":828},{"VI":829},"School of Medicine, Cardiff University, Cardiff, UK",[],{"title":832},{"VI":833},"Eva Martin",{"id":835,"sortIndex":304,"researcher":22,"roles":836,"affiliations":837,"properties":844,"displayName":846,"givenName":22,"familyName":22},"5a8ef00f-ef2e-4eb3-bbf8-8200151d246e",[586],[838],{"id":809,"sortIndex":23,"affiliation":839,"properties":22},{"id":809,"createTime":22,"updateTime":22,"relativeEntities":840,"slug":22,"properties":841,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":843,"statistic":22},[],{"title":842},{"VI":814},[],{"title":845},{"VI":846},"Kathryn J. Peall",{"url":802,"publisher":848,"properties":894},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":849,"slug":10,"properties":850,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":854,"manageAffiliations":863,"indexDatabases":874,"url":22,"thumbnailPath":22,"statistic":889,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":851,"title":852,"eissn":853},{"VOID":15},{"EN":17},{"VOID":13},[855,859],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":856,"label":857,"description":858,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":860,"label":861,"description":862,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[864,869],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":865,"slug":22,"properties":866,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":868,"statistic":22},[],{"title":867},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":870,"slug":22,"properties":871,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":873,"statistic":22},[],{"title":872},{"EN":50},[],[875,882],{"id":54,"indexDatabase":876,"url":67,"indexYears":22,"academicFieldIds":881,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":877,"label":878,"description":879,"key":63,"publicationTags":880,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":883,"url":83,"indexYears":84,"academicFieldIds":888,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":884,"label":885,"description":886,"key":80,"publicationTags":887,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":890,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":891,"totalCitation":123,"totalCitationByYear":892,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":893,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":895,"volume":897},{"VOID":896},"699-708",{"VOID":898},"22",{"total":23,"publishYear":900,"statisticByYear":901},2022,{},"2022-10-06",[88,65],[905,914,922,930,935,944,950,958,964,972,980,988,996,1001,1009,1017,1025,1033,1041,1047,1056,1065,1071,1077,1085,1091,1094,1097,1106,1115,1123,1132,1139,1145,1151,1160,1168,1176,1185,1194,1202,1208,1214,1221,1230,1236,1242,1248,1253,1258,1267,1270,1278,1286,1294,1299,1305,1311,1317,1326,1335,1341,1349,1358,1365,1370,1378,1384,1390,1398,1401,1410,1416,1424],{"id":22,"text":906,"url":907,"identifiers":908},"Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VSC, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–73. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.25475.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.25475",{"mag":909,"pmc":910,"openalex":911,"pm":912,"doi":913},"2131134103","3729880","W2131134103","23649720","10.1002\u002Fmds.25475",{"id":22,"text":915,"url":916,"identifiers":917},"Bailey GA, Rawlings A, Torabi F, Pickrell WO, Peall KJ. Adult-onset idiopathic dystonia: a national data-linkage study to determine epidemiological, social deprivation and mortality characteristics. Eur J Neurol. 2021. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.15114.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.15114",{"mag":918,"openalex":919,"pm":920,"doi":921},"3200835440","W3200835440","34543508","10.1111\u002Fene.15114",{"id":22,"text":923,"url":924,"identifiers":925},"Han V, Skorvanek M, Smit M, Turcanova Koprusakova M, Hoekstra T, van Dijk JP, et al. Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. Acta Neurol Scand. 2020:ane.13304. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fane.13304.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fane.13304",{"mag":926,"openalex":927,"pm":928,"doi":929},"3037214045","W3037214045","32579704","10.1111\u002Fane.13304",{"id":22,"text":931,"url":932,"identifiers":933},"Timmers ER, Smit M, Kuiper A, Bartels AL, van der Veen S, van der Stouwe AMM, et al. Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes. Park Relat Disord. 2019;69:85–90. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2019.10.015.","http:\u002F\u002Fdx.doi.org\u002F10.1016\u002Fj.parkreldis.2019.10.015",{"doi":934},"10.1016\u002Fj.parkreldis.2019.10.015",{"id":22,"text":936,"url":937,"identifiers":938},"Wadon ME, Bailey GA, Yilmaz Z, Hubbard E, AlSaeed M, Robinson A, et al. Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. Brain Behav 2021;11. https:\u002F\u002Fdoi.org\u002F10.1002\u002FBRB3.2292.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fbrb3.2292",{"mag":939,"pmc":940,"openalex":941,"pm":942,"doi":943},"3186692258","8413761","W3186692258","34291595","10.1002\u002Fbrb3.2292",{"id":945,"text":946,"url":947,"identifiers":948},"f4f18a7a-868a-40aa-8929-8951f2e877a8","Peall KJ, Lorentzos MS, Heyman I, Tijssen MAJ, Owen MJ, Dale RC, et al. A review of psychiatric co-morbidity described in genetic and immune mediated movement disorders. Neurosci Biobehav Rev. 2017;80:23–35. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2017.05.014.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0149763417301501",{"doi":949},"10.1016\u002Fj.neubiorev.2017.05.014",{"id":22,"text":951,"url":952,"identifiers":953},"Martino D, Brander G, Svenningsson P, Larsson H, de la Cruz LF. Association and familial coaggregation of idiopathic dystonia with psychiatric outcomes. Mov Disord. 2020;35:2270–8. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.28257. Evidence for potential heritability of psychiatric symptoms in dystonia.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.28257",{"mag":954,"openalex":955,"pm":956,"doi":957},"3087762858","W3087762858","32940390","10.1002\u002Fmds.28257",{"id":959,"text":960,"url":961,"identifiers":962},"c4edadcc-2d21-48c1-8a7e-0df2e2151b1c","Ceylan D, Erer S, Zarifoğlu M, Türkeş N, Özkaya G. Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci. 2019;40:725–31. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10072-019-3719-9.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10072-019-3719-9",{"doi":963},"10.1007\u002Fs10072-019-3719-9",{"id":22,"text":965,"url":966,"identifiers":967},"Romano R, Bertolino A, Gigante A, Martino D, Livrea P, Defazio G. Impaired cognitive functions in adult-onset primary cranial cervical dystonia. Park Relat Disord. 2014;20:162–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2013.10.008.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2013.10.008",{"mag":968,"openalex":969,"pm":970,"doi":971},"1978621236","W1978621236","24161376","10.1016\u002Fj.parkreldis.2013.10.008",{"id":22,"text":973,"url":974,"identifiers":975},"Allam N, Frank JE, Pereira C, Tomaz C. Sustained attention in cranial dystonia patients treated with botulinum toxin. Acta Neurol Scand. 2007;116:196–200. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1600-0404.2007.00862.x.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1600-0404.2007.00862.x",{"mag":976,"openalex":977,"pm":978,"doi":979},"2072260091","W2072260091","17714334","10.1111\u002Fj.1600-0404.2007.00862.x",{"id":22,"text":981,"url":982,"identifiers":983},"Alemán GG, de Erausquin GA, Micheli F. Cognitive disturbances in primary blepharospasm. Mov Disord. 2009;24:2112–20. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.22736.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.22736",{"mag":984,"openalex":985,"pm":986,"doi":987},"2069199574","W2069199574","19705473","10.1002\u002Fmds.22736",{"id":22,"text":989,"url":990,"identifiers":991},"Scott RB, Gregory R, Wilson J, Banks S, Turner A, Parkin S, et al. Executive cognitive deficits in primary dystonia. Mov Disord. 2003;18:539–50. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.10399.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.10399",{"mag":992,"openalex":993,"pm":994,"doi":995},"2034045088","W2034045088","12722168","10.1002\u002Fmds.10399",{"id":22,"text":997,"url":998,"identifiers":999},"Foley JA, Saman Vinke R, Limousin P, Cipolotti L. Examining the impact of motor symptoms on cognitive function in isolated dystonia. Cogn Behav Neurol. 2017;30(1):16–22. https:\u002F\u002Fdoi.org\u002F10.1097\u002FWNN.0000000000000117.","https:\u002F\u002Fdoi.org\u002F10.1097\u002FWNN.0000000000000117",{"doi":1000},"10.1097\u002FWNN.0000000000000117",{"id":22,"text":1002,"url":1003,"identifiers":1004},"Lange F, Seer C, Dengler R, Dressler D, Kopp B. Cognitive flexibility in primary dystonia. J Int Neuropsychol Soc. 2016;22:662–70. https:\u002F\u002Fdoi.org\u002F10.1017\u002FS135561771600045X.","https:\u002F\u002Fdoi.org\u002F10.1017\u002Fs135561771600045x",{"mag":1005,"openalex":1006,"pm":1007,"doi":1008},"2464372810","W2464372810","27333537","10.1017\u002Fs135561771600045x",{"id":22,"text":1010,"url":1011,"identifiers":1012},"Jahanshahi M, Rowe J, Fuller R. Cognitive executive function in dystonia. Mov Disord. 2003;18:1470–81. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.10595.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.10595",{"mag":1013,"openalex":1014,"pm":1015,"doi":1016},"2157802721","W2157802721","14673884","10.1002\u002Fmds.10595",{"id":22,"text":1018,"url":1019,"identifiers":1020},"Jahanshahi M, Torkamani M. The cognitive features of idiopathic and DYT1 dystonia. Mov Disord. 2017;32:1348–55. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27048.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27048",{"mag":1021,"openalex":1022,"pm":1023,"doi":1024},"2680974544","W2680974544","28627117","10.1002\u002Fmds.27048",{"id":22,"text":1026,"url":1027,"identifiers":1028},"Van Tricht MJ, Dreissen YEM, Cath D, Dijk JM, Contarino MF, Van Der Salm SM, et al. Cognition and psychopathology in myoclonus-dystonia. J Neurol Neurosurg Psychiatry. 2012;83:814–20. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjnnp-2011-301386.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjnnp-2011-301386",{"mag":1029,"openalex":1030,"pm":1031,"doi":1032},"2113827147","W2113827147","22626943","10.1136\u002Fjnnp-2011-301386",{"id":22,"text":1034,"url":1035,"identifiers":1036},"Fabbrini G, Berardelli I, Moretti G, Pasquini M, Colosimo C, Berardelli A. Nonmotor symptoms in adult-onset focal dystonia: psychiatric abnormalities. Mov Disord. 2011;26:1764–5. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.23668.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.23668",{"mag":1037,"openalex":1038,"pm":1039,"doi":1040},"1980812605","W1980812605","21442656","10.1002\u002Fmds.23668",{"id":1042,"text":1043,"url":1044,"identifiers":1045},"c0a2826c-865e-400d-ac74-c237e250e059","Berardelli I, Ferrazzano G, Pasquini M, Biondi M, Berardelli A, Fabbrini G. Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Res. 2015;229:583–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.psychres.2015.07.076.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165178115005363",{"doi":1046},"10.1016\u002Fj.psychres.2015.07.076",{"id":22,"text":1048,"url":1049,"identifiers":1050},"Li S, Wang L, Yang Y, Qiao L, Zhang D, Wan X. Non-motor symptoms in Chinese patients with isolated generalized dystonia: a case–control study. Front Neurol. 2020;11:209. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2020.00209.","https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2020.00209",{"mag":1051,"pmc":1052,"openalex":1053,"pm":1054,"doi":1055},"3015971981","7156613","W3015971981","32322234","10.3389\u002Ffneur.2020.00209",{"id":22,"text":1057,"url":1058,"identifiers":1059},"Peall KJ, Smith DJ, Kurian MA, Wardle M, Waite AJ, Hedderly T, et al. SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain. 2013;136:294–303. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Faws308.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Faws308",{"mag":1060,"pmc":1061,"openalex":1062,"pm":1063,"doi":1064},"2032434406","4052887","W2032434406","23365103","10.1093\u002Fbrain\u002Faws308",{"id":1066,"text":1067,"url":1068,"identifiers":1069},"f22b4051-4064-4604-8171-2545a3c9f31c","Berman BD, Junker J, Shelton E, Sillau SH, Jinnah HA, Perlmutter JS, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjnnp-2016-315461.","https:\u002F\u002Fjnnp.bmj.com\u002Flookup\u002Fdoi\u002F10.1136\u002Fjnnp-2016-315461",{"doi":1070},"10.1136\u002Fjnnp-2016-315461",{"id":1072,"text":1073,"url":1074,"identifiers":1075},"4c68646b-0035-4279-8000-0006b275d4fa","Bailey, Grace A.; Rawlings, Anna; Torabi, Fatemeh; Pickrell, W Owen; Peall KJ. Longitudinal analysis of the relationship between motor and psychiatric symptoms in idiopathic dystonia. Eur J Neurol 2022;August. Population-level evidence for onset of psychiatric symptoms prior to dystonia motor diagnosis","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10440-022-00541-7",{"doi":1076},"10.1007\u002Fs10440-022-00541-7",{"id":22,"text":1078,"url":1079,"identifiers":1080},"Conte A, Berardelli I, Ferrazzano G, Pasquini M, Berardelli A, Fabbrini G. Non-motor symptoms in patients with adult-onset focal dystonia: sensory and psychiatric disturbances. Park Relat Disord. 2016;22:S111–4. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2015.09.001.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2015.09.001",{"mag":1081,"openalex":1082,"pm":1083,"doi":1084},"1267576194","W1267576194","26360238","10.1016\u002Fj.parkreldis.2015.09.001",{"id":1086,"text":1087,"url":1088,"identifiers":1089},"e885d2b7-31bb-4049-b5e2-b76b623f8b07","Brüggemann N, Stiller S, Tadic V, Kasten M, Münchau A, Graf J, et al. Non-motor phenotype of dopa-responsive dystonia and quality of life assessment. Park Relat Disord. 2014;20:428–31. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2013.12.014.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1353802014000029",{"doi":1090},"10.1016\u002Fj.parkreldis.2013.12.014",{"id":22,"text":1092,"url":1058,"identifiers":1093},"Peall KJ, Smith DJ, Kurian MA, Wardle M, Waite AJ, Hedderly T, et al. SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain 2013;136. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Faws308.",{"mag":1060,"pmc":1061,"openalex":1062,"pm":1063,"doi":1064},{"id":1072,"text":1095,"url":1074,"identifiers":1096},"Russell C Dale, Julian J Nasti GBP. Familial 7q21.3 microdeletion involving epsilon-sarcoglycan causing myoclonus dystonia, cognitive impairment, and psychosis. Mov Disord 2011;26:1774–5",{"doi":1076},{"id":22,"text":1098,"url":1099,"identifiers":1100},"Mencacci NE, Reynolds R, Ruiz SG, Vandrovcova J, Forabosco P, Sánchez-Ferrer A, et al. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain. 2020;143:2771–87. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawaa217. Evidence for enrichment of psychiatric risk variants in dystonic disorders.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawaa217",{"mag":1101,"pmc":1102,"openalex":1103,"pm":1104,"doi":1105},"3083759085","8354373","W3083759085","32889528","10.1093\u002Fbrain\u002Fawaa217",{"id":22,"text":1107,"url":1108,"identifiers":1109},"Worthley A, Simonyan K. Suicidal ideations and attempts in patients with isolated dystonia. Neurology. 2021;96:e1551-60. https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000011596. First study of self-harm and suicidal ideation in dystonia.","https:\u002F\u002Fdoi.org\u002F10.1212\u002Fwnl.0000000000011596",{"mag":1110,"pmc":1111,"openalex":1112,"pm":1113,"doi":1114},"3122147650","8032380","W3122147650","33504639","10.1212\u002Fwnl.0000000000011596",{"id":22,"text":1116,"url":1117,"identifiers":1118},"Medina Escobar A, Pringsheim T, Goodarzi Z, Martino D. The prevalence of depression in adult onset idiopathic dystonia: systematic review and metaanalysis. Neurosci Biobehav Rev. 2021;125:221–30. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2021.02.036. Meta-analysis of depression point prevalence in dystonia.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2021.02.036",{"mag":1119,"openalex":1120,"pm":1121,"doi":1122},"3133721881","W3133721881","33662441","10.1016\u002Fj.neubiorev.2021.02.036",{"id":22,"text":1124,"url":1125,"identifiers":1126},"Liu J, Li L, Chen L, Liu R, Jiang Y, Fang J, et al. Grey matter changes in Meige syndrome: a voxel-based morphology analysis. Sci Rep. 2020;10:1–8. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-020-71479-9.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-020-71479-9",{"mag":1127,"pmc":1128,"openalex":1129,"pm":1130,"doi":1131},"3082188192","7471903","W3082188192","32884000","10.1038\u002Fs41598-020-71479-9",{"id":22,"text":1133,"url":1134,"identifiers":1135},"Timmers ER, Peretti DE, Smit M, de Jong BM, Dierckx RAJO, Kuiper A, et al. Serotonergic system in vivo with [11C]DASB PET scans in GTP-cyclohydrolase deficient dopa-responsive dystonia patients. Sci Rep. 2022;12:1–9. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-022-10067-5.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-022-10067-5",{"openalex":1136,"pm":1137,"doi":1138},"W4224012946","35428769","10.1038\u002Fs41598-022-10067-5",{"id":1140,"text":1141,"url":1142,"identifiers":1143},"a7b03a5f-b433-4534-8b86-6f02ea0adb25","Timmers ER, van Faassen M, Smit M, Kuiper A, Hof IH, Kema IP, et al. Dopaminergic and serotonergic alterations in plasma in three groups of dystonia patients. Park Relat Disord. 2021;91:48–54. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2021.08.019.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1353802021003138",{"doi":1144},"10.1016\u002Fj.parkreldis.2021.08.019",{"id":1146,"text":1147,"url":1148,"identifiers":1149},"6a35f04a-6ca4-4ca5-9999-808e843074f1","Alves Júnior AC, Daker MV, Machado AMC, Luna AS, Valladares Neto DC, Valadares ER. Neuropsychiatric and sleep study in autosomal dominant dopa-responsive dystonia. Mol Genet Metab Reports. 2022;31:100870. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ymgmr.2022.100870.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2214426922000301",{"doi":1150},"10.1016\u002Fj.ymgmr.2022.100870",{"id":22,"text":1152,"url":1153,"identifiers":1154},"Paracka L, Wegner F, Escher C, Klietz M, de Zwaan M, Abdallat M, et al. Body concept and quality of life in patients with idiopathic dystonia. Brain Sci. 2020;10:1–11. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fbrainsci10080488.","https:\u002F\u002Fdoi.org\u002F10.3390\u002Fbrainsci10080488",{"mag":1155,"pmc":1156,"openalex":1157,"pm":1158,"doi":1159},"3045914933","7464975","W3045914933","32731476","10.3390\u002Fbrainsci10080488",{"id":22,"text":1161,"url":1162,"identifiers":1163},"Ellement B, Jasaui Y, Kathol K, Nosratmirshekarlou E, Pringsheim T, Sarna J, et al. Social cognition in cervical dystonia: phenotype and relationship to anxiety and depression. Eur J Neurol 2020:ene.14508. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.14508. Key evaluation of social cognition in dystonia, and its links to mood disorders.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.14508",{"mag":1164,"openalex":1165,"pm":1166,"doi":1167},"3083772967","W3083772967","32896024","10.1111\u002Fene.14508",{"id":22,"text":1169,"url":1170,"identifiers":1171},"Schneider J, Scholz DS, Altenmüller E. Impact of psychic traumatization on the development of musicians dystonia six exploratory case studies. Med Probl Perform Art. 2021;36:1–9. https:\u002F\u002Fdoi.org\u002F10.21091\u002Fmppa.2021.1001.","https:\u002F\u002Fdoi.org\u002F10.21091\u002Fmppa.2021.1001",{"mag":1172,"openalex":1173,"pm":1174,"doi":1175},"3134200074","W3134200074","33647091","10.21091\u002Fmppa.2021.1001",{"id":22,"text":1177,"url":1178,"identifiers":1179},"Macerollo A, Edwards MJ, Huang HC, Lu MK, Chen HJ, Tsai CH, et al. Peripheral trauma and risk of dystonia: what are the evidences and potential co-risk factors from a population insurance database? PLoS One 2019;14. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0216772.","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0216772",{"mag":1180,"pmc":1181,"openalex":1182,"pm":1183,"doi":1184},"2944714050","6510449","W2944714050","31075156","10.1371\u002Fjournal.pone.0216772",{"id":22,"text":1186,"url":1187,"identifiers":1188},"Ndukwe I, O’Riordan S, Walsh CB, Hutchinson M. Mood disorder affects age at onset of adult-onset cervical dystonia. Clin Park Relat Disord 2020;3. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prdoa.2020.100049.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prdoa.2020.100049",{"mag":1189,"pmc":1190,"openalex":1191,"pm":1192,"doi":1193},"3010838730","8298762","W3010838730","34316634","10.1016\u002Fj.prdoa.2020.100049",{"id":22,"text":1195,"url":1196,"identifiers":1197},"LaHue SC, Albers K, Goldman S, Lo RY, Gu Z, Leimpeter A, et al. Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord. 2020;35:450–6. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27927.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27927",{"mag":1198,"openalex":1199,"pm":1200,"doi":1201},"2991210498","W2991210498","31774238","10.1002\u002Fmds.27927",{"id":1203,"text":1204,"url":1205,"identifiers":1206},"ec850851-b344-4181-8054-ba4ffead036a","Steinlechner S, Jabusch HC, Altenmüller E, Borngräber F, Hagenah J, Klein C, et al. Personality profiles are different in musician’s dystonia and other isolated focal dystonias. Psychiatry Res. 2018;266:26–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.psychres.2018.05.017.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165178117322989",{"doi":1207},"10.1016\u002Fj.psychres.2018.05.017",{"id":1209,"text":1210,"url":1211,"identifiers":1212},"73a4d27f-fbbe-4cd9-bda7-eaed956f5d74","Mahajan A, Jankovic J, Marsh L, Patel A, Jinnah HA, Comella C, et al. Cervical dystonia and substance abuse. J Neurol. 2018;265:970–5. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00415-018-8840-9.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs00415-018-8840-9",{"doi":1213},"10.1007\u002Fs00415-018-8840-9",{"id":22,"text":1215,"url":1216,"identifiers":1217},"Wadon ME, Fenner E, Kendall KM, Bailey GA, Sandor C, Rees E, et al. Clinical and genotypic analysis in determining dystonia non-motor phenotypic heterogeneity: a UK Biobank study. J Neurol. 2022. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00415-022-11307-4. Demonstration of phenotypic heterogeneity within individual dystonia diagnostic groups.","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00415-022-11307-4",{"openalex":1218,"pm":1219,"doi":1220},"W4289754815","35925398","10.1007\u002Fs00415-022-11307-4",{"id":22,"text":1222,"url":1223,"identifiers":1224},"Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2012;135:1668–81. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawr224.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawr224",{"mag":1225,"pmc":1226,"openalex":1227,"pm":1228,"doi":1229},"2082776435","3359748","W2082776435","21933808","10.1093\u002Fbrain\u002Fawr224",{"id":1231,"text":1232,"url":1233,"identifiers":1234},"823bca2a-d50f-4007-9ce4-7cabf4fed9e6","Ospina-García N, Escobar-Barrios M, Rodríguez-Violante M, Benitez-Valenzuela J, Cervantes-Arriaga A. Neuropsychiatric profile of patients with craniocervical dystonia: a case-control study. Clin Neurol Neurosurg 2020;193. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.clineuro.2020.105794.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0303846720301372",{"doi":1235},"10.1016\u002Fj.clineuro.2020.105794",{"id":1237,"text":1238,"url":1239,"identifiers":1240},"3a56e99e-f673-4056-96ed-2f0f748baa8f","Niccolai L, Aita SL, Walker HC, Martin RC, Clay OJ, Crowe M, et al. An examination of the neurocognitive profile and base rate of performance impairment in primary dystonia. J Clin Neurosci. 2020;74:1–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jocn.2019.12.050.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0967586819321575",{"doi":1241},"10.1016\u002Fj.jocn.2019.12.050",{"id":1243,"text":1244,"url":1245,"identifiers":1246},"26fc6272-398c-4a05-bea2-3988e76204a1","Maggi G, D’Iorio A, Mautone G, Peluso S, Manganelli F, Dubbioso R, et al. Cognitive correlates of prospective memory in dystonia. Park Relat Disord. 2019;66:51–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2019.06.027.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1353802019302901",{"doi":1247},"10.1016\u002Fj.parkreldis.2019.06.027",{"id":22,"text":1249,"url":1250,"identifiers":1251},"Tinazzi M, Priori A, Bertolasi L, Frasson E, Mauguière F, Fiaschi A. Abnormal central integration of a dual somatosensory input in dystonia. Evidence for sensory overflow Brain. 2000;123:42–50. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002F123.1.42.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002F123.1.42",{"doi":1252},"10.1093\u002Fbrain\u002F123.1.42",{"id":22,"text":1254,"url":1255,"identifiers":1256},"Molina JA, Sáinz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Ortí-Pareja M, et al. Disturbed sensorimotor processing during control of precision grip in patients with writer’s cramp. Mov Disord. 2000;15:965–72. https:\u002F\u002Fdoi.org\u002F10.1002\u002F1531-8257(200009)15:5%3c965::AID-MDS1030%3e3.0.CO;2-0.","http:\u002F\u002Fdx.doi.org\u002F10.1002\u002F1531-8257(200009)15:5\u003C965::aid-mds1030>3.0.co;2-0",{"doi":1257},"10.1002\u002F1531-8257(200009)15:5\u003C965::aid-mds1030>3.0.co;2-0",{"id":22,"text":1259,"url":1260,"identifiers":1261},"Chillemi G, Calamuneri A, Morgante F, Terranova C, Rizzo V, Girlanda P, et al. Spatial and temporal high processing of visual and auditory stimuli in cervical dystonia. Front Neurol. 2017;8:1–8. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2017.00066.","https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2017.00066",{"mag":1262,"pmc":1263,"openalex":1264,"pm":1265,"doi":1266},"2593406904","5334342","W2593406904","28316586","10.3389\u002Ffneur.2017.00066",{"id":1072,"text":1268,"url":1074,"identifiers":1269},"Bastos MSC, Nickel R, Carlo CHF, Camargo HAGT. Patients with cervical dystnia demonstrated decreased cognitive abilities and visual planning compared to controls. Mov Disord Clin Pract. 2021;8:904–10.",{"doi":1076},{"id":22,"text":1271,"url":1272,"identifiers":1273},"Chillemi G, Formica C, Salatino A, Calamuneri A, Girlanda P, Morgante F, et al. Biased visuospatial attention in cervical dystonia. J Int Neuropsychol Soc. 2017;23:22–32. https:\u002F\u002Fdoi.org\u002F10.1017\u002FS135561771700073X.","https:\u002F\u002Fdoi.org\u002F10.1017\u002Fs135561771700073x",{"mag":1274,"openalex":1275,"pm":1276,"doi":1277},"2745197238","W2745197238","28791940","10.1017\u002Fs135561771700073x",{"id":22,"text":1279,"url":1280,"identifiers":1281},"Tarrano C, Wattiez N, Delorme C, McGovern EM, Brochard V, Thobois S, et al. Visual sensory processing is altered in myoclonus dystonia. Mov Disord. 2020;35:151–60. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27857.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.27857",{"mag":1282,"openalex":1283,"pm":1284,"doi":1285},"2977441677","W2977441677","31571302","10.1002\u002Fmds.27857",{"id":22,"text":1287,"url":1288,"identifiers":1289},"Johnson MH, Senju A, Tomalski P. The two-process theory of face processing: modifications based on two decades of data from infants and adults. Neurosci Biobehav Rev. 2015;50:169–79. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2014.10.009.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2014.10.009",{"mag":1290,"openalex":1291,"pm":1292,"doi":1293},"2130691904","W2130691904","25454353","10.1016\u002Fj.neubiorev.2014.10.009",{"id":22,"text":1295,"url":1296,"identifiers":1297},"Coenen MA, Eggink H, Spikman JM, Tijssen MA. Cognition in children and young adults with myoclonus dystonia – a case control study. Park Relat Disord. 2021;89:162–6. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2021.07.016.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.parkreldis.2021.07.016",{"doi":1298},"10.1016\u002Fj.parkreldis.2021.07.016",{"id":1300,"text":1301,"url":1302,"identifiers":1303},"73f2c5da-590f-4534-849b-f97e6569a411","Burke T, Monaghan R, McCormack D, Cogley C, Pinto-Grau M, O’Connor S, et al. Social cognition in cervical dystonia: a case-control study. Clin Park Relat Disord. 2020;3:1–6. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prdoa.2020.100072.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2590112520300402",{"doi":1304},"10.1016\u002Fj.prdoa.2020.100072",{"id":1306,"text":1307,"url":1308,"identifiers":1309},"da03316d-5c99-4c7a-8607-95064628de59","Czekóová K, Zemánková P, Shaw DJ, Bareš M. Social cognition and idiopathic isolated cervical dystonia. J Neural Transm. 2017;124:1097–104. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00702-017-1725-8.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs00702-017-1725-8",{"doi":1310},"10.1007\u002Fs00702-017-1725-8",{"id":1312,"text":1313,"url":1314,"identifiers":1315},"45255259-48c9-4de3-b48c-2b6d67c0c7f8","Lagravinese G, Santangelo G, Bonassi G, Cuoco S, Marchese R, Di Biasio F, et al. Affective and cognitive theory of mind in patients with cervical dystonia with and without tremor. J Neural Transm. 2021;128:199–206. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00702-020-02237-4.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00702-020-02237-4",{"doi":1316},"10.1007\u002Fs00702-020-02237-4",{"id":22,"text":1318,"url":1319,"identifiers":1320},"Baione V, Ferrazzano G, Celletti C, De Rosa M, Belvisi D, Fabbrini G, et al. Attention-demanding cognitive tasks worsen postural control in patients with cervical dystonia: a case-control study. Front Neurol. 2021;12:1–7. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2021.666438.","https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffneur.2021.666438",{"mag":1321,"pmc":1322,"openalex":1323,"pm":1324,"doi":1325},"3148098551","8056005","W3148098551","33889130","10.3389\u002Ffneur.2021.666438",{"id":22,"text":1327,"url":1328,"identifiers":1329},"Crisafulli O, Trompetto C, Puce L, Marinelli L, Costi S, Abbruzzese G, et al. Dual task gait deteriorates gait performance in cervical dystonia patients: a pilot study. J Neural Transm. 2021;128:1677–85. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00702-021-02393-1.","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00702-021-02393-1",{"mag":1330,"pmc":1331,"openalex":1332,"pm":1333,"doi":1334},"3186174632","8536592","W3186174632","34324056","10.1007\u002Fs00702-021-02393-1",{"id":1336,"text":1337,"url":1338,"identifiers":1339},"a379844c-2b7c-4f44-85d9-36692da47cef","Costanzo M, Belvisi D, Berardelli I, Maraone A, D’Antonio F, Baione V, et al. Motor and non-motor subtypes of cervical dystonia. Parkinsonism Relat Disord. 2021;88:108–13. https:\u002F\u002Fdoi.org\u002F10.1016\u002FJ.PARKRELDIS.2021.06.008.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1353802021002200",{"doi":1340},"10.1016\u002Fj.parkreldis.2021.06.008",{"id":22,"text":1342,"url":1343,"identifiers":1344},"Foley JA, Saman Vinke R, Limousin P, Cipolotti L. Relationship of cognitive function to motor symptoms and mood disorders in patients with isolated dystonia. Cogn Behav Neurol. 2017;30:16–22. https:\u002F\u002Fdoi.org\u002F10.1097\u002FWNN.0000000000000117.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Fwnn.0000000000000117",{"mag":1345,"openalex":1346,"pm":1347,"doi":1348},"2601541166","W2601541166","28323682","10.1097\u002Fwnn.0000000000000117",{"id":22,"text":1350,"url":1351,"identifiers":1352},"Yang J, Shao N, Song W, Wei Q, Ou R, Wu Y, et al. Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. Brain Behav 2017;7. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fbrb3.592.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fbrb3.592",{"mag":1353,"pmc":1354,"openalex":1355,"pm":1356,"doi":1357},"2567455305","5318359","W2567455305","28239516","10.1002\u002Fbrb3.592",{"id":22,"text":1359,"url":1360,"identifiers":1361},"Moriarty A, Rafee S, Ndukwe I, O’Riordan S, Hutchinson M. Longitudinal follow-up of mood in cervical dystonia and influence on age at onset. Mov Disord Clin Pract. 2022;9:614–8. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmdc3.13457.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmdc3.13457",{"openalex":1362,"pm":1363,"doi":1364},"W4223948885","35844277","10.1002\u002Fmdc3.13457",{"id":22,"text":1366,"url":1367,"identifiers":1368},"Timmers ER, Peall KJ, Dijk JM, Zutt R, Tijssen CC, Bergmans B, et al. Natural course of myoclonus-dystonia in adulthood: stable motor signs but increased psychiatry. Mov Disord. 2020;35:1077–8. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.28033.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmds.28033",{"doi":1369},"10.1002\u002Fmds.28033",{"id":22,"text":1371,"url":1372,"identifiers":1373},"Krause P, Koch K, Gruber D, Kupsch A, Gharabaghi A, Schneider GH, et al. Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia. Eur J Neurol. 2021;28:1566–73. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.14737.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fene.14737",{"mag":1374,"openalex":1375,"pm":1376,"doi":1377},"3123938146","W3123938146","33452690","10.1111\u002Fene.14737",{"id":1379,"text":1380,"url":1381,"identifiers":1382},"4c79c011-1ade-418f-b32f-5d1b86dae1cc","Stavrinou LC, Liouta E, Boviatsis EJ, Leonardos A, Gatzonis S, Stathis P, et al. Effect of constant-current pallidal deep brain stimulation for primary dystonia on cognition, mood and quality of life: results from a prospective pilot trial. Clin Neurol Neurosurg 2019;185. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.clineuro.2019.105460.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0303846719302562",{"doi":1383},"10.1016\u002Fj.clineuro.2019.105460",{"id":1385,"text":1386,"url":1387,"identifiers":1388},"0e403b6b-b949-46ff-bd7e-92d48f3c538e","Zoons E, Booij J, Speelman JD, Dreissen YEM, Smit M, Tijssen MAJ. Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms. EJNMMI Res. 2017;7:87. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13550-017-0338-4.","http:\u002F\u002Fejnmmires.springeropen.com\u002Farticles\u002F10.1186\u002Fs13550-017-0338-4",{"doi":1389},"10.1186\u002Fs13550-017-0338-4",{"id":22,"text":1391,"url":1392,"identifiers":1393},"Zoons E, Booij J, Delnooz CCS, Dijk JM, Dreissen YEM, Koelman JHTM, et al. Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks\u002Ftremor. J Neurol Neurosurg Psychiatry. 2018;89:579–85. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjnnp-2017-317352.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjnnp-2017-317352",{"mag":1394,"openalex":1395,"pm":1396,"doi":1397},"2783608857","W2783608857","29326295","10.1136\u002Fjnnp-2017-317352",{"id":1072,"text":1399,"url":1074,"identifiers":1400},"Zoons E, Tijssen M, Dreissen Y, Smit M, Booij J. The effect of escitalopram on central serotonergic and dopaminergic systems in patients with cervical dystonia, and its relationship with clinical treatment effects: a double-blind placebo-controlled trial. Biomolecules. 2020;10:880.",{"doi":1076},{"id":22,"text":1402,"url":1403,"identifiers":1404},"Wadon ME, Winter M, Peall KJ. Internet-based cognitive behavioural therapy programme as an intervention for people diagnosed with adult-onset, focal, isolated, idiopathic cervical dystonia: a feasibility study protocol. Pilot Feasibility Stud. 2020;6:100. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs40814-020-00641-x.","https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs40814-020-00641-x",{"mag":1405,"pmc":1406,"openalex":1407,"pm":1408,"doi":1409},"3042900976","7362556","W3042900976","32685184","10.1186\u002Fs40814-020-00641-x",{"id":1411,"text":1412,"url":1413,"identifiers":1414},"15d2089f-12cf-484b-ae9d-e5081587eb65","Wadon ME, MacIver C, Winter M, Peall KJ. Internet-based cognitive behavioural therapy as a feasible treatment of adult-onset, focal, isolated, idiopathic cervical dystonia. Clin Park Relat Disord. 2021;5:100121. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prdoa.2021.100121.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2590112521000335",{"doi":1415},"10.1016\u002Fj.prdoa.2021.100121",{"id":22,"text":1417,"url":1418,"identifiers":1419},"van den Dool J, Visser B, Koelman JH, Engelbert RH, Tijssen MA. Long-term specialized physical therapy in cervical dystonia: outcomes of a randomized controlled trial. Arch Phys Med Rehabil. 2019;100:1417–25. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.apmr.2019.01.013.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.apmr.2019.01.013",{"mag":1420,"openalex":1421,"pm":1422,"doi":1423},"2918039041","W2918039041","30796919","10.1016\u002Fj.apmr.2019.01.013",{"id":22,"text":1425,"url":1426,"identifiers":1427},"Isabel Useros-Olmo A, Martínez-Pernía D, Huepe D. The effects of a relaxation program featuring aquatic therapy and autogenic training among people with cervical dystonia (a pilot study). Physiother Theory Pract. 2020;36:488–97. https:\u002F\u002Fdoi.org\u002F10.1080\u002F09593985.2018.1488319.","https:\u002F\u002Fdoi.org\u002F10.1080\u002F09593985.2018.1488319",{"mag":1428,"openalex":1429,"pm":1430,"doi":1431},"2810352185","W2810352185","29939827","10.1080\u002F09593985.2018.1488319",{"id":1433,"createTime":1434,"updateTime":1435,"relativeEntities":1436,"slug":1437,"properties":1438,"entityType":195,"verifyStatus":196,"verifyTime":1449,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":1450,"fullTextUrl":22,"authors":1451,"publicationType":243,"publisherRelationship":1558,"citationCount":23,"citationInfo":1610,"publishDate":1613,"publishYear":1611,"citationAnalyzeStatus":306,"lastCitationAnalyze":1614,"indexDatabases":1615,"openAccess":22,"references":22,"isForceReanalyzing":562},"606c661b-5ffc-4b93-811a-d19b8bc4855e","2023-12-31T04:37:00.424+00:00","2026-07-14T15:05:00.201+00:00",[],"Axons-to-Exons-the-Molecular-Diagnosis-of-Rare-Neurological-Diseases-by-Next-Generation-Sequencing",{"abstract":1439,"title":1441,"gsPaper":1443,"references":1445,"doi":1447},{"EN":1440},"Neurological disorders secondary to single gene mutations are an extremely heterogeneous group of diseases, individually rare, and often associated with progressive and severe disability. Given the degree of both clinical and genetic heterogeneity, next-generation sequencing (NGS) has become an important diagnostic tool. Multi-gene panel testing based on NGS is now prominently used, while whole-exome sequencing and whole-genome sequencing are emerging to facilitate the molecular diagnosis for many genetic neurological diseases. Although single-gene testing remains an important first tier test for disorders with clear phenotype-genotype correlation, NGS provides an expanding unbiased approach to identify rare mutations in genes known to be associated with genetically heterogeneous diseases, and those not initially considered by the clinician due to rarity or atypical clinical presentation. Given the decreasing costs and relatively rapid time to results, NGS-based assessment is quickly becoming a standard-of-care test for patients with genetic neurological diseases.",{"EN":1442},"Axons to Exons: the Molecular Diagnosis of Rare Neurological Diseases by Next-Generation Sequencing",{"VOID":1444},"[\"2373690655221758059\"]",{"VOID":1446},"Orphanet. Prevalence of rare diseases: bibliographic data. Orphanet reports series 2014; Rare diseases collection. http:\u002F\u002Fwww.orpha.net\u002Fconsor\u002Fcgi-bin\u002FEducation_Home.php?lng=EN.\nMcKusick VA. Mendelian inheritance in man and its online version, OMIM. Am J Hum Genet. 2007;80:588–604.\nFederico A. Rare neurological diseases: a Pandora’s box for neurology (an European and Italian perspective). Rev Neurol. 2013;169:S12–7.\nMitsuhashi S, Kang PB. Update on the genetics of limb girdle muscular dystrophy. Semin Pediatr Neurol. 2012;19:211–8.\nShashi V, McConkie-Rosell A, Rosell B, Schoch K, Vellore K, McDonald M, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2013;16:176–82.\nGahl WA, Tifft CJ. The NIH Undiagnosed Diseases Program: lessons learned. JAMA. 2011;305:1904–5.\nUS Department of Health Human Services. Report of the National Commission on Orphan Diseases. Publication Number HRP-090-7248. Washington, DC: US Government Printing Office; 1989.\nEurordis. EurordisCare2: survey of diagnostic delays, 8 diseases, Europe. http:\u002F\u002Fwww.eurordis.org\u002FIMG\u002Fpdf\u002Fvoice_12000_patients\u002FEURORDISCARE_FULLBOOKr.pdf.\nKlepper J. GLUT1 deficiency syndrome and ketogenic diet therapies: missing rare but treatable diseases? Dev Med Child Neurol. 2015. doi:10.1111\u002Fdmcn.12807.\nLeen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, van Engelen BG, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133:655–70.\nToscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260:951–9.\nBenveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med. 2011;40:e249–55.\nYang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013;369:1502–11.\nLee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312:1880–7. This publication reports the diagnostic rate of clinical exome sequencing for 814 patients.\nYang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–9. This publication reports the diagnostic rate of clinical exome sequencing for 2000 patients. Many of these patients presented with a neurological or neurodevelopmental disease.\nGilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BW, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511:344–7.\nRehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013;14:295–300.\nBeaulieu CL, Majewski J, Schwartzentruber J, Samuels ME, Fernandez BA, Bernier FP, et al. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. Am J Hum Genet. 2014;94:809–17. This is a commentary on the success rate of 264 disorders studied by exome sequencing as part of a national consortium. It includes a stratification into categories to show the success rate of different approaches.\nBoycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14:681–91. This publication provides an in-depth review of whole-exome and genome sequencing and their research and clinical applications.\nFoo J-N, Liu J-J, Tan E-K. Whole-genome and whole-exome sequencing in neurological diseases. Nat Rev Neurol. 2012;8:508–17.\nBotstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat Genet. 2003;33:228–37.\nOttman R, Hirose S, Jain S, Lerche H, Lopes-Cendes I, Noebels JL, et al. Genetic testing in the epilepsies—report of the ILAE Genetics Commission. Epilepsia. 2010;51:655–70.\nXue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome\u002Fgenome sequencing. Genet Med. 2015;17:444–51.\nAnkala A, Da Silva C, Gualandi F, Ferlini A, Bean LJ, Collins C, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol. 2015;77:206–14.\nSoden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.\nPyle A, Smertenko T, Bargiela D, Griffin H, Duff J, Appleton M, et al. Exome sequencing in undiagnosed inherited and sporadic ataxias. Brain. 2015;138:276–83.\nSawyer SL, Schwartzentruber J, Beaulieu CL, Dyment D, Smith A, Chardon JW, et al. Exome sequencing as a diagnostic tool for pediatric-onset ataxia. Hum Mutat. 2014;35:45–9.\nFarwell KD, Shahmirzadi L, El-Khechen D, Powis Z, Chao EC, Davis BT, et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med. 2015;17:578–86. doi:10.1038\u002Fgim.2014.154.\nTaylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015. doi:10.1038\u002Fng.3304. This publication is a comprehensive study of 217 individuals using clinical whole-genome sequencing.\nMartin HC, Kim GE, Pagnamenta AT, Murakami Y, Carvill GL, Meyer E, et al. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet. 2014;23:3200–11.\nWillig LK, Petrikin JE, Smith LD, Saunders CJ, Thiffault I, Miller NA, et al. Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. Lancet Respir Med. 2015;3:377–87.\nSaunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med. 2012;4:154ra35.\nLupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362:1181–91. This is the first report on the application of whole-genome sequencing in neurological disease; compound heterozygous mutations were identified in SH3TC2 in a family with Charcot -Marie -Tooth disease.\nGonzaga-Jauregui C, Lotze T, Jamal L, Penney S, Campbell IM, Pehlivan D, et al. Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol. 2013;70:1491–8.\nJarinova O, Ekker M. Regulatory variations in the era of next-generation sequencing: implications for clinical molecular diagnostics. Hum Mutat. 2012;33:1021–30.\nMcDonell LM, Mirzaa GM, Alcantara D, Schwartzentruber J, Carter MT, Lee LJ, et al. Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly-capillary malformation syndrome. Nat Genet. 2013;45:556–62.\nSawyer SL, Hartley T, Dyment DA, Beaulieu CL, Schwartzentruber J, Smith AC, et al. Utility of whole-exome sequencing toward the end of the diagnostic odyssey: time to address gaps in care. Clin Genet. 2015. doi:10.1111\u002Fcge.12654.\nMacArthur D, Manolio T, Dimmock D, Rehm H, Shendure J, Abecasis G, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–76.\nRichards S, CAP NA, Bale S, Bick D, Das S, Gastier J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–23.\nFokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v. 2.0: the next generation in gene variant databases. Hum Mutat. 2011;32:557–63.\nLandrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980–5.\nRehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen—the clinical genome resource. N Engl J Med. 2015;372:2235–42.\nGreen RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565–74.\nvan El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, et al. Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2013;21:S1–5.\nBoycott K, Hartley T, Adam S, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: position statement of the Canadian College of Medical Geneticists. J Med Genet. 2015;52:431–7. doi:10.1136\u002Fjmedgenet-2015-103144.\nMoseley ML, Benzow KA, Schut LJ, Bird TD, Gomez CM, Barkhaus PE, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology. 1998;51:1666–71.\nNemeth AH, Kwasniewska AC, Lise S, Parolin Schnekenberg R, Becker EB, Bera KD, et al. Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain. 2013;136:3106–18.\nOhba C, Osaka H, Iai M, Yamashita S, Suzuki Y, Aida N, et al. Diagnostic utility of whole exome sequencing in patients showing cerebellar and\u002For vermis atrophy in childhood. Neurogenetics. 2013;14:225–32.\nFogel BL, Lee H, Deignan JL, Strom SP, Kantarci S, Wang X, et al. Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. JAMA Neurol. 2014;71:1237–46.\nGirdea M, Dumitriu S, Fiume M, Bowdin S, Boycott KM, Chénier S, et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat. 2013;34:1057–65.\nKohler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 2014;42:D966–74.\nSobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A. New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene. Hum Mutat. 2015;36:425–31.\nBragin E, Chatzimichali EA, Wright CF, Hurles ME, Firth HV, Bevan AP, et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. Nucleic Acids Res. 2014;42:D993–D1000.\nGonzalez MA, Lebrigio RF, Van Booven D, Ulloa RH, Powell E, Speziani F, et al. GEnomes Management Application (GEM.app): a new software tool for large-scale collaborative genome analysis. Hum Mutat. 2013;34:842–6.",{"VOID":1448},"10.1007\u002Fs11910-015-0584-7","2024-06-23T13:31:28.691+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-015-0584-7",[1452,1485,1502,1517,1538],{"id":1453,"sortIndex":23,"researcher":22,"roles":1454,"affiliations":1455,"properties":1480,"displayName":1482,"givenName":22,"familyName":22},"aa60ae2a-5d26-4f05-a559-96557233ed51",[586],[1456,1464,1472],{"id":1457,"sortIndex":23,"affiliation":1458,"properties":22},"4b2eb07a-7550-4ffe-97ea-7714e2fd5e74",{"id":1457,"createTime":22,"updateTime":22,"relativeEntities":1459,"slug":22,"properties":1460,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1463,"statistic":22},[],{"title":1461},{"VI":1462},"Division of Neurology, The Ottawa Hospital, Ottawa, Canada",[],{"id":1465,"sortIndex":146,"affiliation":1466,"properties":22},"637477de-264a-405f-8d5f-ae287d2c96d4",{"id":1465,"createTime":22,"updateTime":22,"relativeEntities":1467,"slug":22,"properties":1468,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1471,"statistic":22},[],{"title":1469},{"VI":1470},"Department of Genetics, The Children’s Hospital of Eastern Ontario, Ottawa, Canada",[],{"id":1473,"sortIndex":304,"affiliation":1474,"properties":22},"173586f1-b314-49c0-90d1-2e116aad4f2a",{"id":1473,"createTime":22,"updateTime":22,"relativeEntities":1475,"slug":22,"properties":1476,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1479,"statistic":22},[],{"title":1477},{"VI":1478},"Ottawa Hospital Research Institute, Ottawa, Canada",[],{"title":1481,"gsAuthor":1483},{"VI":1482},"Jodi Warman Chardon",{"VOID":1484},"[\"VKjbJREAAAAJ\"]",{"id":1486,"sortIndex":146,"researcher":22,"roles":1487,"affiliations":1488,"properties":1497,"displayName":1499,"givenName":22,"familyName":22},"ad9f9f2d-b56b-4e87-b4ec-664cfdca319a",[586],[1489],{"id":1490,"sortIndex":23,"affiliation":1491,"properties":22},"0a37bc41-211c-45fe-a539-76b32b40d7d3",{"id":1490,"createTime":22,"updateTime":22,"relativeEntities":1492,"slug":22,"properties":1493,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1496,"statistic":22},[],{"title":1494},{"VI":1495},"Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada",[],{"title":1498,"gsAuthor":1500},{"VI":1499},"Chandree Beaulieu",{"VOID":1501},"[\"AY78OmAAAAAJ\"]",{"id":1503,"sortIndex":304,"researcher":22,"roles":1504,"affiliations":1505,"properties":1512,"displayName":1514,"givenName":22,"familyName":22},"c8c02405-0819-4c44-b277-5f00c6247f10",[586],[1506],{"id":1490,"sortIndex":23,"affiliation":1507,"properties":22},{"id":1490,"createTime":22,"updateTime":22,"relativeEntities":1508,"slug":22,"properties":1509,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1511,"statistic":22},[],{"title":1510},{"VI":1495},[],{"title":1513,"gsAuthor":1515},{"VI":1514},"Taila Hartley",{"VOID":1516},"[\"qRx3p_gAAAAJ\"]",{"id":1518,"sortIndex":1519,"researcher":22,"roles":1520,"affiliations":1521,"properties":1535,"displayName":1537,"givenName":22,"familyName":22},"773c8a23-5476-406a-9419-35f489d8c410",3,[586],[1522,1528],{"id":1465,"sortIndex":23,"affiliation":1523,"properties":22},{"id":1465,"createTime":22,"updateTime":22,"relativeEntities":1524,"slug":22,"properties":1525,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1527,"statistic":22},[],{"title":1526},{"VI":1470},[],{"id":1490,"sortIndex":146,"affiliation":1529,"properties":1534},{"id":1490,"createTime":22,"updateTime":22,"relativeEntities":1530,"slug":22,"properties":1531,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1533,"statistic":22},[],{"title":1532},{"VI":1495},[],{},{"title":1536},{"VI":1537},"Kym M. Boycott",{"id":1539,"sortIndex":122,"researcher":22,"roles":1540,"affiliations":1541,"properties":1555,"displayName":1557,"givenName":22,"familyName":22},"44771baf-e7a0-4ab2-8c7a-ccd53bc94d85",[586],[1542,1548],{"id":1465,"sortIndex":23,"affiliation":1543,"properties":22},{"id":1465,"createTime":22,"updateTime":22,"relativeEntities":1544,"slug":22,"properties":1545,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1547,"statistic":22},[],{"title":1546},{"VI":1470},[],{"id":1490,"sortIndex":146,"affiliation":1549,"properties":1554},{"id":1490,"createTime":22,"updateTime":22,"relativeEntities":1550,"slug":22,"properties":1551,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1553,"statistic":22},[],{"title":1552},{"VI":1495},[],{},{"title":1556},{"VI":1557},"David A. Dyment",{"url":1450,"publisher":1559,"properties":1605},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1560,"slug":10,"properties":1561,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1565,"manageAffiliations":1574,"indexDatabases":1585,"url":22,"thumbnailPath":22,"statistic":1600,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":1562,"title":1563,"eissn":1564},{"VOID":15},{"EN":17},{"VOID":13},[1566,1570],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1567,"label":1568,"description":1569,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1571,"label":1572,"description":1573,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1575,1580],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1576,"slug":22,"properties":1577,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1579,"statistic":22},[],{"title":1578},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":1581,"slug":22,"properties":1582,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1584,"statistic":22},[],{"title":1583},{"EN":50},[],[1586,1593],{"id":54,"indexDatabase":1587,"url":67,"indexYears":22,"academicFieldIds":1592,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":1588,"label":1589,"description":1590,"key":63,"publicationTags":1591,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":1594,"url":83,"indexYears":84,"academicFieldIds":1599,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":1595,"label":1596,"description":1597,"key":80,"publicationTags":1598,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":1601,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":1602,"totalCitation":123,"totalCitationByYear":1603,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":1604,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":1606,"volume":1608},{"VOID":1607},"1-8",{"VOID":1609},"15",{"total":23,"publishYear":1611,"statisticByYear":1612},2015,{},"2015-08-21","2026-07-14T15:05:00.200+00:00",[88,65],{"id":1617,"createTime":1618,"updateTime":1619,"relativeEntities":1620,"slug":1621,"properties":1622,"entityType":195,"verifyStatus":196,"verifyTime":1633,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":1634,"fullTextUrl":22,"authors":1635,"publicationType":243,"publisherRelationship":1677,"citationCount":22,"citationInfo":22,"publishDate":1729,"publishYear":1730,"citationAnalyzeStatus":21,"lastCitationAnalyze":1619,"indexDatabases":1731,"openAccess":22,"references":22,"isForceReanalyzing":562},"32e458df-7372-4173-814a-8fd31bee28b1","2024-01-16T10:55:45.636+00:00","2026-07-14T14:04:41.378+00:00",[],"An-Update-on-Psychogenic-Movement-Disorders",{"abstract":1623,"title":1625,"gsPaper":1627,"references":1629,"doi":1631},{"EN":1624},"Psychogenic movement disorders (PMD) and other conversion disorders (CD) with apparent neurologic signs (neurologic CD) plague patients and perplex physicians. Due to a lack of objective evidence of underlying brain lesions, CD were largely abandoned by neurologists and remained poorly understood psychiatric diagnoses throughout most of the 20th century. Modern neuroscience now supports increasingly comprehensive biological models for these complex disorders, definitively establishing their place in both neurology and psychiatry. Although it is often clinically useful to distinguish a movement disorder as either “organic” or “psychogenic,” this dichotomy is difficult to defend scientifically. Here we describe the neuroimaging and neurophysiologic evidence for dysfunctional neural networks in PMD, explain the diagnostic potential of clinical neurophysiologic testing, discuss the promising if increasingly complex role of neuropsychiatric genetics, and review current treatment strategies.",{"EN":1626},"An Update on Psychogenic Movement Disorders",{"VOID":1628},"[\"4605366577910352788\"]",{"VOID":1630},"Hallett M, Fahn S, Jankovic J, et al. Psychogenic movement disorders: neurology and neuropsychiatry. Philadelphia: Lippincott Williams & Wilkins; 2006.\nBogousslavsky J. Hysteria after Charcot: back to the future. Front Neurol Neurosci. 2011;29:137–61.\nHallett M. Psychogenic movement disorders: a crisis for neurology. Curr Neurol Neurosci Rep. 2006;6:269–71.\nNowak DA, Fink GR. Psychogenic movement disorders: aetiology, phenomenology, neuroanatomical correlates and therapeutic approaches. Neuroimage. 2009;47:1015–25.\nStone J, Wojcik W, Durrance D, et al. What should we say to patients with symptoms unexplained by disease? The “number needed to offend”. BMJ. 2002;325:1449–50.\nFahn S, Williams DT. Psychogenic dystonia. Adv Neurol. 1988;50:431–55.\nWilliams DT, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol. 1995;65:231–57.\nAmerican Psychiatric Association, American Psychiatric Association Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington: American Psychiatric Association; 2000.\nKranick SM, Ellenstein A, Hallett M. Psychiatric comorbidities and risk factors in psychogenic movement disorders: a biopsychosocial approach. European Neurological Journal. 2010;2:1–7.\nKrem MM. Motor conversion disorders reviewed from a neuropsychiatric perspective. J Clin Psychiatry. 2004;65:783–90.\nScott RL, Anson JG. Neural correlates of motor conversion disorder. Mot Control. 2009;13:161–84.\n• Vuilleumier P. The Neurophysiology of Self-Awareness Disorders in Conversion Hysteria. In The Neurology of Consciousness Cognitive Neuroscience and Neuropathology. Edited by Laureys S and Tononi G. Academic Press; 2009:282–302. This chapter cogently discusses the neuroimaging and neurophysiologic studies of conversion hysteria in the context a developing neurobiological model that includes disrupted mechanisms of self-awareness.\nStone J, Carson A. Movement disorders: psychogenic movement disorders: what do neurologists do? Nat Rev Neurol. 2009;5:415–6.\nLaFrance Jr WC, Miller IW, Ryan CE, et al. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav. 2009;14:591–6.\nStone J, LaFrance WC, Jr., Levenson JL, et al. Issues for DSM-5: Conversion disorder. Am J Psychiatry, 167:626–627.\nMayou R, Kirmayer LJ, Simon G, et al. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatry. 2005;162:847–55.\nLowe B, Mundt C, Herzog W, et al. Validity of current somatoform disorder diagnoses: perspectives for classification in DSM-V and ICD-11. Psychopathology. 2008;41:4–9.\nVoon V, Gallea C, Hattori N, et al. The involuntary nature of conversion disorder. Neurology. 2010;74:223–8.\nVoon V, Brezing C, Gallea C, et al. Emotional stimuli and motor conversion disorder. Brain. 2010;133:1526–36.\nHallett M. Physiology of psychogenic movement disorders. J Clin Neurosci. 2010;17:959–65.\nVuilleumier P, Chicherio C, Assal F, et al. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain. 2001;124:1077–90.\nde Lange FP, Roelofs K, Toni I. Increased self-monitoring during imagined movements in conversion paralysis. Neuropsychologia. 2007;45:2051–8.\nCojan Y, Waber L, Carruzzo A, et al. Motor inhibition in hysterical conversion paralysis. Neuroimage. 2009;47:1026–37.\nde Lange FP, Toni I, Roelofs K. Altered connectivity between prefrontal and sensorimotor cortex in conversion paralysis. Neuropsychologia. 2010;48:1782–8.\nStone J, Vuilleumier P, Friedman JH. Conversion disorder: separating “how” from “why”. Neurology. 2010;74:190–1.\nGaig C, Marti MJ, Tolosa E, et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord. 2006;21:1994–8.\nHallett M: Psychogenic Parkinsonism. J Neurol Sci 2011. doi: 10.1016\u002Fj.jns.2011.03.019\nLiepert J, Hassa T, Tuscher O, et al. Motor excitability during movement imagination and movement observation in psychogenic lower limb paresis. J Psychosom Res. 2010;70:59–65.\nDesmurget M, Sirigu A. A parietal-premotor network for movement intention and motor awareness. Trends Cogn Sci. 2009;13:411–9.\nSchwingenschuh P, Katschnig P, Edwards MJ, et al. The blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm. Neurology. 2011;76:610–4.\nHariri AR. The neurobiology of individual differences in complex behavioral traits. Annu Rev Neurosci. 2009;32:225–47.\n• Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010, 167:509–527. Following from a detailed review of the serotonin transporter gene and stress sensitivity, the authors discuss approaches to the challenging field of gene-environment research.\nCaspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006;7:583–90.\nHallett M, Lang AE, Jankovic J, et al. Psychogenic movement disorders & other conversion disorders. Cambridge: Cambridge University Press; 2011.\nFeder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci. 2009;10:446–57.\n• Lupien SJ, McEwen BS, Gunnar MR, et al. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009,10:434–445. The authors synthesize the animal and human research on the age-dependent pathophysiology of stress.\nFeinstein A, Stergiopoulos V, Fine J, et al. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:169–76.\nVoon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry. 2005;66:1529–34.\nBinder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010;67:369–79.\nZhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452:997–1001.\n• Stone J. The bare essentials: Functional symptoms in neurology. Pract Neurol 2009, 9:179–189. This article presents important, practical advice for the neurologist’s approach to patients with CD.\nHinson VK, Weinstein S, Bernard B, et al. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12:177–80.\nSpeckens AE, van Hemert AM, Spinhoven P, et al. Cognitive behavioural therapy for medically unexplained physical symptoms: a randomised controlled trial. BMJ. 1995;311:1328–32.\nLaFrance Jr WC. Friedman JH. cognitive behavioral therapy for psychogenic movement disorder. Mov Disord. 2009;24:1856–7.\nBaslet G, Hill J. Case report: brief mindfulness-based psychotherapeutic intervention during inpatient hospitalization in a patient with conversion and dissociation. Clinical Case Studies 2011. doi: 10.1177\u002F1534650110396359.\nGoldstein LH, Chalder T, Chigwedere C, et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures: a pilot RCT. Neurology. 2010;74:1986–94.\nDallocchio C, Arbasino C, Klersy C, et al. The effects of physical activity on psychogenic movement disorders. Mov Disord. 2010;25:421–5.\nVan Nuenen BF, Wohlgemuth M, Wong Chung RE, et al. Acupuncture for psychogenic movement disorders: treatment or diagnostic tool? Mov Disord. 2007;22:1353–5.\nMoene FC, Spinhoven P, Hoogduin KA, et al. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. Int J Clin Exp Hypn. 2003;51:29–50.\nChastan N, Parain D. Psychogenic paralysis and recovery after motor cortex transcranial magnetic stimulation. Mov Disord. 2010;25:1501–4.",{"VOID":1632},"10.1007\u002Fs11910-011-0205-z","2024-06-26T03:06:50.959+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-011-0205-z",[1636,1651,1664],{"id":1637,"sortIndex":23,"researcher":22,"roles":1638,"affiliations":1639,"properties":1648,"displayName":1650,"givenName":22,"familyName":22},"4be08e97-022d-4e38-83a2-90eb49eba802",[586],[1640],{"id":1641,"sortIndex":23,"affiliation":1642,"properties":22},"9ffbbdfe-f6a6-49ec-8433-7762a131f1dd",{"id":1641,"createTime":22,"updateTime":22,"relativeEntities":1643,"slug":22,"properties":1644,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1647,"statistic":22},[],{"title":1645},{"EN":1646},"Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA",[],{"title":1649},{"VI":1650},"Aviva Ellenstein",{"id":1652,"sortIndex":146,"researcher":22,"roles":1653,"affiliations":1654,"properties":1661,"displayName":1663,"givenName":22,"familyName":22},"a901834f-8593-4c42-974a-4efa525adbfb",[586],[1655],{"id":1641,"sortIndex":23,"affiliation":1656,"properties":22},{"id":1641,"createTime":22,"updateTime":22,"relativeEntities":1657,"slug":22,"properties":1658,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1660,"statistic":22},[],{"title":1659},{"EN":1646},[],{"title":1662},{"VI":1663},"Sarah M. Kranick",{"id":1665,"sortIndex":304,"researcher":22,"roles":1666,"affiliations":1667,"properties":1674,"displayName":1676,"givenName":22,"familyName":22},"543a4cee-fd69-4075-8568-2b39c28d983e",[586],[1668],{"id":1641,"sortIndex":23,"affiliation":1669,"properties":22},{"id":1641,"createTime":22,"updateTime":22,"relativeEntities":1670,"slug":22,"properties":1671,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1673,"statistic":22},[],{"title":1672},{"EN":1646},[],{"title":1675},{"VI":1676},"Mark Hallett",{"url":1634,"publisher":1678,"properties":1724},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1679,"slug":10,"properties":1680,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1684,"manageAffiliations":1693,"indexDatabases":1704,"url":22,"thumbnailPath":22,"statistic":1719,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":1681,"title":1682,"eissn":1683},{"VOID":15},{"EN":17},{"VOID":13},[1685,1689],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1686,"label":1687,"description":1688,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1690,"label":1691,"description":1692,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1694,1699],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1695,"slug":22,"properties":1696,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1698,"statistic":22},[],{"title":1697},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":1700,"slug":22,"properties":1701,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1703,"statistic":22},[],{"title":1702},{"EN":50},[],[1705,1712],{"id":54,"indexDatabase":1706,"url":67,"indexYears":22,"academicFieldIds":1711,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":1707,"label":1708,"description":1709,"key":63,"publicationTags":1710,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":1713,"url":83,"indexYears":84,"academicFieldIds":1718,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":1714,"label":1715,"description":1716,"key":80,"publicationTags":1717,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":1720,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":1721,"totalCitation":123,"totalCitationByYear":1722,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":1723,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":1725,"volume":1727},{"VOID":1726},"396-403",{"VOID":1728},"11","2011-05-11",2011,[88,65],{"id":1733,"createTime":1734,"updateTime":1735,"relativeEntities":1736,"slug":1737,"properties":1738,"entityType":195,"verifyStatus":196,"verifyTime":1749,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":1750,"fullTextUrl":22,"authors":1751,"publicationType":243,"publisherRelationship":1824,"citationCount":22,"citationInfo":22,"publishDate":1875,"publishYear":1876,"citationAnalyzeStatus":21,"lastCitationAnalyze":1735,"indexDatabases":1877,"openAccess":22,"references":22,"isForceReanalyzing":562},"6a4ce4da-1aa4-460f-8108-e1c23372bd82","2024-01-18T05:05:27.685+00:00","2026-04-23T20:33:12.194+00:00",[],"Non-pharmacological-Management-of-Behavioral-Symptoms-in-Frontotemporal-and-Other-Dementias",{"abstract":1739,"title":1741,"gsPaper":1743,"references":1745,"doi":1747},{"EN":1740},"Worldwide prevalence of dementia is predicted to double every 20 years. The most common cause in individuals over 65 is Alzheimer’s disease (AD), but in those under 65, frontotemporal dementia (FTD) is as frequent. The physical and cognitive decline that characterizes these diseases is commonly accompanied by troublesome behavioral symptoms. These behavioral symptoms contribute to significant morbidity and mortality among both patients and caregivers. Medications have been largely ineffective in managing these symptoms and carry significant adverse effects. Non-pharmacological interventions have been recommended to precede the utilization of pharmacological treatments. This article reviews the research about these interventions with special attention to the variations by etiology, especially FTD. The authors offer recommendations for improving utilization of these strategies and future research recommendations.",{"EN":1742},"Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias",{"VOID":1744},"[\"560356381951486896\"]",{"VOID":1746},"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63,75. e2.\nWaldo ML. The frontotemporal dementias. Psychiatr Clin North Am. 2015;38(2):193–209.\nSeltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26(10):841–70.\nSrikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer’s disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236(1–2):43–8.\nLyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.\nLyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.\nMiller BL, Darby A, Benson DF, Cummings JL, Miller MH. Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. Br J Psychiatry. 1997;170:150–4.\nShinagawa S, Ikeda M, Fukuhara R, Tanabe H. Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21(2):74–80.\nBathgate D, Snowden JS, Varma A, Blackshaw A, Neary D. Behaviour in frontotemporal dementia, Alzheimer’s disease and vascular dementia. Acta Neurol Scand. 2001;103(6):367–78.\nSadak TI, Katon J, Beck C, Cochrane BB, Borson S. Key neuropsychiatric symptoms in common dementias: prevalence and implications for caregivers, clinicians, and health systems. Res Gerontol Nurs. 2014;7(1):44–52.\nSimard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2000;12(4):425–50.\nThompson C, Brodaty H, Trollor J, Sachdev P. Behavioral and psychological symptoms associated with dementia subtype and severity. Int Psychogeriatr. 2010;22(2):300–5.\nAllegri RF, Sarasola D, Serrano CM, Taragano FE, Arizaga RL, Butman J, et al. Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2006;2(1):105–10.\nMatsumoto N, Ikeda M, Fukuhara R, Shinagawa S, Ishikawa T, Mori T, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23(4):219–24.\nOkura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81.\nYaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287(16):2090–7.\nGilley DW, Bienias JL, Wilson RS, Bennett DA, Beck TL, Evans DA. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer’s disease. Psychol Med. 2004;34(6):1129–35.\nWorld Alzheimer Report 2012: Overcoming the stigma of dementia [Internet].; 2012 []. Available from: http:\u002F\u002Fwww.alz.org\u002Fdocuments_custom\u002Fworld_report_2012_final.pdf.\nBeeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatr. 2002;17(5):403–8.\nde Vugt ME, Riedijk SR, Aalten P, Tibben A, van Swieten JC, Verhey FR. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer’s disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22(1):35–41.\nRicci M, Guidoni SV, Sepe-Monti M, Bomboi G, Antonini G, Blundo C, et al. Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Arch Gerontol Geriatr. 2009;49(2):e101–4.\nMassimo L, Evans LK, Benner P. Caring for loved ones with frontotemporal degeneration: the lived experiences of spouses. Geriatr Nurs. 2013;34(4):302–6.\nMa H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915–37.\nSchneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.\nSchneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.\nSadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012;25(3):350–66.\nKales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.\nAyalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166(20):2182–8.\nBrodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53. Brodaty et al. reviewed 23 studies between 1985 and 2010 of trials and discuss the limitations and strengths. They propose a similar efficacy to pharmacological management in these studies.\nRosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain. 2005;128(Pt 11):2612–25.\nGarcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–9.\nKales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. Kales et al. reviewed manuscripts between 1992 and 2014 and present a thorough review of pharmacological and nonpharmacological management as well as a logical framework for providers to approach assessment of these symptoms.\nSparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick’s disease. Arch Neurol. 1991;48(8):796–9.\nGeda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8.\nSha SJ, Takada LT, Rankin KP, Yokoyama JS, Rutherford NJ, Fong JC, et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012;79(10):1002–11.\nLanata SC, Miller BL. The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry. J Neurol Neurosurg Psychiatry. 2015. Lanata and Miller review the overlap between the clinical symptoms of FTD and several primary psychiatric disorders by reviewing cases originally diagnosed with psychiatric disorders. They also discuss the current genetic implications.\nCohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986;34(10):711–21.\nCohen-Mansfield J, Werner P, Marx MS. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr. 1989;1(2):153–65.\nHall GR, Buckwalter KC. Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer’s disease. Arch Psychiatr Nurs. 1987;1(6):399–406.\nRichards KC, Beck CK. Progressively lowered stress threshold model: understanding behavioral symptoms of dementia. J Am Geriatr Soc. 2004;52(10):1774–5.\nCummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.\nde Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984–94.\nKaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–9.\nWood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, et al. The use of the neuropsychiatric inventory in nursing home residents. characterization and measurement. Am J Geriatr Psychiatr. 2000;8(1):75–83.\nReisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(Suppl):9–15.\nReisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, et al. The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord. 2014;38(1–2):89–146.\nKnopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131(Pt 11):2957–68.\nMioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010;74(20):1591–7.\nGitlin LN, Marx KA, Stanley IH, Hansen BR, Van Haitsma KS. Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. Int Psychogeriatr. 2014;26(11):1805–48.\nSmith M, Buckwalter K. Back to the A-B-C’s: understanding and responding to behavioral symptoms in dementia. Geriatr Mental Health Train Ser,. Rev 2005.\nTeri L, McCurry SM, Logsdon R, Gibbons LE. Training community consultants to help family members improve dementia care: a randomized controlled trial. Gerontologist. 2005;45(6):802–11.\nMerrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21(4):S64–9.\nHodgson NA, Gitlin LN, Winter L, Czekanski K. Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord. 2011;25(2):109–15.\nSegal-Gidan F, Cherry D, Jones R, Williams B, Hewett L, Chodosh J, et al. Alzheimer’s disease management guideline: update 2008. Alzheimers Dement. 2011;7(3):e51–9.\nGitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020–9.\nDementia: principles of care for patients with dementia resulting from alzheimer disease [Internet].; 2006 []. Available from: www.aagponlin.org\u002Fpositionstatement.\nAPA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5–56.\nKortte KB, Rogalski EJ. Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatr. 2013;25(2):237–45.\nTrahan MA, Kuo J, Carlson MC, Gitlin LN. A systematic review of strategies to foster activity engagement in persons with dementia. Health Educ Behav. 2014;41(1 Suppl):70S–83S.\nWatson R, Green SM. Feeding and dementia: a systematic literature review. J Adv Nurs. 2006;54(1):86–93.\nPalmer CV, Adams SW, Bourgeois M, Durrant J, Rossi M. Reduction in caregiver-identified problem behaviors in patients with Alzheimer disease post-hearing-aid fitting. J Speech Lang Hear Res. 1999;42(2):312–28.\nRaglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. Alzheimer Dis Assoc Disord. 2008;22(2):158–62.\nLivingston G, Johnston K, Katona C, Paton J, Lyketsos CG, Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996–2021.\nMoniz Cook ED, Swift K, James I, Malouf R, De Vugt M, Verhey F. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev. 2012;2:CD006929.\nO’Connor CM, Clemson L, Brodaty H, Jeon YH, Mioshi E, Gitlin LN. Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness. Int Psychogeriatr. 2014;26(5):857–69.\nGitlin LN, Winter L, Burke J, Chernett N, Dennis MP, Hauck WW. Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. Am J Geriatr Psychiatr. 2008;16(3):229–39.\nGitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–74.\nO’Connor CM, Clemson L, Brodaty H, Gitlin LN, Piguet O, Mioshi E. Enhancing caregivers’ understanding of dementia and tailoring activities in frontotemporal dementia: two case studies. Disabil Rehabil. 2015;9:1–11.\nIkeda M, Tanabe H, Horino T, Komori K, Hirao K, Yamada N, et al. Care for patients with Pick’s disease by using their preserved procedural memory. Sheishin Shinkeigaku Zasshi. 1995;97:179.\nFerrero-Arias J, Goni-Imizcoz M, Gonzalez-Bernal J, Lara-Ortega F, da Silva-Gonzalez A, Diez-Lopez M. The efficacy of nonpharmacological treatment for dementia-related apathy. Alzheimer Dis Assoc Disord. 2011;25(3):213–9.\nKim SY, Yoo EY, Jung MY, Park SH, Park JH. A systematic review of the effects of occupational therapy for persons with dementia: a meta-analysis of randomized controlled trials. NeuroRehabilitation. 2012;31(2):107–15.\nHulme C, Wright J, Crocker T, Oluboyede Y, House A. Non-pharmacological approaches for dementia that informal carers might try or access: a systematic review. Int J Geriatr Psychiatr. 2010;25(7):756–63.\nTeri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003;290(15):2015–22.\nForbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;4:CD006489.\nMcCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L. Nighttime insomnia treatment and education for Alzheimer’s disease: a randomized, controlled trial. J Am Geriatr Soc. 2005;53(5):793–802.\nForbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. Cochrane Database Syst Rev. 2014;2:CD003946.\nKales HC, Gitlin LN, Lyketsos CG. The time is now to address behavioral symptoms of dementia. Generations - J Am Soc Aging. 2014;38(86–95).\nParker D, Mills S, Abbey J. Effectiveness of interventions that assist caregivers to support people with dementia living in the community: a systematic review. Int J Evid Based Healthc. 2008;6(2):137–72.\nGitlin LN, Winter L, Corcoran M, Dennis MP, Schinfeld S, Hauck WW. Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative. Gerontologist. 2003;43(4):532–46.\nGitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA. 2010;304(9):983–91.\nDiehl J, Mayer T, Kurz A, Forstl H. Features of frontotemporal dementia from the perspective of a special family support group. Nervenarzt. 2003;74(5):445–9.\nBarton C, Merrilees J, Ketelle R, Wilkins S, Miller B. Implementation of advanced practice nurse clinic for management of behavioral symptoms in dementia: a dyadic intervention (innovative practice). Dementia (London). 2014;13(5):686–96.\nSamia LW, Aboueissa AM, Halloran J, Hepburn K. The Maine Savvy Caregiver Project: translating an evidence-based dementia family caregiver program within the RE-AIM Framework. J Gerontol Soc Work. 2014;57(6–7):640–61.\nKally Z, Cote SD, Gonzalez J, Villarruel M, Cherry DL, Howland S, et al. The Savvy Caregiver Program: impact of an evidence-based intervention on the well-being of ethnically diverse caregivers. J Gerontol Soc Work. 2014;57(6–7):681–93.\nHepburn K, Lewis M, Tornatore J, Sherman CW, Bremer KL. The Savvy Caregiver program: the demonstrated effectiveness of a transportable dementia caregiver psychoeducation program. J Gerontol Nurs. 2007;33(3):30–6.\nHinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, et al. Non-pharmacological management for patients with frontotemporal dementia: a systematic review. J Alzheimers Dis. 2015;45(1):283–93. Shinagawa et al. reviewed the literature for evidence of efficacy of nonpharmacological strategies in managing the challenging behaviors in FTD. They found no randomized controlled trials and make recommendations for future research.\nBuchanan JA, Christenson A, Houlihan D, Ostrom C. The role of behavior analysis in the rehabilitation of persons with dementia. Behav Ther. 2011;42(1):9–21.\nSpector A, Charlesworth G, King M, Lattimer M, Sadek S, Marston L, et al. Cognitive-behavioural therapy for anxiety in dementia: pilot randomised controlled trial. Br J Psychiatry. 2015;206(6):509–16.\nFick WF, van der Borgh JP, Jansen S, Koopmans RT. The effect of a lollipop on vocally disruptive behavior in a patient with frontotemporal dementia: a case-study. Int Psychogeriatr. 2014;26(12):2023–6.\nLavretsky H. Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials? Am J Geriatr Psychiatr. 2008;16(7):523–7.\nTune LE, Rosenberg J. Nonpharmacological treatment of inappropriate sexual behavior in dementia: the case of the pink panther. Am J Geriatr Psychiatr. 2008;16(7):612–3.\nCovinsky KE, Johnston CB. Envisioning better approaches for dementia care. Ann Intern Med. 2006;145(10):780–1.\nFraker J, Kales HC, Blazek M, Kavanagh J, Gitlin LN. The role of the occupational therapist in the management of neuropsychiatric symptoms of dementia in clinical settings. Occup Ther Health Care. 2014;28(1):4–20.",{"VOID":1748},"10.1007\u002Fs11910-015-0618-1","2024-05-16T20:41:57.844+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-015-0618-1",[1752,1776,1791,1811],{"id":1753,"sortIndex":23,"researcher":22,"roles":1754,"affiliations":1755,"properties":1773,"displayName":1775,"givenName":22,"familyName":22},"790bfd4c-81a1-4758-8b06-11de24aa8ca1",[586],[1756,1764],{"id":1757,"sortIndex":23,"affiliation":1758,"properties":22},"50bf712c-f98f-4bf6-9eb6-cf1f8234bdef",{"id":1757,"createTime":22,"updateTime":22,"relativeEntities":1759,"slug":22,"properties":1760,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1763,"statistic":22},[],{"title":1761},{"VI":1762},"Department of Neurology, Memory and Aging Center, University of California, San Francisco, USA",[],{"id":1765,"sortIndex":146,"affiliation":1766,"properties":1772},"7c751286-2e48-4b50-9efb-a326d48f1b0b",{"id":1765,"createTime":22,"updateTime":22,"relativeEntities":1767,"slug":22,"properties":1768,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1771,"statistic":22},[],{"title":1769},{"VI":1770},"School of Nursing, University of California, San Francisco, USA",[],{},{"title":1774},{"VI":1775},"Cynthia Barton",{"id":1777,"sortIndex":146,"researcher":22,"roles":1778,"affiliations":1779,"properties":1786,"displayName":1788,"givenName":22,"familyName":22},"a2fe3432-cc3c-4a16-bde5-4df0c9ba6390",[586],[1780],{"id":1757,"sortIndex":23,"affiliation":1781,"properties":22},{"id":1757,"createTime":22,"updateTime":22,"relativeEntities":1782,"slug":22,"properties":1783,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1785,"statistic":22},[],{"title":1784},{"VI":1762},[],{"title":1787,"gsAuthor":1789},{"VI":1788},"Robin Ketelle",{"VOID":1790},"[\"M2A2_uQAAAAJ\"]",{"id":1792,"sortIndex":304,"researcher":22,"roles":1793,"affiliations":1794,"properties":1808,"displayName":1810,"givenName":22,"familyName":22},"726f5aaa-c918-45d6-a7b9-0e316ed6e56f",[586],[1795,1801],{"id":1757,"sortIndex":23,"affiliation":1796,"properties":22},{"id":1757,"createTime":22,"updateTime":22,"relativeEntities":1797,"slug":22,"properties":1798,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1800,"statistic":22},[],{"title":1799},{"VI":1762},[],{"id":1765,"sortIndex":146,"affiliation":1802,"properties":1807},{"id":1765,"createTime":22,"updateTime":22,"relativeEntities":1803,"slug":22,"properties":1804,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1806,"statistic":22},[],{"title":1805},{"VI":1770},[],{},{"title":1809},{"VI":1810},"Jennifer Merrilees",{"id":1812,"sortIndex":1519,"researcher":22,"roles":1813,"affiliations":1814,"properties":1821,"displayName":1823,"givenName":22,"familyName":22},"12e4d779-4a9e-4fea-9b33-0210c6ef574b",[586],[1815],{"id":1757,"sortIndex":23,"affiliation":1816,"properties":22},{"id":1757,"createTime":22,"updateTime":22,"relativeEntities":1817,"slug":22,"properties":1818,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1820,"statistic":22},[],{"title":1819},{"VI":1762},[],{"title":1822},{"VI":1823},"Bruce Miller",{"url":1750,"publisher":1825,"properties":1871},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1826,"slug":10,"properties":1827,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1831,"manageAffiliations":1840,"indexDatabases":1851,"url":22,"thumbnailPath":22,"statistic":1866,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":1828,"title":1829,"eissn":1830},{"VOID":15},{"EN":17},{"VOID":13},[1832,1836],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1833,"label":1834,"description":1835,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1837,"label":1838,"description":1839,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1841,1846],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1842,"slug":22,"properties":1843,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1845,"statistic":22},[],{"title":1844},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":1847,"slug":22,"properties":1848,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1850,"statistic":22},[],{"title":1849},{"EN":50},[],[1852,1859],{"id":54,"indexDatabase":1853,"url":67,"indexYears":22,"academicFieldIds":1858,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":1854,"label":1855,"description":1856,"key":63,"publicationTags":1857,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":1860,"url":83,"indexYears":84,"academicFieldIds":1865,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":1861,"label":1862,"description":1863,"key":80,"publicationTags":1864,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":1867,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":1868,"totalCitation":123,"totalCitationByYear":1869,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":1870,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":1872,"volume":1873},{"VOID":1607},{"VOID":1874},"16","2016-01-11",2016,[88,65],{"id":1879,"createTime":1880,"updateTime":1881,"relativeEntities":1882,"slug":1883,"properties":1884,"entityType":195,"verifyStatus":196,"verifyTime":1893,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":1894,"fullTextUrl":22,"authors":1895,"publicationType":243,"publisherRelationship":1924,"citationCount":23,"citationInfo":1976,"publishDate":1979,"publishYear":1977,"citationAnalyzeStatus":21,"lastCitationAnalyze":1881,"indexDatabases":1980,"openAccess":22,"references":1981,"isForceReanalyzing":562},"42528aa2-6fd6-4e47-807a-accba2563b7d","2024-01-04T10:41:53.009+00:00","2026-04-18T18:06:05.707+00:00",[],"Sensory-Neuronopathies",{"abstract":1885,"title":1887,"gsPaper":1889,"doi":1891},{"EN":1886},"The sensory neuronopathies are sensory-predominant polyneuropathies that result from damage to the dorsal root and trigeminal sensory ganglia. This review explores the various causes of acquired sensory neuronopathies, the approach to diagnosis, and treatment. Diagnostic criteria have recently been published and validated to allow differentiation of sensory neuronopathies from other polyneuropathies. On the basis of serial electrodiagnostic studies, the treatment window for the acquired sensory neuronopathies has been identified as approximately 8 months. If treatment is initiated within 2 months of symptom onset, there is a better opportunity for improvement of the patient's condition. Even though sensory neuronopathies are rare, significant progress has been made regarding characterization of their clinical, electrophysiologic, and imaging features. This does not hold true, however, for treatment. There have been no randomized controlled clinical trials to guide management of these diseases, and a standard treatment approach remains undetermined.",{"EN":1888},"Sensory Neuronopathies",{"VOID":1890},"[\"17638823674470027712\",\"12749946683823877541\"]",{"VOID":1892},"10.1007\u002Fs11910-017-0784-4","2024-05-03T03:40:15.459+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-017-0784-4",[1896,1911],{"id":1897,"sortIndex":23,"researcher":22,"roles":1898,"affiliations":1899,"properties":1908,"displayName":1910,"givenName":22,"familyName":22},"5ce289ca-23d5-4231-a6ac-4b911219e528",[586],[1900],{"id":1901,"sortIndex":23,"affiliation":1902,"properties":22},"2935f229-7462-4d43-8a9b-9bbd1ad47c83",{"id":1901,"createTime":22,"updateTime":22,"relativeEntities":1903,"slug":22,"properties":1904,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1907,"statistic":22},[],{"title":1905},{"VI":1906},"Department of Neurology, University of Virginia, Charlottesville, USA",[],{"title":1909},{"VI":1910},"Allison Crowell",{"id":1912,"sortIndex":146,"researcher":22,"roles":1913,"affiliations":1914,"properties":1921,"displayName":1923,"givenName":22,"familyName":22},"22306349-b7c2-4d67-b7e1-8e6e7efd7871",[586],[1915],{"id":1901,"sortIndex":23,"affiliation":1916,"properties":22},{"id":1901,"createTime":22,"updateTime":22,"relativeEntities":1917,"slug":22,"properties":1918,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1920,"statistic":22},[],{"title":1919},{"VI":1906},[],{"title":1922},{"VI":1923},"Kelly G. Gwathmey",{"url":1894,"publisher":1925,"properties":1971},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1926,"slug":10,"properties":1927,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1931,"manageAffiliations":1940,"indexDatabases":1951,"url":22,"thumbnailPath":22,"statistic":1966,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":1928,"title":1929,"eissn":1930},{"VOID":15},{"EN":17},{"VOID":13},[1932,1936],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1933,"label":1934,"description":1935,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1937,"label":1938,"description":1939,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1941,1946],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1942,"slug":22,"properties":1943,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1945,"statistic":22},[],{"title":1944},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":1947,"slug":22,"properties":1948,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1950,"statistic":22},[],{"title":1949},{"EN":50},[],[1952,1959],{"id":54,"indexDatabase":1953,"url":67,"indexYears":22,"academicFieldIds":1958,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":1954,"label":1955,"description":1956,"key":63,"publicationTags":1957,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":1960,"url":83,"indexYears":84,"academicFieldIds":1965,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":1961,"label":1962,"description":1963,"key":80,"publicationTags":1964,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":1967,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":1968,"totalCitation":123,"totalCitationByYear":1969,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":1970,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":1972,"volume":1974},{"VOID":1973},"1-10",{"VOID":1975},"17",{"total":23,"publishYear":1977,"statisticByYear":1978},2017,{},"2017-08-23",[88,65],[1982,1985,1988,1991,1994,1997,2003,2009,2012,2015,2021,2024,2027,2030,2033,2036,2039,2042,2048,2051,2054,2057,2060,2066,2069,2072,2075,2078,2081,2084,2087,2090,2093,2096,2102,2105,2108,2114,2117,2120,2123,2126,2129,2132,2135,2138,2144,2150,2153,2156,2159,2162,2165,2168,2171,2174,2179,2182,2185,2188,2191,2194,2197,2200,2203,2206,2209,2215,2218,2221,2224,2230,2233,2236,2239,2242,2245,2248,2251,2254,2257,2263,2266,2269,2272,2275,2278,2281,2284,2290,2293,2296,2299,2305,2311,2314,2317,2320,2323,2326,2329,2332,2335,2338,2344,2350,2353,2356,2359],{"id":1072,"text":1983,"url":1074,"identifiers":1984},"Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72:78–90.",{"doi":1076},{"id":1072,"text":1986,"url":1074,"identifiers":1987},"Lax NZ, Whittaker RG, Hepplewhite PD, Reeve AK, Blakely EL, Jaros E, et al. Sensory neuronopathy in patients harbouring recessive polymerase γ mutations. Brain. 2012;135:62–71.",{"doi":1076},{"id":1072,"text":1989,"url":1074,"identifiers":1990},"Szmulewicz DJ, McLean CA, Rodriguez ML, Chancellor AM, Mossman S, Lamont D, et al. Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology. 2014;82:1410–5.",{"doi":1076},{"id":1072,"text":1992,"url":1074,"identifiers":1993},"Bejaoui K, Wu C, Scheffler MD, Haan G, Ashby P, Wu L, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001;27:261–2.",{"doi":1076},{"id":1072,"text":1995,"url":1074,"identifiers":1996},"Vucic S, Tian D, Chong PST, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006;129:3384–90.",{"doi":1076},{"id":1998,"text":1999,"url":2000,"identifiers":2001},"640ba601-f17d-474a-bc22-8c3f8715463c","Colli BO, Carlotti CG, Assirati JA. Lopes L da S, Marques W, Chimelli L, et al. Dorsal root ganglionectomy for the diagnosis of sensory neuropathies. Surgical technique and results. Surg Neurol. 2008;69:266–73. discussion 273","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS009030190700198X",{"doi":2002},"10.1016\u002Fj.surneu.2007.01.057",{"id":2004,"text":2005,"url":2006,"identifiers":2007},"b0e8be37-e85d-4965-b773-212fb7d14c1d","Oh SJ, Gürtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116:28–34.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1388245704002810",{"doi":2008},"10.1016\u002Fj.clinph.2004.07.012",{"id":1072,"text":2010,"url":1074,"identifiers":2011},"Antoine JC, Honnorat J, Camdessanché JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49:214–21.",{"doi":1076},{"id":1072,"text":2013,"url":1074,"identifiers":2014},"Ogawa M, Nishie M, Kurahashi K, Kaimori M, Wakabayashi K. Anti-Hu associated paraneoplastic sensory neuronopathy with upper motor neurone involvement. J Neurol Neurosurg Psychiatry. 2004;75:1051–3.",{"doi":1076},{"id":2016,"text":2017,"url":2018,"identifiers":2019},"315bfb73-e103-4fde-9ecd-36fcf13f5f8a","Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis\u002Fsensory neuronopathy. J Neurol. 2002;249:745–53.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs00415-002-0706-4",{"doi":2020},"10.1007\u002Fs00415-002-0706-4",{"id":1072,"text":2022,"url":1074,"identifiers":2023},"Wabbels BK, Elflein H, Lorenz B, Kolling G. Bilateral tonic pupils with evidence of anti-Hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica. 218:141–3.",{"doi":1076},{"id":22,"text":2025,"url":22,"identifiers":2026},"Wymenga ANM, Slebos DJ, van der Naalt J, van Putten JWG, Peters FTM. Buikklachten en neurologische symptomen als vroege manifestatie van longkanker: een uiting van het anti-Hu-syndroom. Ned Tijdschr Geneeskd. 2003;147:616–9.",{},{"id":1072,"text":2028,"url":1074,"identifiers":2029},"Briellmann RS, Sturzenegger M, Gerber HA, Schaffner T, Hess CW. Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Eur Neurol. 1996;36:369–73.",{"doi":1076},{"id":1072,"text":2031,"url":1074,"identifiers":2032},"Wildhaber B, Niggli F, Stallmach T, Willi U, Stauffer UG, Sacher P. Intestinal pseudoobstruction as a paraneoplastic syndrome in ganglioneuroblastoma. Eur J Pediatr Surg. 2002;12:429–31.",{"doi":1076},{"id":1072,"text":2034,"url":1074,"identifiers":2035},"Camdessanché J-P, Antoine J-C, Honnorat J, Vial C, Petiot P, Convers P, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125:166–75.",{"doi":1076},{"id":1072,"text":2037,"url":1074,"identifiers":2038},"Taieb G, Renard D, Deverdal M, Honnorat J, Labauge P, Castelnovo G. Pure monomelic sensory neuronopathy associated with anti-yo antibodies. Muscle Nerve. 2012;45:297–8.",{"doi":1076},{"id":1072,"text":2040,"url":1074,"identifiers":2041},"Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56:172–7.",{"doi":1076},{"id":2043,"text":2044,"url":2045,"identifiers":2046},"a94e6755-3ef2-42d3-b4a7-3b5a685af9a2","Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.","https:\u002F\u002Facademic.oup.com\u002Fbrain\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Fbrain\u002F124.6.1138",{"doi":2047},"10.1093\u002Fbrain\u002F124.6.1138",{"id":1072,"text":2049,"url":1074,"identifiers":2050},"Côté-Mantha E, Savard M. Paraneoplastic anti-HU syndrome associated with uterine tumor. Can J Neurol Sci. 2012;39:254–5.",{"doi":1076},{"id":22,"text":2052,"url":22,"identifiers":2053},"Fournier CN, Kalra A, Lachance DH, Zarwan C, Srinivasan J. ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor. Muscle Nerve. 2013;47:776–7.",{},{"id":1072,"text":2055,"url":1074,"identifiers":2056},"Sano T, Tanaka K, Ito N. Anti-Hu-antibody-associated paraneoplastic neurological syndrome accompanying testicular cancer. Int J Urol. 2010;17:99.",{"doi":1076},{"id":1072,"text":2058,"url":1074,"identifiers":2059},"Lukacs S, Szabo N, Woodhams S. Rare association of anti-Hu antibody positive paraneoplastic neurological syndrome and transitional cell bladder carcinoma. Case Rep Urol. 2012;2012:724940.",{"doi":1076},{"id":2061,"text":2062,"url":2063,"identifiers":2064},"68ea53ca-2975-404f-94a9-e5237385bf01","Cowley A, Pascoe S. Paraneoplastic subacute sensory neuronopathy in association with adenocarcinoma of the prostate. BMJ Case Rep. 2011; doi:10.1136\u002Fbcr.04.2011.4077.","https:\u002F\u002Fcasereports.bmj.com\u002Flookup\u002Fdoi\u002F10.1136\u002Fbcr.04.2011.4077",{"doi":2065},"10.1136\u002Fbcr.04.2011.4077",{"id":1072,"text":2067,"url":1074,"identifiers":2068},"Matsui T, Hori Y, Nagano H, Eguchi H, Marubashi S, Wada H, et al. Poorly differentiated hepatocellular carcinoma accompanied by anti-Hu antibody-positive paraneoplastic peripheral neuropathy. Pathol Int. 2015;65:388–92.",{"doi":1076},{"id":1072,"text":2070,"url":1074,"identifiers":2071},"Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51:1146–50.",{"doi":1076},{"id":1072,"text":2073,"url":1074,"identifiers":2074},"Tomita M, Koike H, Kawagashira Y, Iijima M, Adachi H, Taguchi J, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136:2563–78.",{"doi":1076},{"id":22,"text":2076,"url":22,"identifiers":2077},"Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2:e27384.",{},{"id":1072,"text":2079,"url":1074,"identifiers":2080},"Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol. 1995;38:102–10.",{"doi":1076},{"id":1072,"text":2082,"url":1074,"identifiers":2083},"Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Cañete A, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer. 1995;75:99–109.",{"doi":1076},{"id":1072,"text":2085,"url":1074,"identifiers":2086},"Kuntzer T, Antoine J-C, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30:255–68.",{"doi":1076},{"id":22,"text":2088,"url":22,"identifiers":2089},"•• Antoine J-C, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci. 2016;361:187–91. The authors retrospectively studied the electrophysiological study findings of 86 patients with inflammatory sensory neuronopathy. They used the sensory nerve action potentials as a surrogate marker of neuronal degeneration. The sensory responses declined rapidly in the first 2 months, the decline slowed down after 7 months, and stabilized after 10 months. They concluded that there is a brief therapeutic window of 8 months. Abatement of the disease is possible if treatment is initiated in the first 2 months.",{},{"id":1072,"text":2091,"url":1074,"identifiers":2092},"Antoine J-C, Camdessanché J-P. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol. 2013;15:210–23.",{"doi":1076},{"id":1072,"text":2094,"url":1074,"identifiers":2095},"Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve. 1997;20:1576–82.",{"doi":1076},{"id":2097,"text":2098,"url":2099,"identifiers":2100},"bc0eeee8-bba9-425a-b24e-f0d41804ac22","Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol. 2013;14:528–38.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11864-013-0249-1",{"doi":2101},"10.1007\u002Fs11864-013-0249-1",{"id":1072,"text":2103,"url":1074,"identifiers":2104},"Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388–92.",{"doi":1076},{"id":1072,"text":2106,"url":1074,"identifiers":2107},"Graus F, Vega F, Delattre JY, Bonaventura I, Reñé R, Arbaiza D, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536–40.",{"doi":1076},{"id":2109,"text":2110,"url":2111,"identifiers":2112},"48d6e85d-b827-46b6-997f-39f0d8d38302","Shams’ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van’t Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253:16–20.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00415-005-0882-0",{"doi":2113},"10.1007\u002Fs00415-005-0882-0",{"id":1072,"text":2115,"url":1074,"identifiers":2116},"de Jongste AH, van Gelder T, Bromberg JE, de Graaf MT, Gratama JW, Schreurs MW, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro Oncol. 2015;17:145–50.",{"doi":1076},{"id":1072,"text":2118,"url":1074,"identifiers":2119},"Malinow K, Yannakakis GD, Glusman SM, Edlow DW, Griffin J, Pestronk A, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren’s syndrome. Ann Neurol. 1986;20:535–7.",{"doi":1076},{"id":1072,"text":2121,"url":1074,"identifiers":2122},"Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27–33.",{"doi":1076},{"id":22,"text":2124,"url":22,"identifiers":2125},"• Pereira PR, Viala K, Maisonobe T, Haroche J, Mathian A, Hié M, et al. Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine (Baltimore). 2016;95:e3632. This is a retrospective study of 13 patients with Sjögren's syndrome-associated sensory neuronopathy. Patients presented most often with ataxia and areflexia. They were treated with a number of therapies, including corticosteroids, mycophenolate mofetil, hydroxychloroquine, and intravenous immune globulin. The authors concluded that Sjögren's syndrome-associated sensory neuronopathy is heterogeneous, insidious, chronic, and debilitating despite treatment. The patients treated with immunosuppressive drugs such as mycophenolate mofetil and corticosteroids did well compared with those treated with intravenous immune globulin.",{},{"id":22,"text":2127,"url":22,"identifiers":2128},"Brito-Zerón P, Akasbi M, Bosch X, Bové A, Pérez-De-Lis M, Diaz-Lagares C, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2013;31:103–10.",{},{"id":22,"text":2130,"url":22,"identifiers":2131},"Carvajal Alegria G, Guellec D, Devauchelle-Pensec V, Saraux A. Is there specific neurological disorders of primary Sjögren’s syndrome? Joint Bone Spine. 2015;82:86–9.",{},{"id":1072,"text":2133,"url":1074,"identifiers":2134},"Fauchais A-L, Magy L, Vidal E. Central and peripheral neurological complications of primary Sjögren’s syndrome. Presse Med. 2012;41:e485–93.",{"doi":1076},{"id":1072,"text":2136,"url":1074,"identifiers":2137},"Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol. 1990;27:304–15.",{"doi":1076},{"id":2139,"text":2140,"url":2141,"identifiers":2142},"97f9927a-805c-4057-9f27-eb4c34267d0c","Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128:2518–34.","http:\u002F\u002Facademic.oup.com\u002Fbrain\u002Farticle\u002F128\u002F11\u002F2518\u002F339557\u002FThe-wide-spectrum-of-clinical-manifestations-in",{"doi":2143},"10.1093\u002Fbrain\u002Fawh605",{"id":2145,"text":2146,"url":2147,"identifiers":2148},"1c7acf25-8a18-41d2-8507-c2255f3b5d7e","Damasceno A, França MC, Cury H, Nucci A. Autonomic dysfunction in non-paraneoplastic sensory neuronopathy: beyond sensory abnormalities. J Neurol. 2011;258:231–7.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs00415-010-5730-1",{"doi":2149},"10.1007\u002Fs00415-010-5730-1",{"id":22,"text":2151,"url":22,"identifiers":2152},"Mellgren SI, Göransson LG, Omdal R. Primary Sjögren’s syndrome associated neuropathy. Can J Neurol Sci. 2007;34:280–7.",{},{"id":1072,"text":2154,"url":1074,"identifiers":2155},"Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren’s syndrome. Eur Neurol. 2001;45:270–4.",{"doi":1076},{"id":1072,"text":2157,"url":1074,"identifiers":2158},"Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35:66–9.",{"doi":1076},{"id":22,"text":2160,"url":22,"identifiers":2161},"Santosa A, Lim AYN, Vasoo S, Lau TC, Teng GG. Neurosjögren: early therapy is associated with successful outcomes. J Clin Rheumatol. 2012;18:389–92.",{},{"id":1072,"text":2163,"url":1074,"identifiers":2164},"Martinez ARM, Nunes MB, Nucci A, França MC. Sensory neuronopathy and autoimmune diseases. Autoimmune Dis. 2012;2012:873587.",{"doi":1076},{"id":1072,"text":2166,"url":1074,"identifiers":2167},"Rist S, Sellam J, Hachulla E, Sordet C, Puéchal X, Hatron P, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63:1339–44.",{"doi":1076},{"id":22,"text":2169,"url":22,"identifiers":2170},"Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003;60:503–5.",{},{"id":1072,"text":2172,"url":1074,"identifiers":2173},"Caroyer J-M, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren’s syndrome. Neurology. 2002;59:1113–4.",{"doi":1076},{"id":22,"text":2175,"url":2176,"identifiers":2177},"Goodman BP. Immunoresponsive autonomic neuropathy in Sjögren syndrome—case series and literature review. Am J Ther. 2017; doi:10.1097\u002FMJT.0000000000000583.","http:\u002F\u002Fdx.doi.org\u002F10.1097\u002Fmjt.0000000000000583",{"doi":2178},"10.1097\u002Fmjt.0000000000000583",{"id":22,"text":2180,"url":22,"identifiers":2181},"Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grünewald RA, Davies-Jones AGB. Sensory ganglionopathy due to gluten sensitivity. Neurology. 2010;75:1003–8.",{},{"id":1072,"text":2183,"url":1074,"identifiers":2184},"Marsh MN. The natural history of gluten sensitivity: defining, refining and re-defining. QJM. 1995;88:9–13.",{"doi":1076},{"id":1072,"text":2186,"url":1074,"identifiers":2187},"Hadjivassiliou M, Williamson CA, Woodroofe N. The immunology of gluten sensitivity: beyond the gut. Trends Immunol. 2004;25:578–82.",{"doi":1076},{"id":1072,"text":2189,"url":1074,"identifiers":2190},"Reda H, Chin RL. Peripheral neuropathies of rheumatologic disease and gluten-related disorders. Semin Neurol. 2014;34:413–24.",{"doi":1076},{"id":22,"text":2192,"url":22,"identifiers":2193},"Brannagan TH, Hays AP, Chin SS, Sander HW, Chin RL, Magda P, et al. Small-fiber neuropathy\u002Fneuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol. 2005;62:1574–8.",{},{"id":1072,"text":2195,"url":1074,"identifiers":2196},"McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J. The neurologic significance of celiac disease biomarkers. Neurology. 2014;83:1789–96.",{"doi":1076},{"id":1072,"text":2198,"url":1074,"identifiers":2199},"Volta U, De Giorgio R. Gluten sensitivity: an emerging issue behind neurological impairment? Lancet Neurol. 2010;9:233–5.",{"doi":1076},{"id":1072,"text":2201,"url":1074,"identifiers":2202},"Merchut MP, Adams EM, Morrissey M. Sensory neuronopathy in autoimmune chronic active hepatitis. Neurology. 1993;43:2410–1.",{"doi":1076},{"id":22,"text":2204,"url":22,"identifiers":2205},"Magy L, Bassez G, Chassande B, Poynard T, Léger JM. Neuronopathie sensitive associee a une hepatite chronique auto-immune. Rev Neurol (Paris). 1997;153:70–2.",{},{"id":22,"text":2207,"url":22,"identifiers":2208},"Liedholm LJ, Månsson A, Holmgren H. Subakuta sensoriska neuropatier. Nord Med. 1994;109:296–7. 309",{},{"id":2210,"text":2211,"url":2212,"identifiers":2213},"7248ea34-7d4b-492e-90f5-95d00f19da70","Navinan MR, Piranavan P, Akram AUA, Yudhishdran J, Kandeepan T, Kulatunga A. Sensory neuronopathy complicating systemic lupus erythematosus: a case report. J Med Case Rep. 2014;8:141.","https:\u002F\u002Fjmedicalcasereports.biomedcentral.com\u002Farticles\u002F10.1186\u002F1752-1947-8-141",{"doi":2214},"10.1186\u002F1752-1947-8-141",{"id":1072,"text":2216,"url":1074,"identifiers":2217},"Wang J-C, Lin Y-C, Yang T-F, Lin H-Y. Ataxic sensory neuronopathy in a patient with systemic lupus erythematosus. Lupus. 2012;21:905–9.",{"doi":1076},{"id":1072,"text":2219,"url":1074,"identifiers":2220},"Alix JJP, Hadjivassiliou M, Ali R, Slater D, Messenger AG, Rao DG. Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy. Muscle Nerve. 2015;51:296–301.",{"doi":1076},{"id":22,"text":2222,"url":22,"identifiers":2223},"•• Antoine J-C, Boutahar N, Lassablière F, Reynaud E, Ferraud K, Rogemond V, et al. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry. 2015;86:1347–55. The authors identified anti-fibroblast growth factor receptor 3 antibodies in 17 patients, 16 of whom had a sensory neuropathy. The authors concluded that these antibodies may be seen in patients with an underlying autoimmune disorder affecting the dorsal root and trigeminal nerve ganglia as 87% of patients had a non-length-dependent neuropathy consistent with sensory neuronopathy.",{},{"id":2225,"text":2226,"url":2227,"identifiers":2228},"f2a20fbc-9049-4c7f-94f5-4f28725829b0","Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuronopathy and neuropathy: revisited. Neurol Sci. 2014;35:1827–30.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10072-014-1902-6",{"doi":2229},"10.1007\u002Fs10072-014-1902-6",{"id":22,"text":2231,"url":22,"identifiers":2232},"Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309:445–8.",{},{"id":1072,"text":2234,"url":1074,"identifiers":2235},"Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology. 1989;39:1077–83.",{"doi":1076},{"id":1072,"text":2237,"url":1074,"identifiers":2238},"Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466–8.",{"doi":1076},{"id":1072,"text":2240,"url":1074,"identifiers":2241},"Perry TA, Weerasuriya A, Mouton PR, Holloway HW, Greig NH. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol. 2004;190:133–44.",{"doi":1076},{"id":1072,"text":2243,"url":1074,"identifiers":2244},"Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27–46.",{"doi":1076},{"id":1072,"text":2246,"url":1074,"identifiers":2247},"Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.",{"doi":1076},{"id":1072,"text":2249,"url":1074,"identifiers":2250},"Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116:2322–31.",{"doi":1076},{"id":1072,"text":2252,"url":1074,"identifiers":2253},"Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130:1076–88.",{"doi":1076},{"id":1072,"text":2255,"url":1074,"identifiers":2256},"Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86.",{"doi":1076},{"id":2258,"text":2259,"url":2260,"identifiers":2261},"6f085632-5f6b-44ed-9244-b1201207bc99","Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 2011;41:661–8.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS096999611000392X",{"doi":2262},"10.1016\u002Fj.nbd.2010.11.017",{"id":1072,"text":2264,"url":1074,"identifiers":2265},"Maj MA, Ma J, Krukowski KN, Kavelaars A, Heijnen CJ. Inhibition of mitochondrial p53 accumulation by PFT-μ prevents cisplatin-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:108.",{"doi":1076},{"id":1072,"text":2267,"url":1074,"identifiers":2268},"Novak P, Pimentel DA, Sundar B, Moonis M, Qin L, Novak V. Association of statins with sensory and autonomic ganglionopathy. Front Aging Neurosci. 2015;7:191.",{"doi":1076},{"id":1072,"text":2270,"url":1074,"identifiers":2271},"Rance NE, McArthur JC, Cornblath DR, Landstrom DL, Griffin JW, Price DL. Gracile tract degeneration in patients with sensory neuropathy and AIDS. Neurology. 1988;38:265–71.",{"doi":1076},{"id":1072,"text":2273,"url":1074,"identifiers":2274},"Scaravilli F, Sinclair E, Arango JC, Manji H, Lucas S, Harrison MJ. The pathology of the posterior root ganglia in AIDS and its relationship to the pallor of the gracile tract. Acta Neuropathol. 1992;84:163–70.",{"doi":1076},{"id":1072,"text":2276,"url":1074,"identifiers":2277},"Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol. 2005;4:349–61.",{"doi":1076},{"id":1072,"text":2279,"url":1074,"identifiers":2280},"Rubin DI, Daube JR. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve. 1999;22:1607–10.",{"doi":1076},{"id":1072,"text":2282,"url":1074,"identifiers":2283},"Ramos F, Monforte C, Luengo Neuronopatia aguda sensitiva asociada a infeccion por virus varicela-zoster. Rev. Neurol. 1999;28:1067–9.",{"doi":1076},{"id":2285,"text":2286,"url":2287,"identifiers":2288},"614be255-ff66-4e44-bcca-bec046ad232d","Shimazaki R, Ueyama H, Mori T, Mori M, Fujimoto S, Kumamoto T, et al. Chronic sensory neuronopathy associated with human T-cell lymphotropic virus type I infection. J Neurol Sci. 2002;194:55–8.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022510X0100675X",{"doi":2289},"10.1016\u002Fs0022-510x(01)00675-x",{"id":1072,"text":2291,"url":1074,"identifiers":2292},"Mansukhani KA, Khadilkar SV. Consider leprosy as an etiology of sensory neuronopathy. Muscle Nerve. 2017;55:928.",{"doi":1076},{"id":1072,"text":2294,"url":1074,"identifiers":2295},"Chiu C-C, Yang C-Y, Yang T-F, Lin K-P, Huang S-H, Wang J-C. Acute sensory neuronopathy following enterovirus infection in a 3-year-old girl. Neuropediatrics. 2017;48:190–3.",{"doi":1076},{"id":1072,"text":2297,"url":1074,"identifiers":2298},"Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol. 1986;19:545–54.",{"doi":1076},{"id":2300,"text":2301,"url":2302,"identifiers":2303},"f27f9857-a633-4809-9579-de62d3407ca3","van Dijk GW, Wokke JH, Notermans NC, van den Berg LH, Bär PR. Indications for an immune-mediated etiology of idiopathic sensory neuronopathy. J Neuroimmunol. 1997;74:165–72.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165572896002251",{"doi":2304},"10.1016\u002Fs0165-5728(96)00225-1",{"id":2306,"text":2307,"url":2308,"identifiers":2309},"e766c5d8-7e14-4cec-aa04-603a74040f1a","Camdessanché J-P, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132:1723–33.","https:\u002F\u002Facademic.oup.com\u002Fbrain\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Fbrain\u002Fawp136",{"doi":2310},"10.1093\u002Fbrain\u002Fawp136",{"id":1072,"text":2312,"url":1074,"identifiers":2313},"• Antoine J-C, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, et al. Testing the validity of a set of diagnostic criteria for sensory neuronopathies: a francophone collaborative study. J Neurol. 2014;261:2093–100. The sensory neuronopathy criteria, published in 2009, were validated in 210 patients in a multicenter French study.",{"doi":1076},{"id":1072,"text":2315,"url":1074,"identifiers":2316},"Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. Eur Neurol. 2003;50:146–52.",{"doi":1076},{"id":1072,"text":2318,"url":1074,"identifiers":2319},"Sterman AB, Schaumburg HH, Asbury AK. The acute sensory neuronopathy syndrome: a distinct clinical entity. Ann Neurol. 1980;7:354–8.",{"doi":1076},{"id":22,"text":2321,"url":22,"identifiers":2322},"Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy: clinical features and electrophysiologic and pathologic changes. Neurology. 1990;40:584–91.",{},{"id":22,"text":2324,"url":22,"identifiers":2325},"Rothwell JC, Traub MM, Day BL, Obeso JA, Thomas PK, Marsden CD. Manual motor performance in a deafferented man. Brain. 1982;105(Pt 3):515–42.",{},{"id":1072,"text":2327,"url":1074,"identifiers":2328},"Molinuevo JL, Graus F, Serrano C, Reñe R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol. 1998;44:976–80.",{"doi":1076},{"id":1072,"text":2330,"url":1074,"identifiers":2331},"Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci. 1992;19:346–51.",{"doi":1076},{"id":1072,"text":2333,"url":1074,"identifiers":2334},"Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.",{"doi":1076},{"id":1072,"text":2336,"url":1074,"identifiers":2337},"Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Roentgenol. 1998;170:1513–7.",{"doi":1076},{"id":2339,"text":2340,"url":2341,"identifiers":2342},"b5e555a2-5c6b-4970-afaa-3daff818f4b5","Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET\u002FCT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923–30.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00330-009-1606-0",{"doi":2343},"10.1007\u002Fs00330-009-1606-0",{"id":2345,"text":2346,"url":2347,"identifiers":2348},"5a68f2ad-e69e-403e-ac0c-29a7e4472efb","Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e3.","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1468-1331.2010.03220.x",{"doi":2349},"10.1111\u002Fj.1468-1331.2010.03220.x",{"id":1072,"text":2351,"url":1074,"identifiers":2352},"Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol. 2000;47:104–9.",{"doi":1076},{"id":1072,"text":2354,"url":1074,"identifiers":2355},"Bao Y-F, Tang W-J, Zhu D-Q, Li Y-X, Zee C-S, Chen X-J, et al. Sensory neuronopathy involves the spinal cord and brachial plexus: a quantitative study employing multiple-echo data image combination (MEDIC) and turbo inversion recovery magnitude (TIRM). Neuroradiology. 2013;55:41–8.",{"doi":1076},{"id":1072,"text":2357,"url":1074,"identifiers":2358},"Casseb RF, de Paiva JLR, Branco LMT, Martinez ARM, Reis F, de Lima-Junior JC, et al. Spinal cord diffusion tensor imaging in patients with sensory neuronopathy. Neuroradiology. 2016;58:1103–8.",{"doi":1076},{"id":1072,"text":2360,"url":1074,"identifiers":2361},"Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications. Muscle Nerve. 2003;28:553–60.",{"doi":1076},{"id":2363,"createTime":2364,"updateTime":2365,"relativeEntities":2366,"slug":2367,"properties":2368,"entityType":195,"verifyStatus":196,"verifyTime":2377,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":2378,"fullTextUrl":22,"authors":2379,"publicationType":243,"publisherRelationship":2426,"citationCount":23,"citationInfo":2477,"publishDate":2479,"publishYear":663,"citationAnalyzeStatus":21,"lastCitationAnalyze":2480,"indexDatabases":2481,"openAccess":22,"references":2482,"isForceReanalyzing":562},"1efb8fc9-5f88-4e91-8041-a0b3cc4d0c4c","2024-01-01T07:11:51.976+00:00","2026-04-14T20:33:22.305+00:00",[],"Management-of-Psychological-Complications-Following-Mild-Traumatic-Brain-Injury",{"abstract":2369,"title":2371,"gsPaper":2373,"doi":2375},{"EN":2370},"It has been clear for decades that psychological factors often contribute to mild traumatic brain injury (mTBI) outcome, but an emerging literature has begun to clarify which specific factors are important, when, for whom, and how they impact recovery. This review aims to summarize the contemporary evidence on psychological determinants of recovery from mTBI and its implications for clinical management. Comorbid mental health disorders and specific illness beliefs and coping behaviors (e.g., fear avoidance) are associated with worse recovery from mTBI. Proactive assessment and intervention for psychological complications can improve clinical outcomes. Evidence-based treatments for primary mental health disorders are likely also effective for treating mental health disorders after mTBI, and can reduce overall post-concussion symptoms. Broad-spectrum cognitive-behavioral therapy may modestly improve post-concussion symptoms, but tailoring delivery to individual psychological risk factors and\u002For symptoms may improve its efficacy. Addressing psychological factors in treatments delivered primarily by non-psychologists is a promising and cost-effective approach for enhancing clinical management of mTBI. Recent literature emphasizes a bio-psycho-socio-ecological framework for understanding mTBI recovery and a precision rehabilitation approach to maximize recovery. Integrating psychological principles into rehabilitation and tailoring interventions to specific risk factors may improve clinical management of mTBI.",{"EN":2372},"Management of Psychological Complications Following Mild Traumatic Brain Injury",{"VOID":2374},"[\"12819341275976540389\"]",{"VOID":2376},"10.1007\u002Fs11910-023-01251-9","2024-05-01T08:14:38.886+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11910-023-01251-9",[2380,2405],{"id":2381,"sortIndex":23,"researcher":22,"roles":2382,"affiliations":2383,"properties":2400,"displayName":2402,"givenName":22,"familyName":22},"58357629-0eb8-46d4-aa50-fb72b0ec739c",[586],[2384,2392],{"id":2385,"sortIndex":23,"affiliation":2386,"properties":22},"70c1d119-db99-4ff3-8633-3e2a50f577eb",{"id":2385,"createTime":22,"updateTime":22,"relativeEntities":2387,"slug":22,"properties":2388,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2391,"statistic":22},[],{"title":2389},{"VI":2390},"Department of Psychology, University of British Columbia, Vancouver, Canada",[],{"id":2393,"sortIndex":146,"affiliation":2394,"properties":22},"67adafa8-19a0-41e4-9d34-531b34bd495c",{"id":2393,"createTime":22,"updateTime":22,"relativeEntities":2395,"slug":22,"properties":2396,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2399,"statistic":22},[],{"title":2397},{"VI":2398},"Rehabilitation Research Program, Vancouver Coastal Health Research Institute, Vancouver, Canada",[],{"title":2401,"gsAuthor":2403},{"VI":2402},"Noah D. Silverberg",{"VOID":2404},"[\"V7xhlQ4AAAAJ\"]",{"id":2406,"sortIndex":146,"researcher":22,"roles":2407,"affiliations":2408,"properties":2421,"displayName":2423,"givenName":22,"familyName":22},"d6f573aa-1f62-4748-ab08-9960ed132991",[586],[2409,2415],{"id":2385,"sortIndex":23,"affiliation":2410,"properties":22},{"id":2385,"createTime":22,"updateTime":22,"relativeEntities":2411,"slug":22,"properties":2412,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2414,"statistic":22},[],{"title":2413},{"VI":2390},[],{"id":2393,"sortIndex":146,"affiliation":2416,"properties":22},{"id":2393,"createTime":22,"updateTime":22,"relativeEntities":2417,"slug":22,"properties":2418,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2420,"statistic":22},[],{"title":2419},{"VI":2398},[],{"title":2422,"gsAuthor":2424},{"VI":2423},"Ana Mikolić",{"VOID":2425},"[\"THhhHJYAAAAJ\"]",{"url":2378,"publisher":2427,"properties":2473},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2428,"slug":10,"properties":2429,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2433,"manageAffiliations":2442,"indexDatabases":2453,"url":22,"thumbnailPath":22,"statistic":2468,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":2430,"title":2431,"eissn":2432},{"VOID":15},{"EN":17},{"VOID":13},[2434,2438],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2435,"label":2436,"description":2437,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2439,"label":2440,"description":2441,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2443,2448],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2444,"slug":22,"properties":2445,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2447,"statistic":22},[],{"title":2446},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":2449,"slug":22,"properties":2450,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2452,"statistic":22},[],{"title":2451},{"EN":50},[],[2454,2461],{"id":54,"indexDatabase":2455,"url":67,"indexYears":22,"academicFieldIds":2460,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":2456,"label":2457,"description":2458,"key":63,"publicationTags":2459,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":2462,"url":83,"indexYears":84,"academicFieldIds":2467,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":2463,"label":2464,"description":2465,"key":80,"publicationTags":2466,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":2469,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":2470,"totalCitation":123,"totalCitationByYear":2471,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":2472,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":2474,"volume":2476},{"VOID":2475},"49-58",{"VOID":660},{"total":23,"publishYear":663,"statisticByYear":2478},{},"2023-02-10","2026-04-14T20:33:22.304+00:00",[88,65],[2483,2486,2489,2492,2495,2498,2501,2504,2507,2510,2513,2516,2519,2522,2525,2528,2531,2534,2540,2543,2546,2549,2552,2555,2558,2561,2564,2567,2570,2573,2579,2582,2585,2588,2591,2594,2600,2603,2611,2614,2617,2620,2623,2626,2629,2633,2637,2641,2644,2647,2650,2653,2656,2659,2662,2665,2668,2671,2674,2677,2680,2683,2689,2692,2698,2701,2704,2707,2710,2713,2716,2719,2722,2725,2728,2731,2734,2740,2743,2746,2749,2752,2759,2765,2768,2771,2774,2777,2780,2783,2786,2792,2795,2798,2801,2804,2807,2810,2813,2816,2819,2822,2825,2828,2831,2834,2837,2840,2843,2846,2849,2855,2858,2861,2864,2872,2875,2878,2881,2884,2887,2890,2893,2896,2902,2905,2908,2911,2914,2917,2920,2926],{"id":22,"text":2484,"url":22,"identifiers":2485},"Matney C, et al. Understanding patients with traumatic brain injury. In: Traumatic Brain Injury: A Roadmap for Accelerating Progress. US: National Academies Press; 2022.",{},{"id":1072,"text":2487,"url":1074,"identifiers":2488},"Van Praag DLG, et al. Post-traumatic stress disorder after civilian traumatic brain injury: a systematic review and meta-analysis of prevalence rates. J Neurotrauma. 2019;36(23):3220–32.",{"doi":1076},{"id":1072,"text":2490,"url":1074,"identifiers":2491},"Iljazi A, et al. Post-traumatic stress disorder after traumatic brain injury—a systematic review and meta-analysis. Neurol Sci. 2020;41(10):2737–46.",{"doi":1076},{"id":1072,"text":2493,"url":1074,"identifiers":2494},"Stein MB, et al. Risk of posttraumatic stress disorder and major depression in civilian patients after mild traumatic brain injury: a TRACK-TBI study. JAMA Psychiat. 2019;76(3):249–58.",{"doi":1076},{"id":1072,"text":2496,"url":1074,"identifiers":2497},"van der Vlegel M, et al. The association of post-concussion and post-traumatic stress disorder symptoms with health-related quality of life, health care use and return-to-work after mild traumatic brain injury. J Clin Med. 2021;10(11):2473.",{"doi":1076},{"id":1072,"text":2499,"url":1074,"identifiers":2500},"Delmonico RL, et al. Prevalence of depression and anxiety disorders following mild traumatic brain injury. PM R. 2022;14(7):753–63.",{"doi":1076},{"id":1072,"text":2502,"url":1074,"identifiers":2503},"Costello K, Greenwald BD. Update on domestic violence and traumatic brain injury: a narrative review. Brain Sci. 2022;12(1).",{"doi":1076},{"id":1072,"text":2505,"url":1074,"identifiers":2506},"Galovski TE, et al. A multi-method approach to a comprehensive examination of the psychiatric and neurological consequences of intimate partner violence in women: a methodology protocol. Front Psych. 2021;12:569335.",{"doi":1076},{"id":1072,"text":2508,"url":1074,"identifiers":2509},"Lamontagne G, et al. Anxiety symptoms and disorders in the first year after sustaining mild traumatic brain injury. Rehabil Psychol. 2022;67(1):90–9.",{"doi":1076},{"id":1072,"text":2511,"url":1074,"identifiers":2512},"Hellewell SC, et al. Characterizing the risk of depression following mild traumatic brain injury: a meta-analysis of the literature comparing chronic mTBI to non-mTBI populations. Front Neurol. 2020;11:350.",{"doi":1076},{"id":1072,"text":2514,"url":1074,"identifiers":2515},"Ledoux A-A, et al. Risk of mental health problems in children and youths following concussion. JAMA Netw Open. 2022;5(3):e221235.",{"doi":1076},{"id":1072,"text":2517,"url":1074,"identifiers":2518},"Wang B, et al. Longitudinal analyses of the reciprocity of depression and anxiety after traumatic brain injury and its clinical implications. J Clin Med. 2021;10(23):5597.",{"doi":1076},{"id":1072,"text":2520,"url":1074,"identifiers":2521},"Iverson GL, Greenberg J, Cook NE. Anxiety is associated with diverse physical and cognitive symptoms in youth presenting to a multidisciplinary concussion clinic. Front Neurol. 2022;12:811462.",{"doi":1076},{"id":1072,"text":2523,"url":1074,"identifiers":2524},"Terry DP, et al. Effect of depression on cognition after mild traumatic brain injury in adults. Clin Neuropsychol. 2019;33(1):124–36.",{"doi":1076},{"id":1072,"text":2526,"url":1074,"identifiers":2527},"Zahniser E, et al. The temporal relationship of mental health problems and functional limitations following mTBI: a TRACK-TBI and TED study. J Neurotrauma. 2019;36(11):1786–93.",{"doi":1076},{"id":1072,"text":2529,"url":1074,"identifiers":2530},"Durga Roy MDMS, et al. Prevalence and correlates of depressive symptoms within 6 months after first-time mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 34(4):367–377.",{"doi":1076},{"id":1072,"text":2532,"url":1074,"identifiers":2533},"Popov N, et al. Factors associated with quality of life in adults with persistent post-concussion symptoms. Can J Neurol Sci. 2022;49(1):109–17.",{"doi":1076},{"id":2535,"text":2536,"url":2537,"identifiers":2538},"ca16983a-0d36-49bf-92a0-a72f0e54a1d0","Helmrich IRAR, et al. Development of prognostic models for health-related quality of life following traumatic brain injury. Qual Life Res. 2022;31(2):451–471.","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11136-021-02932-z",{"doi":2539},"10.1007\u002Fs11136-021-02932-z",{"id":1072,"text":2541,"url":1074,"identifiers":2542},"• Maas AI, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21(11):1004–1060. This publication reviews insights on TBI (including outcomes after mTBI) from contemporary observational cohorts CENTER-TBI and TRACK-TBI.",{"doi":1076},{"id":1072,"text":2544,"url":1074,"identifiers":2545},"Lange RT, Iverson GL, Rose A. Depression strongly influences postconcussion symptom reporting following mild traumatic brain injury. J Head Trauma Rehabil. 2011;26(2):127–37.",{"doi":1076},{"id":1072,"text":2547,"url":1074,"identifiers":2548},"Wilson L, et al. Tailoring multidimensional outcomes to level of functional recovery after traumatic brain injury. J Neurotrauma. 2022;39(19–20):1363–1381.",{"doi":1076},{"id":1072,"text":2550,"url":1074,"identifiers":2551},"Campbell-Sills L, et al. Risk factors for suicidal ideation following mild traumatic brain injury: a TRACK-TBI study. J Head Trauma Rehabil. 2021;36(1):E30–9.",{"doi":1076},{"id":1072,"text":2553,"url":1074,"identifiers":2554},"Scholten AC, et al. Prevalence of and risk factors for anxiety and depressive disorders after traumatic brain injury: a systematic review. J Neurotrauma. 2016;33(22):1969–94.",{"doi":1076},{"id":1072,"text":2556,"url":1074,"identifiers":2557},"Silverberg ND, et al. Systematic review of multivariable prognostic models for mild traumatic brain injury. J Neurotrauma. 2015;32(8):517–26.",{"doi":1076},{"id":1072,"text":2559,"url":1074,"identifiers":2560},"Mikolic A, et al. Prediction of global functional outcome and post-concussive symptoms after mild traumatic brain injury: external validation of prognostic models in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study. J Neurotrauma. 2021;38(2):196–209.",{"doi":1076},{"id":1072,"text":2562,"url":1074,"identifiers":2563},"Mah K, Hickling A, Reed N. Perceptions of mild traumatic brain injury in adults: a scoping review. Disabil Rehabil. 2018;40(8):960–73.",{"doi":1076},{"id":1072,"text":2565,"url":1074,"identifiers":2566},"Snell DL, et al. Wrestling with uncertainty after mild traumatic brain injury: a mixed methods study. Disabil Rehabil. 2020;42(14):1942–53.",{"doi":1076},{"id":1072,"text":2568,"url":1074,"identifiers":2569},"Greenberg J, et al. Pain catastrophizing and limiting behavior mediate the association between anxiety and postconcussion symptoms. Psychosomatics. 2020;61(1):49–55.",{"doi":1076},{"id":1072,"text":2571,"url":1074,"identifiers":2572},"Hou R, et al. When a minor head injury results in enduring symptoms: a prospective investigation of risk factors for postconcussional syndrome after mild traumatic brain injury. J Neurol Neurosurg Psychiatry. 2012;83(2):217–23.",{"doi":1076},{"id":2574,"text":2575,"url":2576,"identifiers":2577},"6e4d78ed-ee38-48d6-802b-c1770bfa616e","van der Naalt J, et al. Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol. 2017;16(7):532–40.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1474442217301175",{"doi":2578},"10.1016\u002Fs1474-4422(17)30117-5",{"id":1072,"text":2580,"url":1074,"identifiers":2581},"Silverberg ND, Panenka WJ, Iverson GL. Fear avoidance and clinical outcomes from mild traumatic brain injury. J Neurotrauma. 2018;35(16):1864–73.",{"doi":1076},{"id":1072,"text":2583,"url":1074,"identifiers":2584},"Cassetta BD, et al. Avoidance and endurance coping after mild traumatic brain injury are associated with disability outcomes. Rehabil Psychol. 2021;66(2):160.",{"doi":1076},{"id":1072,"text":2586,"url":1074,"identifiers":2587},"Faulkner JW, Snell DL, Theadom A. Psychological flexibility moderates the influence of fear avoidance on outcomes after mild traumatic brain injury. Brain Inj. 2022;36(8):991–999.",{"doi":1076},{"id":1072,"text":2589,"url":1074,"identifiers":2590},"Mäki K, et al. Perceived injustice after mild traumatic brain injury. J Head Trauma Rehabil. 2022;37(3):E157–E164.",{"doi":1076},{"id":1072,"text":2592,"url":1074,"identifiers":2593},"Battigelli G, Hussain MW. The role of blame attribution in post-concussion syndrome morbidity: a retrospective analysis of patients at a subspecialty clinic. Neurology. 2020;95(20 Supplement 1):S11–2.",{"doi":1076},{"id":2595,"text":2596,"url":2597,"identifiers":2598},"48fae2fd-ca78-4519-afad-374c88618385","Tuborgh A, et al. Attachment and symptom reporting in adolescents and young adults after a concussion. J Psychosom Res. 2021;150:110603.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022399921002488",{"doi":2599},"10.1016\u002Fj.jpsychores.2021.110603",{"id":1072,"text":2601,"url":1074,"identifiers":2602},"Fordal L, et al. Trajectories of persistent postconcussion symptoms and factors associated with symptom reporting after mild traumatic brain injury. Arch Phys Med Rehabil. 2022;103(2):313–22.",{"doi":1076},{"id":22,"text":2604,"url":2605,"identifiers":2606},"Summerell PA, Smillie LD, Anderson JFI. Personality traits beyond Neuroticism predict post-concussive symptomatology in the post-acute period after mild traumatic brain injury in premorbidly healthy adults. Appl Neuropsychol Adult. 2021:1–10. https:\u002F\u002Fdoi.org\u002F10.1080\u002F23279095.2021.1970554.","https:\u002F\u002Fdoi.org\u002F10.1080\u002F23279095.2021.1970554",{"mag":2607,"openalex":2608,"pm":2609,"doi":2610},"3199488275","W3199488275","34514926","10.1080\u002F23279095.2021.1970554",{"id":1072,"text":2612,"url":1074,"identifiers":2613},"Caze T, et al. Influence of anxiety sensitivity and negative affect on concussion outcomes. Orthop J Sports Med. 2022;10(5_suppl2):2325967121S00424.",{"doi":1076},{"id":1072,"text":2615,"url":1074,"identifiers":2616},"Picon EL, et al. Memory perfectionism is associated with persistent memory complaints after concussion. Arch Clin Neuropsychol. 2022;37(6):1177–1184.",{"doi":1076},{"id":1072,"text":2618,"url":1074,"identifiers":2619},"Elliott TR, et al. Resilience facilitates adjustment through greater psychological flexibility among Iraq\u002FAfghanistan war veterans with and without mild traumatic brain injury. Rehabil Psychol. 2019;64(4):383–97.",{"doi":1076},{"id":1072,"text":2621,"url":1074,"identifiers":2622},"Ernst N, et al. Lower post-injury psychological resilience is associated with increased recovery time and symptom burden following sport-related concussion. Appl Neuropsychol Child. 2022;11(4):781–788.",{"doi":1076},{"id":1072,"text":2624,"url":1074,"identifiers":2625},"Spikman JM, et al. Coping with stress before and after mild traumatic brain injury: a pilot hair cortisol study. Brain Inj. 2021;35(8):871–9.",{"doi":1076},{"id":1072,"text":2627,"url":1074,"identifiers":2628},"Parker HA, et al. Personality characteristics and acute symptom response predict chronic symptoms after mild traumatic brain injury. J Int Neuropsychol Soc. 2021;27(10):992–1003.",{"doi":1076},{"id":22,"text":2630,"url":2631,"identifiers":2632},"Reed N, Zemek R. Living guidelines for pediatric concussion care. 2022. Available from:https:\u002F\u002Fpedsconcussion.com\u002F.","https:\u002F\u002Fpedsconcussion.com\u002F",{},{"id":22,"text":2634,"url":2635,"identifiers":2636},"Marshall S, Bayley M, McCullagh S, Berrigan L, Fischer L, Ouchterlony D, Rockwell C, Velikonja D, et al. Guideline for concussion\u002Fmild traumatic brain injury and persistent symptoms: 3rd edition (for Adults 18+ years of age). Toronto, ON: Ontario Neurotrauma Foundation; 2018. Available at: https:\u002F\u002Fbraininjuryguidelines.org\u002Fconcussion\u002Ffileadmin\u002Fpdf\u002FConcussion_guideline_3rd_edition_final.pdf. Accessed 20 Sept 2022.","https:\u002F\u002Fbraininjuryguidelines.org\u002Fconcussion\u002Ffileadmin\u002Fpdf\u002FConcussion_guideline_3rd_edition_final.pdf",{},{"id":22,"text":2638,"url":2639,"identifiers":2640},"Department of Veterans Affairs and Department of Defense. VA\u002FDoD clinical practice guidelines for the management and rehabilitation of post-acute mild traumatic brain injury. 2021. Available at: https:\u002F\u002Fwww.healthquality.va.gov\u002Fguidelines\u002Frehab\u002Fmtbi\u002F. Accessed 20 Sept 2022","https:\u002F\u002Fwww.healthquality.va.gov\u002Fguidelines\u002Frehab\u002Fmtbi\u002F",{},{"id":1072,"text":2642,"url":1074,"identifiers":2643},"Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Annals. 2002;32(9):509–15.",{"doi":1076},{"id":22,"text":2645,"url":22,"identifiers":2646},"Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.",{},{"id":1072,"text":2648,"url":1074,"identifiers":2649},"Bovin MJ, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379–91.",{"doi":1076},{"id":1072,"text":2651,"url":1074,"identifiers":2652},"Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94(3):135–40.",{"doi":1076},{"id":1072,"text":2654,"url":1074,"identifiers":2655},"von Steinbuechel N, et al. Translation and linguistic validation of outcome instruments for traumatic brain injury research and clinical practice: a step-by-step approach within the observational CENTER-TBI study. J Clin Med. 2021;10(13):2863.",{"doi":1076},{"id":1072,"text":2657,"url":1074,"identifiers":2658},"Steinbuechel NV, et al. Psychometric characteristics of the patient-reported outcome measures applied in the CENTER-TBI study. J Clin Med. 2021;10(11):2396.",{"doi":1076},{"id":1072,"text":2660,"url":1074,"identifiers":2661},"Teymoori A, et al. Measurement invariance of assessments of depression (PHQ-9) and anxiety (GAD-7) across sex, strata and linguistic backgrounds in a European-wide sample of patients after Traumatic Brain Injury. J Affect Disord. 2020;262:278–85.",{"doi":1076},{"id":1072,"text":2663,"url":1074,"identifiers":2664},"Zachar-Tirado CN, Donders J. Clinical utility of the GAD-7 in identifying anxiety disorders after traumatic brain injury. Brain Inj. 2021;35(6):655–60.",{"doi":1076},{"id":1072,"text":2666,"url":1074,"identifiers":2667},"Donders J, Pendery A. Clinical utility of the Patient Health Questionnaire-9 in the assessment of major depression after broad-spectrum traumatic brain injury. Arch Phys Med Rehabil. 2017;98(12):2514–9.",{"doi":1076},{"id":1072,"text":2669,"url":1074,"identifiers":2670},"Fann JR, et al. Validity of the Patient Health Questionnaire-9 in assessing depression following traumatic brain injury. J Head Trauma Rehabil. 2005;20(6):501–11.",{"doi":1076},{"id":1072,"text":2672,"url":1074,"identifiers":2673},"Cook KF, et al. Do somatic and cognitive symptoms of traumatic brain injury confound depression screening? Arch Phys Med Rehabil. 2011;92:818–23.",{"doi":1076},{"id":1072,"text":2675,"url":1074,"identifiers":2676},"Teymoori A, et al. Factorial Structure and Validity of Depression (PHQ-9) and Anxiety (GAD-7) scales after traumatic brain injury. J Clin Med. 2020;9(3):873.",{"doi":1076},{"id":1072,"text":2678,"url":1074,"identifiers":2679},"Ouellet M-C, et al. Depression in the first year after traumatic brain injury. J Neurotrauma. 2018;35:1620–9.",{"doi":1076},{"id":1072,"text":2681,"url":1074,"identifiers":2682},"Silverberg ND, et al. Promoting early treatment for mild traumatic brain injury in primary care with a guideline implementation tool: a pilot cluster randomised trial. BMJ Open. 2020;10(10):e035527.",{"doi":1076},{"id":2684,"text":2685,"url":2686,"identifiers":2687},"99ffd333-6408-413f-9430-b0d839f1a987","McCarty CA, et al. Collaborative care model for treatment of persistent symptoms after concussion among youth (CARE4PCS-II): study protocol for a randomized, controlled trial. Trials. 2019;20(1):567.","https:\u002F\u002Ftrialsjournal.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13063-019-3662-3",{"doi":2688},"10.1186\u002Fs13063-019-3662-3",{"id":22,"text":2690,"url":22,"identifiers":2691},"McCrory P, et al. Consensus statement on concussion in sport-the 5(th) international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017;51(11):838–47.",{},{"id":2693,"text":2694,"url":2695,"identifiers":2696},"73bd97df-b14f-48c7-872c-050436ed00b1","Broadbent E, et al. The brief illness perception questionnaire. J Psychosom Res. 2006;60(6):631–7.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022399905004915",{"doi":2697},"10.1016\u002Fj.jpsychores.2005.10.020",{"id":1072,"text":2699,"url":1074,"identifiers":2700},"Plourde V, et al. Perceptions of symptom duration are associated with emotional distress and functioning in adolescents with protracted concussion recovery. J Pediatr Psychol. 2022.",{"doi":1076},{"id":1072,"text":2702,"url":1074,"identifiers":2703},"Moss-Morris R, et al. The revised illness Perception Questionnaire (IPQ-R). Psychol Health. 2002;17(1):1–16.",{"doi":1076},{"id":1072,"text":2705,"url":1074,"identifiers":2706},"Snell DL, et al. An examination of the factor structure of the Revised Illness Perception Questionnaire modified for adults with mild traumatic brain injury. Brain Inj. 2010;24(13-14):1595–605.",{"doi":1076},{"id":1072,"text":2708,"url":1074,"identifiers":2709},"Spence M, Moss-Morris R, Chalder T. The Behavioural Responses to Illness Questionnaire (BRIQ): a new predictive measure of medically unexplained symptoms following acute infection. Psychol Med. 2005;35:583–93.",{"doi":1076},{"id":22,"text":2711,"url":22,"identifiers":2712},"•• Thastum MM, et al. Novel interdisciplinary intervention, GAIN, vs. enhanced usual care to reduce high levels of post-concussion symptoms in adolescents and young adults 2–6 months post-injury: a randomised trial. EClinical Medicine. 2019;17:100214. This randomized trial focused on modifying specific illness-related cognitions and behaviours within an interdisciplinary intervention showed promising results. It also showed that therapists non-psychologists, with input from a neuropsychologist, can successfully address psychological factors.",{},{"id":1072,"text":2714,"url":1074,"identifiers":2715},"Snell DL, et al. Evaluation of the fear avoidance behavior after Traumatic Brain Injury Questionnaire. J Neurotrauma. 2020;37(13):1566–73.",{"doi":1076},{"id":1072,"text":2717,"url":1074,"identifiers":2718},"•• Silverberg ND, et al. Feasibility of concussion rehabilitation approaches tailored to psychological coping styles: a randomized controlled trial. Arch Phys Med Rehabil. 2022;103(8):1565–1573.e2 This trial demonstrates the potential of matching participants to treatment based on their coping styles for improving outcomes.",{"doi":1076},{"id":1072,"text":2720,"url":1074,"identifiers":2721},"Cairncross M, et al. Normative data for the fear avoidance behavior after Traumatic Brain Injury Questionnaire in a clinical sample of adults with mild TBI. J Head Trauma Rehabil. 2021;36(5):E355–62.",{"doi":1076},{"id":1072,"text":2723,"url":1074,"identifiers":2724},"Cairncross M, et al. Fear avoidance behavior in youth with poor recovery from concussion: measurement properties and correlates of a new scale. Child Neuropsychol. 2021;27(7):911–21.",{"doi":1076},{"id":1072,"text":2726,"url":1074,"identifiers":2727},"Stubbs JL, et al. Atypical somatic symptoms in adults with prolonged recovery from mild traumatic brain injury. Front Neurol. 2020;11:43.",{"doi":1076},{"id":1072,"text":2729,"url":1074,"identifiers":2730},"Soumoff AA, et al. Somatic symptom severity, not injury severity, predicts probable posttraumatic stress disorder and major depressive disorder in wounded service members. J Trauma Stress. 2022;35(1):210–21.",{"doi":1076},{"id":1072,"text":2732,"url":1074,"identifiers":2733},"Nelson LD, et al. Preinjury somatization symptoms contribute to clinical recovery after sport-related concussion. Neurology. 2016;86(20):1856–63.",{"doi":1076},{"id":2735,"text":2736,"url":2737,"identifiers":2738},"f9380978-dcb8-4fef-9a8b-f0c51b86dfee","Picon EL, et al. Unexpected symptoms after concussion: potential links to functional neurological and somatic symptom disorders. J Psychosom Res. 2021;151:110661.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022399921003068",{"doi":2739},"10.1016\u002Fj.jpsychores.2021.110661",{"id":1072,"text":2741,"url":1074,"identifiers":2742},"Iverson GL, et al. “Good old days” bias following mild traumatic brain injury. Clin Neuropsychol. 2010;24(1):17–37.",{"doi":1076},{"id":1072,"text":2744,"url":1074,"identifiers":2745},"Voormolen DC, et al. Rating of pre-injury symptoms over time in patients with mild traumatic brain injury: the good-old-days bias revisited. Brain Inj. 2020;34(8):1001–9.",{"doi":1076},{"id":1072,"text":2747,"url":1074,"identifiers":2748},"Yang C-C, et al. “Good-old-days” bias: a prospective follow-up study to examine the preinjury supernormal status in patients with mild traumatic brain injury. J Clin Exp Neuropsychol. 2014;36(4):399–409.",{"doi":1076},{"id":1072,"text":2750,"url":1074,"identifiers":2751},"Silverberg ND, et al. The nature and clinical significance of preinjury recall bias following mild traumatic brain injury. J Head Trauma Rehabil. 2016;31(6):388–396.",{"doi":1076},{"id":22,"text":2753,"url":2754,"identifiers":2755},"Terpstra AR, et al. Psychological contributions to symptom provocation testing after concussion. J Head Trauma Rehabil. 2022.https:\u002F\u002Fdoi.org\u002F10.1097\u002FHTR.0000000000000796.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Fhtr.0000000000000796",{"openalex":2756,"pm":2757,"doi":2758},"W4281772422","35687896","10.1097\u002Fhtr.0000000000000796",{"id":2760,"text":2761,"url":2762,"identifiers":2763},"6a56a6a8-898a-4add-b85a-c886723af770","Van Praag DLG, et al. Neurocognitive correlates of probable posttraumatic stress disorder following traumatic brain injury. Brain Spine. 2022;2:100854.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2772529421008547",{"doi":2764},"10.1016\u002Fj.bas.2021.100854",{"id":1072,"text":2766,"url":1074,"identifiers":2767},"Hromas GA, et al. Making a difference: affective distress explains discrepancy between objective and subjective cognitive functioning after mild traumatic brain injury. J Head Trauma Rehabil. 2021;36(3):186–95.",{"doi":1076},{"id":1072,"text":2769,"url":1074,"identifiers":2770},"Stenberg J, et al. Change in self-reported cognitive symptoms after mild traumatic brain injury is associated with changes in emotional and somatic symptoms and not changes in cognitive performance. Neuropsychology. 2020;34(5):560–8.",{"doi":1076},{"id":1072,"text":2772,"url":1074,"identifiers":2773},"Anderson JFI. Cognitive complaint and objective cognition during the post-acute period after mild traumatic brain injury in pre-morbidly healthy adults. Brain Inj. 2021;35(1):103–13.",{"doi":1076},{"id":1072,"text":2775,"url":1074,"identifiers":2776},"Jurick SM, et al. Prevalence and correlates of self-reported cognitive difficulties in deployment-injured U.S. military personnel. J Trauma Stress. 2022;35(5):1343–1356.",{"doi":1076},{"id":1072,"text":2778,"url":1074,"identifiers":2779},"Silverberg ND, et al. Barriers and facilitators to the management of mental health complications after mild traumatic brain injury. Concussion. 2021;6(3):CNC92.",{"doi":1076},{"id":1072,"text":2781,"url":1074,"identifiers":2782},"Silverberg ND, et al. Management of concussion and mild traumatic brain injury: a synthesis of practice guidelines. Arch Phys Med Rehabil. 2020;101(2):382–393.",{"doi":1076},{"id":1072,"text":2784,"url":1074,"identifiers":2785},"Cook JM, et al. VA residential provider perceptions of dissuading factors to the use of two evidence-based PTSD treatments. Prof Psychol Res Pract. 2014;45(2):136–42.",{"doi":1076},{"id":2787,"text":2788,"url":2789,"identifiers":2790},"2a4fd422-85dc-4df8-9c88-4ea92d474a4c","Silverberg ND, Panenka WJ. Antidepressants for depression after concussion and traumatic brain injury are still best practice. BMC Psychiatry. 2019;19(1):100.","https:\u002F\u002Fbmcpsychiatry.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12888-019-2076-9",{"doi":2791},"10.1186\u002Fs12888-019-2076-9",{"id":1072,"text":2793,"url":1074,"identifiers":2794},"van der Horn HJ, et al. Brain network dysregulation, emotion, and complaints after mild traumatic brain injury. Hum Brain Mapp. 2016;37(4):1645–54.",{"doi":1076},{"id":1072,"text":2796,"url":1074,"identifiers":2797},"Medeiros GC, et al. Neuroimaging correlates of depression after traumatic brain injury: a systematic review. J Neurotrauma. 2022;39(11-12):755–72.",{"doi":1076},{"id":1072,"text":2799,"url":1074,"identifiers":2800},"Mikolić A, et al. Treatment for posttraumatic stress disorder in patients with a history of traumatic brain injury: a systematic review. Clin Psychol Rev. 2019;73:101776.",{"doi":1076},{"id":1072,"text":2802,"url":1074,"identifiers":2803},"Jak AJ, et al. SMART-CPT for veterans with comorbid post-traumatic stress disorder and history of traumatic brain injury: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2019;90(3):333–41.",{"doi":1076},{"id":22,"text":2805,"url":22,"identifiers":2806},"McGeary DD, et al. Cognitive behavioral therapy for veterans with comorbid posttraumatic headache and posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Neurol. 2022;79(8):746–57.",{},{"id":1072,"text":2808,"url":1074,"identifiers":2809},"Little A, Byrne C, Coetzer R. The effectiveness of cognitive behaviour therapy for reducing anxiety symptoms following traumatic brain injury: a meta-analysis and systematic review. NeuroRehabilitation. 2021;48(1):67–82.",{"doi":1076},{"id":1072,"text":2811,"url":1074,"identifiers":2812},"Kreitzer N, et al. The effect of antidepressants on depression after traumatic brain injury: a meta-analysis. J Head Trauma Rehabil. 2019;34(3):E47–54.",{"doi":1076},{"id":1072,"text":2814,"url":1074,"identifiers":2815},"Tsai PY, et al. Effect of repetitive transcranial magnetic stimulation on depression and cognition in individuals with traumatic brain injury: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16940.",{"doi":1076},{"id":1072,"text":2817,"url":1074,"identifiers":2818},"•• Teo SH, et al. Cognitive and psychological interventions for the reduction of post-concussion symptoms in patients with mild traumatic brain injury: a systematic review. Brain Inj. 2020;34(10):1305–21 Review and meta-analysis of psyhological interventions for symptoms after mTBI.",{"doi":1076},{"id":1072,"text":2820,"url":1074,"identifiers":2821},"•• Chen CL, et al. Effects of cognitive behavioral therapy for adults with post-concussion syndrome: a systematic review and meta-analysis of randomized controlled trials. J Psychosom Res. 2020;136:110190 Review and meta-analysis of cognitive-behavioral therapies for symptoms after mTBI.",{"doi":1076},{"id":22,"text":2823,"url":22,"identifiers":2824},"•• Rytter HM, et al. Nonpharmacological treatment of persistent postconcussion symptoms in adults: a systematic review and meta-analysis and guideline recommendation. JAMA Netw Open. 2021;4(11):e2132221 Review and meta-analysis of nonpharmacological treatments for symptoms after mTBI.",{},{"id":1072,"text":2826,"url":1074,"identifiers":2827},"• Sullivan KA, et al. Psychological approaches for the management of persistent postconcussion symptoms after mild traumatic brain injury: a systematic review, in Disability and Rehabilitation. 2020, Disabil Rehabil. p. 2243-2251. Review of psyhological interventions for symptoms after mTBI.",{"doi":1076},{"id":1072,"text":2829,"url":1074,"identifiers":2830},"Minen M, Jinich S, Vallespir Ellett G. Behavioral therapies and mind-body interventions for posttraumatic headache and post-concussive symptoms: a systematic review. Headache. 2019;59(2):151–63.",{"doi":1076},{"id":1072,"text":2832,"url":1074,"identifiers":2833},"Tomfohr-Madsen L, et al. A pilot randomized controlled trial of cognitive-behavioral therapy for insomnia in adolescents with persistent postconcussion symptoms. J Head Trauma Rehabil. 2020;35(2):E103–E112.",{"doi":1076},{"id":1072,"text":2835,"url":1074,"identifiers":2836},"Terpstra AR, et al. Psychological mediators of avoidance and endurance behavior after concussion. Rehabil Psychol. 2021;66:470–8.",{"doi":1076},{"id":1072,"text":2838,"url":1074,"identifiers":2839},"Gilliam WP, et al. Pain catastrophizing as a treatment process variable in cognitive behavioural therapy for adults with chronic pain. Eur J Pain. 2021;25(2):339–47.",{"doi":1076},{"id":1072,"text":2841,"url":1074,"identifiers":2842},"Acabchuk RL, et al. Therapeutic effects of meditation, yoga, and mindfulness-based interventions for chronic symptoms of mild traumatic brain injury: a systematic review and meta-analysis. Appl Psychol Health Well Being. 2021;13(1):34–62.",{"doi":1076},{"id":1072,"text":2844,"url":1074,"identifiers":2845},"Sander AM, et al. A randomized controlled trial of acceptance and commitment therapy for psychological distress among persons with traumatic brain injury. Neuropsychol Rehabil. 2021;31(7):1105–29.",{"doi":1076},{"id":1072,"text":2847,"url":1074,"identifiers":2848},"Bissell DA, Ziadni MS, Sturgeon JA. Perceived injustice in chronic pain: an examination through the lens of predictive processing. Pain Manag. 2018;8(2):129–38.",{"doi":1076},{"id":2850,"text":2851,"url":2852,"identifiers":2853},"ec28a723-0c3f-48f5-91b8-307fad2e6dc9","Rauwenhoff J, et al. The BrainACT study: acceptance and commitment therapy for depressive and anxiety symptoms following acquired brain injury: study protocol for a randomized controlled trial. Trials. 2019;20(1):773.","https:\u002F\u002Ftrialsjournal.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13063-019-3952-9",{"doi":2854},"10.1186\u002Fs13063-019-3952-9",{"id":1072,"text":2856,"url":1074,"identifiers":2857},"Greenberg J, et al. A live video mind-body treatment to prevent persistent symptoms following mild traumatic brain injury: protocol for a mixed methods study. JMIR Res Protoc. 2021;10(1):e25746.",{"doi":1076},{"id":1072,"text":2859,"url":1074,"identifiers":2860},"Næss-Schmidt ET, et al. Interdisciplinary intervention (GAIN) for adults with post-concussion symptoms: a study protocol for a stepped-wedge cluster randomised trial. Trials. 2022;23(1):613.",{"doi":1076},{"id":1072,"text":2862,"url":1074,"identifiers":2863},"Herdman D, et al. The INVEST trial: a randomised feasibility trial of psychologically informed vestibular rehabilitation versus current gold standard physiotherapy for people with Persistent Postural Perceptual Dizziness. J Neurol. 2022;269(9):4753–63.",{"doi":1076},{"id":22,"text":2865,"url":2866,"identifiers":2867},"Liu TW, et al. Decreasing fear of falling in chronic stroke survivors through cognitive behavior therapy and task-oriented training. Stroke. 2018; https:\u002F\u002Fdoi.org\u002F10.1161\u002FSTROKEAHA.118.022406.","https:\u002F\u002Fdoi.org\u002F10.1161\u002Fstrokeaha.118.022406",{"mag":2868,"openalex":2869,"pm":2870,"doi":2871},"2905780739","W2905780739","30580723","10.1161\u002Fstrokeaha.118.022406",{"id":1072,"text":2873,"url":1074,"identifiers":2874},"Clark CN, et al. Reframing postconcussional syndrome as an interface disorder of neurology, psychiatry and psychology. Brain. 2022;145(6):1906–15.",{"doi":1076},{"id":22,"text":2876,"url":22,"identifiers":2877},"National Academies of Sciences, E. and Medicine, Traumatic Brain Injury: a roadmap for accelerating progress. 2022.",{},{"id":22,"text":2879,"url":22,"identifiers":2880},"•• Iverson GL. Network analysis and precision rehabilitation for the post-concussion syndrome. Front Neurol. 2019;10:489 This publication reviews the persistent symptoms after mTBI from a network perspective.",{},{"id":1072,"text":2882,"url":1074,"identifiers":2883},"van der Horn HJ, et al. An integrated perspective linking physiological and psychological consequences of mild traumatic brain injury. J Neurol. 2020;267(9):2497–506.",{"doi":1076},{"id":1072,"text":2885,"url":1074,"identifiers":2886},"Silverberg ND, Iverson GL. Etiology of the post-concussion syndrome: physiogenesis and psychogenesis revisited. NeuroRehabilitation. 2011;29(4):317–29.",{"doi":1076},{"id":1072,"text":2888,"url":1074,"identifiers":2889},"Fink P, et al. Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients. Psychosom Med. 2007;69(1):30–9.",{"doi":1076},{"id":1072,"text":2891,"url":1074,"identifiers":2892},"Green K, et al. History of functional somatic syndromes and persistent symptoms after mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2021;33(2):109–15.",{"doi":1076},{"id":1072,"text":2894,"url":1074,"identifiers":2895},"Vuu S, et al. Physical exercise for people with mild traumatic brain injury: a systematic review of randomized controlled trials. NeuroRehabilitation. 2022;51(2):185–200.",{"doi":1076},{"id":2897,"text":2898,"url":2899,"identifiers":2900},"ef7594b6-ab25-49e7-b8ce-5bde7b048c2c","Leddy JJ, et al. Early targeted heart rate aerobic exercise versus placebo stretching for sport-related concussion in adolescents: a randomised controlled trial. Lancet Child Adolesc Health. 2021;5(11):792–9.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2352464221002674",{"doi":2901},"10.1016\u002FS2352-4642(21)00267-4",{"id":1072,"text":2903,"url":1074,"identifiers":2904},"Chrisman SPD, et al. Pilot randomized controlled trial of an exercise program requiring minimal in-person visits for youth with persistent sport-related concussion. Front Neurol. 2019;10:623.",{"doi":1076},{"id":1072,"text":2906,"url":1074,"identifiers":2907},"Wijenberg M, et al. Do fear and catastrophizing about mental activities relate to fear-avoidance behavior in a community sample? An experimental study. J Clin Exp Neuropsychol. 2021;43(1):66–77.",{"doi":1076},{"id":22,"text":2909,"url":22,"identifiers":2910},"Ashar YK, et al. Effect of pain reprocessing therapy vs placebo and usual care for patients with chronic back pain: a randomized clinical trial. JAMA Psychiat. 2022;79(1):13–23.",{},{"id":1072,"text":2912,"url":1074,"identifiers":2913},"Jungilligens J, et al. A new science of emotion: implications for functional neurological disorder. Brain. 2022;145(8):2648–63.",{"doi":1076},{"id":1072,"text":2915,"url":1074,"identifiers":2916},"Mollica A, et al. Neuromodulation treatments for mild traumatic brain injury and post-concussive symptoms. Curr Neurol Neurosci Rep. 2022;22(3):171–81.",{"doi":1076},{"id":1072,"text":2918,"url":1074,"identifiers":2919},"Vlaeyen JWS, et al. Towards a dynamic account of chronic pain. Pain. 2022;163(9):e1038–e1039.",{"doi":1076},{"id":2921,"text":2922,"url":2923,"identifiers":2924},"f035ec58-3fd0-4519-8882-3e24b800bff6","Price M, et al. The symptoms at the center: examining the comorbidity of posttraumatic stress disorder, generalized anxiety disorder, and depression with network analysis. J Psychiatr Res. 2019;109:52–8.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022395618307088",{"doi":2925},"10.1016\u002Fj.jpsychires.2018.11.016",{"id":1072,"text":2927,"url":1074,"identifiers":2928},"Afzali MH, et al. A network approach to the comorbidity between posttraumatic stress disorder and major depressive disorder: the role of overlapping symptoms. J Affect Disord. 2017;208:490–6.",{"doi":1076},{"id":2930,"createTime":2931,"updateTime":2932,"relativeEntities":2933,"slug":2934,"properties":2935,"entityType":195,"verifyStatus":196,"verifyTime":2946,"verifyNote":198,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":2947,"fullTextUrl":22,"authors":2948,"publicationType":243,"publisherRelationship":2964,"citationCount":22,"citationInfo":22,"publishDate":3016,"publishYear":3017,"citationAnalyzeStatus":21,"lastCitationAnalyze":2932,"indexDatabases":3018,"openAccess":22,"references":22,"isForceReanalyzing":562},"d08ee33a-e92d-4bfd-80f3-3fbd18e28b47","2023-12-06T04:51:42.441+00:00","2026-04-13T19:40:45.806+00:00",[],"Neurocognitive-effects-of-obstructive-sleep-apnea-syndrome",{"abstract":2936,"title":2938,"gsPaper":2940,"references":2942,"doi":2944},{"EN":2937},"The nature of the neurocognitive deficits found in obstructive sleep apnea is still debatable. What is the extent of higher executive versus alertness-based cognitive dysfunction? Are cognitive impairments caused by nighttime hypoxemia or daytime sleepiness? This paper demonstrates the importance of a sound theoretical neurocognitive framework to be able to answer these questions. A strategy to assess executive function is proposed and illustrated with well-known neuropsychological tests. It seems that the pervasive effects of decreased alertness on higher cognitive functioning were not fully taken into account in those studies in which executive dysfunction has been found and has been related to prefrontal lobe damage caused by intermittent hypoxemia. Therefore, a basal slowing in information processing, primarily due to sleepiness, may explain most of the neurocognitive deficits in sleep apnea. This conjecture appears to be in agreement with recent functional MRI studies indicating sleep loss as the primary cause of neurocognitive deficits, more so than hypoxemia.",{"EN":2939},"Neurocognitive effects of obstructive sleep apnea syndrome",{"VOID":2941},"[\"11844686091317238607\"]",{"VOID":2943},"Gottlieb DJ, Whitney CW, Bonekat WH, et al.: Relation of sleepiness to respiratory disturbance index: The Sleep Heart Health Study. Am J Respir Crit Care Med 1999, 159:502–507.\nYoung T, Palta M, Dempsey J, et al.: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230–1235.\nShamsuzzaman AS, Gersh BJ, Somers VK: Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003, 290:1906–1914.\nBonnet MH, Arand DL: Clinical effects of sleep fragmentation versus sleep deprivation. Sleep Med Rev 2003, 7:297–310.\nBeebe DW, Gozal D: Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res 2002, 11:1–16.\nFulda S, Schulz H: Cognitive dysfunction in sleep-related breathing disorders: a meta-analysis. Sleep Res Online 2003, 5:19–51.\nVerstraeten E, Cluydts R: Executive control of attention in sleep apnea patients: Theoretical concepts and methodological considerations. Sleep Med Rev 2004, 8:257–267.\nAloia MS, Arnedt JT, Davis JD, et al.: Neuropsychological sequelae of obstructive sleep apnea-hypopnea syndrome: a critical review. J Int Neuropsychol Soc 2004, 10:772–785.\nBeebe DW, Groesz L, Wells C, et al.: The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep 2003, 26:298–307.\nEngleman H, Joffe D: Neuropsychological function in obstructive sleep apnoea. Sleep Med Rev 1999, 3:59–78.\nFulda S, Schulz H: Cognitive dysfunction in sleep disorders. Sleep Med Rev 2001, 5:423–45.\nMazza S, Pepin JL, Naegele B, et al.: Most obstructive sleep apnoea patients exhibit vigilance and attention deficits on an extended battery of tests. Eur Respir J 2005, 25:75–80.\nHarrison Y, Horne J: The impact of sleep deprivation on decision making: a review. J Exp Psychol 2000, 6:236–249.\nDrummond SP, Brown GG, Stricker JL, et al.: Sleep deprivation-induced reduction in cortical functional response to serial subtraction. Neuroreport 1999, 10:3745–3748.\nTurkington PM, Sircar M, Saralaya D, Elliott MW: Time course of changes in driving simulator performance with and without treatment in patients with sleep apnoea hypopnoea syndrome. Thorax 2004, 59:56–59.\nEngleman HM, Martin SE, Kingshott RN, et al.: Randomised placebo controlled trial of daytime function after continuous positive airway pressure (CPAP) therapy for the sleep apnoea\u002Fhypopnoea syndrome. Thorax 1998, 53:341–345.\nJenkinson C, Davies RJ, Mullins R, Stradling JR: Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999, 353:2100–2105.\nLamphere J, Roehrs T, Wittig R: Recovery of alertness after CPAP in apnea. Chest 1989, 96:1364–1367.\nEngleman HM, Cheshire KE, Deary IJ, Douglas NJ: Daytime sleepiness, cognitive performance and mood after continuous positive airway pressure for the sleep apnoea\u002Fhypopnoea syndrome. Thorax 1993, 48:911–914.\nEngleman HM, Kingshott RN, Wraith PK, et al.: Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea\u002FHypopnea syndrome. Am J Respir Crit Care Med 1999, 159:461–467.\nPatel SR, White DP, Malhotra A, et al.: Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 2003, 163:565–571.\nGeorge CF, Boudreau AC, Smiley A: Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea. Thorax 1997, 52:648–653.\nHack M, Davies RJ, Mullins R, et al.: Randomised prospective parallel trial of therapeutic versus subtherapeutic nasal continuous positive airway pressure on simulated steering performance in patients with obstructive sleep apnoea. Thorax 2000, 55:224–231.\nMazza S, Pépin JL, Naegelé B, et al.: Driving ability in sleep apnoea patients before and after CPAP treatment: evaluation on a road safety platform. Eur Respir J 2006, 28:1020–1028.\nEngleman HM, Martin SE, Deary IJ, Douglas NJ: Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea\u002Fhypopnoea syndrome. Lancet 1994, 343:572–575.\nHenke KG, Grady JJ, Kuna ST: Effect of nasal continuous positive airway pressure on neuropsychological function in sleep apnea-hypopnea syndrome. A randomized, placebo-controlled trial. Am J Respir Crit Care Med 2001, 163:911–917.\nKrieger J, Kurtz D, Petiau C, et al.: Long-term compliance with CPAP therapy in obstructive sleep apnea patients and in snorers. Sleep 1996, 19:S136–S143.\nKribbs NB, Pack AI, Kline LR, et al.: Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993, 147:887–895.\nWeaver TE, Kribbs NB, Pack AI, et al.: Night-to-night variability in CPAP use over the first three months of treatment. Sleep 1997, 20:278–283.\nKribbs NB, Pack AI, Kline LR, et al.: Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis 1993, 147:1162–1168.\nBédard MA, Montplaisir J, Richer F, et al.: Obstructive sleep apnea syndrome: pathogenesis of neuropsychological deficits. J Clin Exp Neuropsychol 1991, 13:950–964.\nNaëgelé B, Thouvard V, Pépin JL, et al.: Deficits of cognitive executive functions in patients with sleep apnea syndrome. Sleep 1995, 18:43–52.\nKim HC, Young T, Matthews CG, et al.: Sleep-disordered breathing and neuropsychological deficits: a population-based study. Am J Respir Crit Care Med 1997, 156:1813–1819.\nRedline S, Strauss ME, Adams N, et al.: Neuropsychological function in mild sleep-disordered breathing. Sleep 1997, 20:160–167.\nLee MM, Strauss ME, Adams N, Redline S: Executive functions in persons with sleep apnea. Sleep Breath 1999, 3:13–16.\nVerstraeten E, Cluydts R, Pevernagie D, Hoffmann G: Executive function in sleep apnea: controlling for attentional capacity in assessing executive attention. Sleep 2004, 27:685–693.\nBaddeley A: Working memory. Science 1992, 255:556–559.\nD’Esposito M, Detre JA, Alsop DC, et al.: The neural basis of the central executive system of working memory. Nature 1995, 378:279–281.\nBaddeley A: Exploring the central executive. Q J Exp Psychol A 1996, 49:5–28.\nLehto J: Are executive function tests dependent on working memory capacity? Q J Exp Psychol A 1996, 49:29–50.\nBorak J, Cieslicki JK, Koziej M, et al.: Effects of CPAP treatment on psychological status in patients with severe obstructive sleep apnoea. J Sleep Res 1996, 5:123–127.\nMorris N, Jones DM: Memory updating in working memory: the role of the central executive. Br J Psychol 1990, 81:111–121.\nHenik A: Paying attention to the Stroop effect? J Int Neuropsychol Soc 1996, 2:467–470.\nAbramczyk RR, Jordan DE, Hegel M: “Reverse” Stroop effect in the performance of schizophrenics. Percept Mot Skills 1983, 56:99–106.\nBuchanan RW, Strauss ME, Kirkpatrick B, et al.: Neuropsychological impairments in deficit vs. nondeficit forms of schizophrenia. Arch Gen Psychiatry 1994, 51:804–811.\nDurmer JS, Dinges DF: Neurocognitive consequences of sleep deprivation. Semin Neurol 2005, 25:117–129.\nO’Donoghue FJ, Briellmann RS, Rochford PD, et al.: Cerebral structural changes in severe obstructive sleep apnea. Am J Respir Crit Care Med 2005, 171:1185–1190.\nRobbins J, Redline S, Ervin A, et al.: Associations of sleep-disordered breathing and cerebral changes on MRI. J Clin Sleep Med 2005, 1:159–165.\nAyalon L, Ancoli-Israel S, Klemfuss Z, et al.: Increased brain activation during verbal learning in obstructive sleep apnea. NeuroImage 2006, 31:1817–1825.\nThomas RJ, Rosen BR, Stern CE, et al.: Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol 2005, 98:2226–2234.\nJansen GF, Krins A, Basnyat B: Cerebral vasomotor reactivity at high altitude in humans. J Appl Physiol 1999, 86:681–686.\nVan Dongen HP, Baynard MD, Maislin G, Dinges DF: Systematic interindividual differences in neurobehavioral impairment from sleep loss: evidence of trait-like differential vulnerability. Sleep 2004, 27:423–433.\nMu Q, Mishory A, Johnson KA, et al.: Decreased brain activation during a working memory task at rested baseline is associated with vulnerability to sleep deprivation. Sleep 2005, 28:433–446.\nAlchanatis M, Zias N, Deligiorgis N, et al.: Sleep apnea-related deficits and intelligence: an implication of cognitive reserve theory. J Sleep Res 2005, 14:69–75.",{"VOID":2945},"10.1007\u002Fs11910-007-0012-8","2024-05-15T16:13:10.432+00:00","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11910-007-0012-8",[2949],{"id":2950,"sortIndex":23,"researcher":22,"roles":2951,"affiliations":2952,"properties":2961,"displayName":2963,"givenName":22,"familyName":22},"a8074216-c4a0-4b56-9b60-c51e4666d2fa",[586],[2953],{"id":2954,"sortIndex":23,"affiliation":2955,"properties":22},"771db6b5-15df-4ebe-884a-c847304aa74c",{"id":2954,"createTime":22,"updateTime":22,"relativeEntities":2956,"slug":22,"properties":2957,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2960,"statistic":22},[],{"title":2958},{"VI":2959},"Department of Psychology, Swansea University, Swansea, UK",[],{"title":2962},{"VI":2963},"Edwin Verstraeten",{"url":2947,"publisher":2965,"properties":3011},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2966,"slug":10,"properties":2967,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2971,"manageAffiliations":2980,"indexDatabases":2991,"url":22,"thumbnailPath":22,"statistic":3006,"gsStatistic":22,"type":173,"analyzePriority":22},[],{"issn":2968,"title":2969,"eissn":2970},{"VOID":15},{"EN":17},{"VOID":13},[2972,2976],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2973,"label":2974,"description":2975,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2977,"label":2978,"description":2979,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2981,2986],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2982,"slug":22,"properties":2983,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2985,"statistic":22},[],{"title":2984},{"EN":43},[],{"id":46,"createTime":22,"updateTime":22,"relativeEntities":2987,"slug":22,"properties":2988,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2990,"statistic":22},[],{"title":2989},{"EN":50},[],[2992,2999],{"id":54,"indexDatabase":2993,"url":67,"indexYears":22,"academicFieldIds":2998,"indexDatabaseRanking":22},{"id":56,"createTime":22,"updateTime":22,"relativeEntities":2994,"label":2995,"description":2996,"key":63,"publicationTags":2997,"standard":22},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69,70],{"id":72,"indexDatabase":3000,"url":83,"indexYears":84,"academicFieldIds":3005,"indexDatabaseRanking":88},{"id":74,"createTime":22,"updateTime":22,"relativeEntities":3001,"label":3002,"description":3003,"key":80,"publicationTags":3004,"standard":22},[],{"EN":77,"VI":77},{"EN":77,"VI":79},[82],[86,87],{"impactFactor":23,"impactFactorByYear":3007,"i10Index":103,"i10IndexLast5Year":104,"totalPublication":105,"totalPublicationByYear":3008,"totalCitation":123,"totalCitationByYear":3009,"totalCitationPerPublication":147,"totalCitationPerPublicationByYear":3010,"hindexLast5Year":172,"hindex":172},{"2012":91,"2013":92,"2014":93,"2015":94,"2016":95,"2017":96,"2018":97,"2019":98,"2020":99,"2021":100,"2022":101,"2023":102},{"2001":107,"2002":108,"2003":109,"2004":110,"2005":111,"2006":112,"2007":113,"2008":114,"2009":115,"2010":112,"2011":108,"2012":116,"2013":117,"2014":114,"2015":111,"2016":118,"2017":114,"2018":119,"2019":118,"2020":113,"2021":120,"2022":121,"2023":112,"2024":122},{"2001":125,"2002":126,"2003":126,"2004":127,"2005":128,"2006":129,"2007":130,"2008":131,"2009":132,"2010":133,"2011":134,"2012":135,"2013":136,"2014":137,"2015":138,"2016":139,"2017":140,"2018":141,"2019":142,"2020":143,"2021":144,"2022":110,"2023":145,"2024":146},{"2001":149,"2002":150,"2003":151,"2004":152,"2005":153,"2006":154,"2007":155,"2008":156,"2009":157,"2010":158,"2011":159,"2012":160,"2013":161,"2014":162,"2015":147,"2016":163,"2017":164,"2018":165,"2019":166,"2020":167,"2021":168,"2022":169,"2023":170,"2024":171},{"pages":3012,"volume":3014},{"VOID":3013},"161-166",{"VOID":3015},"7","2007-04-16",2007,[88,65]]